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CO-TRANSCRIPTIONAL SPLICING AND FUNCTIONAL ROLE OF PKCβ IN 
INSULIN-SENSITIVE L6 SKELETAL MUSCLE CELLS AND 3T3-L1 
ADIPOCYTES 
 
Eden Kleiman 
 
ABSTRACT 
 
PKCβII is alternatively spliced during acute insulin stimulation in L6 skeletal 
muscle cells.  This PKCβII isoform is critical in propagating GLUT4 translocation.   
PKCβ protein and promoter dysfunction correlate with human insulin resistance.  TZD 
treatment ameliorates whole-body insulin-resistance.  Its primary target is adipocyte 
PPARγ, which it activates upon binding.  This causes both altered circulating serum FFA 
concentrations and adipokine secretion profile.  How TZDs affect the intracellular 
signaling of skeletal muscle cells is unknown.  RT-PCR and Western blot analysis 
showed that TZDs elevated PKCβII by a process that involves co-transcriptional splicing.  
PGC1α overexpression most closely resembled TZD treatment by increasing PKCβII 
protein levels and keeping PKCβI levels relatively constant.  Use of a heterologous PKCβ 
promoter driven PKCβ minigene demonstrated that PPARγ could regulate the PKCβ 
promoter, but whether this is direct or indirect is unclear.  SRp40 splicing factor has been 
shown to dock onto the PGC1α CTD and influence splicing.  SRp40, through 
overexpression and silencing, appears to play a part in PKCβ promoter regulation.   
 PKCβ promoter regulation was also studied in 3T3-L1 cells.  TZDs were 
experimentally shown to have no role in PKCβ promoter regulation despite PPARγ 
xviii 
activation.  Chromatin immunoprecipitation assays revealed PU.1 as a putative PKCβ 
transcription factor that can cross-talk with the spliceosome, possibly through SRp40 
which was also associated with the PKCβ promoter.  3T3-L1 adipocyte differentiation 
revealed a novel developmentally-regulated switch from PKCβI to PKCβII, using 
western blot and Real-Time PCR analysis.  Pharmacological inhibition of PKCβII using 
CGP53353 and LY379196 blocked [3H]2-deoxyglucose uptake and revealed a functional 
role for PKCβII in adipocyte ISGT.  CGP53353 specifically inhibited phosphorylation of 
PKCβII Serine 660 and not other critical upstream components of the insulin signaling 
pathway.  Subcellular fractionation and PM sheet assay pointed to PKCβII-mediated 
regulation of GLUT4 translocation to the PM.  Co-immunoprecipitation between PKCβII 
and GLUT4 allude to possible direct interaction.  Western blot and immunofluorescence 
assays show PKCβII activity is linked with Akt Serine 473 phosphorylation, thus full Akt 
activity.  Western blot and co-immunoprecipitation suggested that insulin caused active 
mTORC2 to directly activate PKCβII.    Data support a model whereby PKCβII is 
downstream of mTORC2 yet upstream of Akt, thereby regulating GLUT4 translocation.  
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INTRODUCTION 
 
Protein Kinase C: Brief History 
Protein Kinase C (PKC) was discovered by Nishizuka and coworkers as a histone 
protein kinase isolated from the rat brain that could be activated by limited proteolysis 
[1], Ca2+ and (phospho)lipids [2] or phorbol esters and phospholipids [3].  Diacylglycerol 
(DAG), an early product of signal-induced inositol phospholipid breakdown, enhanced 
the affinity of PKC for calcium and thereby activating it [4].  Phorbol esters, which 
promoted tumors, were able to substitute for DAG in PKC activation [3].  This activation 
by phorbol esters was believed to be the reason PKC was a tumor promoter [5; 6], 
bringing it to the forefront on cancer research [7].   Early biochemical studies and 
purifications indicated PKC represented a group of several isoenzymes [8].  The major 
breakthrough came from cloning cDNAs of PKC isoforms, mostly from brain cDNA 
libraries.  PKCβ cDNA has been cloned from various sources including bovine, human, 
rat and mouse [9].   
Signaling and Physiolocial Impact  
PKC′s role in signal transduction was first demonstrated in release of serotonin 
from platelets [10; 11].   A variety of agonist-induced cellular responses involve PKC 
including hormones, neurotransmitters and some growth factors [12].   One of the main 
pathways activated by PKC is the MEK-ERK pathway which promotes proliferation and 
differentiation [13].  However, there are many other signaling cascades of which PKC is 
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at the epicenter.  Figure 1 illustrates the many proposed effects of protein kinase C 
activation [14].  
In cancer signaling, PKC is also involved in cellular adhesion.  This allows for 
cancer cell invasion via integrin binding, activation of metalloproteinases and expression 
of extracellular matrix proteins.  Inhibition of PKC reduces invasiveness [14].   A PKCβ 
selective inhibitor, Enzastaurin, has recently been evaluated for its potential as an 
anticancer agent in lung cancer [15].   
PKC is also involved in the PI3K-Akt pathway [14].  This places PKC in the 
middle of the insulin signaling cascade.  PKC is involved in insulin-stimulated glucose 
uptake as a downstream effector of PI3K-PDK1 [16].  As proof of its central role in 
insulin signaling, PKC dysregulation is associated with many diabetic complications such 
as diabetic nephropathy, diabetic retinopathy and cardiovascular disease [17; 18].   
PKC Family and Structure  
The Protein Kinase C family are serine/threonine kinases that are members of the 
AGC (cAMP-dependent, cGMP-dependent, and protein kinase C) family of protein 
kinases which have structural features in common (includes PKA, PKB and PKC).  AGC 
kinases contain highly conserved catalytic domains (motifs required for ATP/substrate-
binding and catalysis) and a regulatory domain that keeps that enzyme in an inactive 
conformation.  PKC regulatory domains occupy the amino terminal and contain an 
autoinhibitory pseudosubstrate domain (sequence where alanine substitutes for 
serine/threonine phosphoacceptor site) and two distinct plasma membrane targeting 
modules, C1 and C2.  PKC isoforms are classified based on differences in their amino 
terminal regulatory domain (Figure 2) and cofactor requirement [14; 19; 20; 21].   
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The PKC family comprises 10 isozymes and their splice variants grouped into 3 
classes based on co-factor requirement [21].  Conventional PKC (cPKC) isoforms include 
α, γ, βI and alternatively spliced βII.   Starting at the N-terminal, cPKCs are allosterically 
regulated by the pseudosubstrate which as mentioned before resembles a substrate 
binding domain [20].  This was discovered by using peptides based on the sequence and 
showed that they were effective competitive inhibitors of PKC [22].  Activation of PKC 
(and downstream signaling) necessitates the release of the pseudosubstrate domain from 
the kinase core (Figure 3) [6; 23].   
Antibodies targeting the pseudosubstrate domain resulted in co-factor independent 
PKC activation [24].  PKC is resistant to proteolysis when inactive (pseudosubstrate-
kinase core binding) but highly sensitive to proteolysis in the pseudosubstrate domain 
(specific Arginine within) when active.  The activation of PKC is dependent on 
pseudosubstrate unmasking [25].  cPKCs contain a C1 domain that binds DAG/PMA.  
The C1 domain consists of tandem (roughly 50) residue sequences, named C1A and C1B.  
C1A and C1B domains both have a zinc finger (Zn2+) held by 6 cysteines and 2 
histidines.  This is used for DAG/phorbol ester binding [19].   The C1B domain contains 
a Tyrosine at position 22 making it a weak DAG responder [21].  The C2 domain binds 
calcium and subsequently binds anionic/acidic phospholipids [19].  Ca2+ is bound by a β-
sandwich structure composed of eight β-strands creating two flat sheets connected with a 
short helix hinge.  This β sandwich can bind 2-3 calcium ions.   It is this positively 
charged ion that helps interact with negatively charged phospholipids such as 
phosphatidylserine [26]. The double positive symbol (Figure 2) in the cPKC C2 domain 
represents a basic patch (located in the distal area of the Ca2+-dependent lipid binding 
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site) that specifically recognizes PIP2 and distinguishes cPKC from other PKCs (among 
other things) in terms of activation [21].  Novel PKCs (nPKCs) include δ, ε, θ, η.  δ/θ or 
ε/η could be further subdivided based on structural features.  nPKCs have C1 and C2 
domains, however, the order is switched relative to cPKCs (Figure 2).  The nPKC C2 
domain (C2-like) lacks the acidic residues necessary for calcium binding.  This is the 
main pharmacological difference between cPKCs and nPKCs.  As shown in Table 3, 
nPKCs are maximally activated by DAG/PMA and phosphatidylserine without the 
requirement for calcium [19].  nPKCs have stronger DAG responsiveness compared to 
cPKCs due to a tryptophan at position 22 (Figure 2) in the C1B domain [21].     Atypical 
PKCs (aPKCs) include ζ, ι/λ.  They lack a calcium sensitive C2 domain and have an 
atypical C1 domain with only one cysteine-rich membrane-targeting structure that binds 
PIP3 or ceramide (not DAG or PMA).  Upstream of the C1 domain is a PB1 domain that 
mediates interactions with other PB1-containing scaffolding proteins such as PAR-6 and 
MEK5.  The activity of aPKCs are regulated mainly by protein-protein interactions and 
PDK-1 mediated phosphorylation [19].   
The PKC ATP-binding domain (C3) contains a lobe with β-sheets with a glycine-
rich ATP-binding loop with the consensus GXGXXG.  It has an invariant lysine which 
structures the enzyme for phosphoryl-transfer.  The C4 domain is predominantly α-
helical and contains the activation loop segment that positions magnesium and peptide 
substrates for catalysis.  In between the C3 and C4 lobes of the kinase domain, there is a 
“gatekeeper” residue (methionine in PKCβII) that controls access to a cavity in the ATP 
binding pocket.  The V5 domain contains highly conserved priming/regulatory 
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phosphorylation sites (discussed in further detail below) that play a crucial role in 
structuring the catalytic pocket [19]. 
PKC μ and ν are considered by some to constitute a fourth class of PKCs named 
Protein Kinase D [20].  Initially, human PKD (PKCμ) was discovered followed by the 
murine ortholog PKD [27; 28].  PKD is a serine/threonine kinase that consists of an N-
terminal regulatory domain and a C-terminal catalytic domain.  The N-terminal domain 
has 2 cysteine-rich, zinc finger-like motifs and a pleckstrin homology (PH) domain.  
Cys1 and Cys2 domains (Figure 2) bind DAG/PMA with high affinity [29].  The PH 
domain is involved in protein:protein interactions as well as PH domain-dependent 
autoinhibitory intramolecular interactions that maintain the enzyme in an inactive state 
with low basal activity in resting cells.  An interesting connection exists between PKD 
and nPKCs.  nPKCs activate PKD by phosphorylating them at highly conserved serine 
residues in the activation loop which relieves autoinhibition [30].    PKD2 and PKD3 
have also recently been added to the list.  PKD is distinct from PKC with respect to 
structural and enzymatic properties.  For instance, PKD does not phosphorylate many 
bona-fide PKC substrates.  PKD family members have been grouped into the 
calcium/calmodulin-dependent protein kinase (CaMK) based on catalytic domain 
structure and substrate specificity.  However, unlike CaMK, PKDs are activated 
indirectly by calcium through DAG production [29].   
Recently, another group of PKCs has been discovered.  Protein kinase C-related 
kinase (PRK) consists of at least three members, PRK1-3.  PRKs are insensitive to Ca2+, 
DAG and phorbol esters but can be activated by limited proteolysis and phospholipids.  
Both PRK1 and PRK2 can bind activated RhoA GTPase proteins, which increases their 
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activity.  This binding occurs in the HR1 domain.  It is composed of three repeats of a 55 
amino acid motif.  In PRK1, the first HR1 repeat (HR1a) binds to activated GTP-RhoA 
complex but not to the inactive GDP-bound form.  HR1b is the second motif and binds 
(less affinity) to either active of inactive RhoA.  The HR1c repeat does not bind RhoA 
and its function is unknown [31; 32].   
PKCβ Gene  
PKCβI and PKCβII are derived from alternative splicing of the same pre-mRNA 
from the same gene (16p11.2 in humans).  The region of splicing that determines the β 
isoform is the V5 region.  Rat and rabbit PKCβI and PKCβII cDNAs encode proteins 
composed of 671 and 673 amino acids, respectively.  The difference in the C-terminal V5 
exon is a PKCβI product that is 50 amino acids and a PKCβII product that is 52 amino 
acids (Figure 4) [33; 34].  This is also the case for human PKCβ [35].   
Figure 5 depicts the possible products arising from PKCβ alternative splicing [33; 
36].   Splice sites 1 & 2 are shown.  However, it is predicted that additional splice sites 
are possible.  These additional splice sites may be involved in conferring additional 
stability for the mature RNA (unpublished observation).  The stop codon in the PKCβII 
exon prevents the PKCβI exon from being translated (Figure 4 & 5).  The intronic SRp40 
binding site binds phosphorylated SRp40 (Figure 4).  This splicing factor promotes 
PKCβII exon inclusion [37; 38].     
PKCβ V5 Domain  
Since PKβI and PKCβII are identical up to the V5 region, then it is logical that 
this domain distinguishes the two isoforms in terms of subcellular location (at rest and 
activated) and function, even within the same cell type [19].   A classic example was 
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deciphered by the Cooper lab.  In BC3H-1 myocytes, insulin treatment induced the 
alternative splicing of the PKCβII exon.  Within 15 minutes of insulin treatment, basal 
PKCβI was replaced by the PKCβII isoform.  It was hypothesized that PKCβII, as 
opposed to PKCβI, had a more significant role in glucose uptake.  Subsequent 
overexpression of PKCβII in NIH-3T3 cells resulted in enhanced insulin-stimulated 
glucose uptake [39].  PKCβII′s unique role was further confirmed by experiments 
utilizing a C-terminal truncated PKCβII that acted as a dominant negative and 
pharmacologic inhibition via CGP53353 (a specific PKCβII inhibitor).  Both mutant 
PKCβII and CGP53353 inhibited L6 skeletal muscle insulin-stimulated glucose uptake 
[40].  Another example of diametrically opposed PKCβ isoform function is in A10 
vascular smooth muscle cells (rat).  Here, PKCβI stimulates A10 growth while PKCβII 
inhibits A10 growth [41].  Distinct localizations are possible as well based on the V5 
region.  In cardiomyocytes, PKCβI localizes to the cytosol and perinuclear region and 
translocates to the nucleus following PMA treatment.  PKCβII associates with fibrillar 
cytoskeletal structures at rest and translocates to the cell periphery and perinuclear region 
upon PMA treatment.  Here, PKCβII co-localizes with RACK1 [42].   
The V5 region shows specificity in its substrate targets.  For instance, PKCβII activates 
PLD, whereas PKCβI does not [19].   
PKC Tissue Expression 
Select mammlian cells and tissues are listed below (Table 1) to give a general 
overview of PKC isoforms expression (either mRNA or protein detection) [11; 12; 43; 
44; 45; 46; 47; 48; 49; 50; 51; 52].  Distibution may vary between species.   
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Table 1. PKC Isoform Tissue/Cell Expression 
 PKC isoform 
Cell /Tissue α βI βII γ δ ε η Ζ Θ λ/ι μ 
Brain + + + + + + ? + ? ? ? 
Central 
Nervous 
Tissue 
+ + + - + + + + + + + 
Heart  + + + - + + + + + + ? 
Small 
Intestine 
? ? ? - + ? ? ? ? + ? 
Kidney + + + - + + ? + ? ? + 
Liver + + + - + + ? + + + ? 
Airways 
Smooth 
Muscle 
+ + + - + + + + + + + 
Lung + + + - + + + + + + + 
Neutrophil + + + - + ? ? + ? ? ? 
Monocyte + + + - + + + + - - + 
Macrophage + + + - + + + + - - + 
Eosinophile + + + - + + - - - + + 
Platelet + + + - + + ? + + ? ? 
T-
Lymphocyte 
+ + + - + + + + ? ? ? 
B-
Lymphocyte 
+ + + - + + + + ? ? ? 
Vascular 
Smooth 
Muscle 
+ + + - + + + ? ? + ? 
Retina + + + - + + ? + ? ? ? 
Spleen + + + - + + + ? ? + ? 
Testis + + + - + + ? + ? + ? 
Ovary + + + - + + ? + ? + ? 
Pancreas + + + - ? + ? ? ? + ? 
Thymus + + + - ? - ? ? ? ? ? 
Fibroblast + + - + + + ? + ? ? + 
Skeletal 
muscle 
+ + + - + + + + + + + 
Adipocyte + + + + + + + + + + + 
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PKC Size  [12] 
 
Table 2. PKC Isoform Size 
 α βI βII γ δ Ε η(L) θ ζ λ 
Amino 
Acids 
672 671 673 697 673 737 683 707 592 586 
Daltons 76,7
99 
76,79
0 
76,93
3 
78,36
6 
77,51
7 
83,47
4 
77,97
2 
81,57
1 
67,740 67,200
 
PKC Activation 
Newly translated PKCs are unphosphorylated and associated with the 
cytoskeleton.  Maturation (catalytic competence) must take place in order for PKC to 
translocate to the plasma membrane [53].  Before this maturation, interaction with the 
plasma membrane is very weak [19].   Using PKCβII as a model, physiological stimuli 
initiate one of three phosphorylations necessary for catalytic competence (Figure 6).  
First, threonine 500 in the activation loop is phosphorylated by PDK1.  This is the rate-
limiting step in the processing of PKC [20].  This phosphorylation aligns the active site 
with the downstream sites.  Next, Threonine 641 is phosphorylated in the proline-rich 
turn motif via mTORC2 [54; 55].  Phosphorylation at this site locks the protein in a 
catalytically competent, thermally stable and phosphatase-resistant conformation.  Also, 
this phosphorylation may serve as a docking pad for protein interactions [20].   Based on 
the sequence surrounding this motif, 14-3-3 protein is speculated to bind.  Lastly, the 
hydrophobic motif is autophosphorylated at Serine 660 (S660).  This hydrophobic site is 
the least conserved among PKCs.  This phosphorylation is not essential for function, but 
without it they have less thermal stability and increased phosphatase sensitivity [20].  It 
should be noted that mammalian target of rapamycin complex 2 (mTORC2) is involved 
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in PKC′s intrinsic kinase activity by regulating phosphorylation of the turn motif which 
leads to autophosphorylation at the hydrophobic motif [21; 56]. 
Once the C-terminal serine and threonines are phosphorylated, PKCβII assumes 
its mature conformation.  Subsequent dephosphorylation at Threonine 500 (T500) would 
not alter its mature status.  However, dephosphorylation at the turn motif abolishes kinase 
activity.  The three phosphorylation sites are conserved suggesting most PKCs undergo 
similar processing.  The exceptions would be aPKCs.  The aPKCs have a glutamic acid 
instead of serine and threonine in the hydrophobic motif.  PKCδ, for example, T505 in 
the activation loop is not required because of the negative charge brought about by 
Glutamic acid at residue 500.  Ultimately these phosphorylations are required for 
intracellular localization of PKCs [53].   
   In the traditional model of PKC activation, agonists promote phosphoinositide 
hydrolysis to produce DAG and IP3 generation which mobilizes calcium.  Calcium, a 
soluble ligand, binds to the C2 domain to increase PKC′s affinity for PhosphatidylSerine 
(PS).  This interaction is relatively weak, however, once anchored to membranes the C1A 
domain interacts with DAG.  The interaction between C1A and DAG would not be 
possible if it were not for PS binding to C2 which disrupts an electrostatic C1A/C2 
interdomain binding.  The C1A domain now penetrates the lipid bilayer to bind DAG.  
When both C1A and C2 domains are engaged with the membrane, the pseudosubstrate 
domain is expelled from the substrate-binding pocket which facilitates full PKC 
activation [19; 57].    DAG is thought to induce membrane alterations (inverted 
miscelles) improving the hydrophobic interaction with proteins that can integrate with the 
plasma membrane [58].   
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The traditional model of PKC activation was thought to be punctuated by 
cytoplasmic to plasma membrane translocation.  However, this is not the case with every 
PKC isoform.  PKCs can be targeted to many intracellular locations for activation [53].   
Again, using PKCβII as an example, translocation to the plasma membrane is initiated by 
acute PLC-derived DAG accumulation.  However, in cells that display a biphasic DAG 
response, catalytically active PKCβII is released from the plasma membrane to go to the 
pericentron region (subset of recycling endosomes containing small GTPase Rab11) [59; 
60].  Pericentronic localization is due to PLD-derived DAG (Figure 7).   PKCβII at this 
location can control the trafficking of continuously recycling membrane signaling 
proteins such as caveolin-1.  PKCβII pericentron accumulation can be inhibited by PP1 
(protein phosphatase I) stimulation via ceramide.  PP1 dephosphorylates PKCβII at the 
activation loop [19].   
 A detailed overview of cPKC activation is shown in Figure 8.  * was inserted to 
remind the reader that mTORC2 does not constitutively phosphorylate PKCβII in all 
cases.  It has been shown in mouse embryonic fibroblasts (MEFs) that this is the case [54; 
55].  However, our data concerning 3T3-L1 adipocytes suggests that mTORC2 
phosphorylation is mediated by insulin [52].  It has also been reported that in HEK293 
cells, mTORC2 is activated via insulin stimulation [61].  This would suggest that whether 
cPKCs are constitutively or agonist-induced phosphorylated depends on the cell type.   
. As stated above, DAG can be produced by disparate mechanisms. 
De novo synthesis is one way DAG is induced (Figure 9).  There are two main pathways 
for this biosynthesis.  One is from glycerol-3-phosphate as a result of triacylglycerol 
mobilization.  The other is use of dihydroxyacetone-3-phosphate, which is a glycolysis 
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intermediate.  These two precursors undergo several modifications.  These include two 
acylation steps that give rise to lysophosphatidic acid (LPA) and then phosphatidic acid 
(PA).  PA can subsequently be transformed into DAG through PA phosphohydrolases 
(PAPs) [58].   DAG production in response to stimuli has many facets (Figure10).  Acute 
DAG is produced via agonist-induced hydrolysis of phosphatidylinositol 4,5-
bisphosphate PIP2 by PLC.  PLD-mediated hydrolysis of phosphatidylcholine (PC) 
produces another type of DAG [53].  The initial DAG (PLC-dependent) is 
polyunsaturated and consists of the following three types; 1-steroyl-2-arachidonoyl-sn-
glycerol (SAG), 1-steroyl-2-doxosahexaaenoyl-sn-glycerol (SDG) and 1-steroyl-2-
eicosapentaenoyl-glycerol (SEG) [62; 63; 64].  PKC isotypes are differentially activated 
by DAGs.  SDG activates PKCα and PKCδ most powerfully.  PKCβI is activated by 
SDG and SEG rather than SAG [53].  PLD-derived DAG is monounsaturated or saturated 
[64].  Polyunsaturated DAG is frequently transient with sustained DAG being 
predominantly monounsaturated (generally sc-2 acyl group) [65].  To generate DAG, 
PLD hydrolyzes phosphatidylcholine to PA and choline.  PA is a bioreactive lipid 
whereas choline is not thought to participiate in intracellular signaling [66].  PLD-derived 
PA is further processed by phosphatidic acid phosphohydrolases (PAPs) into DAG (1-
palmitoyl 2-oleoyl-sn-glycerol).  DAG can be converted back to PA via phosphorylation 
by diacylglycerol kinases (DGKs).  In addition, PA can be deacylated by phospholipase 
A2 (PLA) to form monoacylated LysoPA.  LysoPA can also be converted back to PA by 
lysophosphatidic acid acyltransferases (LPAAT) [67; 68].  PLA hydolization of 
phospholipids can also liberate free fatty acids [12].  Fatty acids activate PKCs in an 
isotype-specific manner [53; 69].  PKCβ (along with α, γ and ε) are activated by fatty 
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acids with carbon lengths between C13 and C18 in vitro.  Cis unsaturated fatty acids 
including oleic, linolenic, arachadonic and docosahexaenoic acids are all produced from 
phospholipids via PLA.  These fatty acids allow PKC to exhibit almost full activity in the 
presence of Ca2+ concentrations less than 1μM.  This effect is enhanced by the co-
presence of DAG [12; 70; 71].   PC can also be converted to DAG by two other routes 
besides PLD-derived.  One is a PC-PLC catalyzed pathway that releases choline 
phosphate to produce DAG.  The other is the conversion of ceramide to sphingomyelin 
catalyzed by sphingomyelin synthase (SMS).  SMS manufactures sphingomyelin from 
phsophatidylcholine by catalyzing replacement of a glycerol molecular by ceramide, 
resulting in the release of DAG [58; 65].   
The following table (Table 3) summarizes the main activators of the various PKC 
isoforms [12; 20; 72; 73; 74; 75; 76; 77; 78] (activation may vary across species and 
cell/tissue type): 
Table 3. PKC Isoform Activators 
 α βI βII γ δ ε η(L) θ ζ λ 
PS + + + + + + + + + + 
Ca2+  + + + + - - - - - - 
DAG + + + + + + + + - - 
FFA + + + + + + ? + + + 
LysoPC + + + + + + ? + + + 
 
Tyrosine phosphorylation can mediate PKC activation in the absence of PS.  
PKCα, βI, δ, γ, and ζ can be tyrosine phosphorylated induced by hydrogen peroxide [79].  
In skeletal muscle, PKCδ undergoes insulin-induced tyrosine phosphorylation 
(activation) directly via Src tyrosine kinase which leads to insulin receptor (IR) activation 
[80].  Almost all PKCs can be proteolytically cleaved at the V3 region by the calcium-
activated protease calpain to produce a cofactor independent free catalytic subunit known 
 14
as protein kinase M (PKM).   Calpain exists as two distinct isoforms that have a low (μ) 
and high (m) requirement for Ca2+, millimolar and micromolar respectively [43; 81].  
Even though proteolysis is normally responsible for PKC downregulation, cleavage at the 
hinge region renders PKC constitutively active [82].  All PKCs except PKCδ contain 
PEST sequences (hydrophilic polypeptide segments enriched in proline (P), glutamic acid 
(E), serine (S) and threonine (T)) that target them for degradation by the 
ubiquitin/proteosome pathway.  Dephosphorylation of actived PKCs predisposes them to 
this degradation pathway [43; 83; 84].    
Oxidation is another way to regulate PKC activity.  PKCs isolated from tissues 
have been shown to be oxidized by a variety of agents including peroxide, N-
chlorosuccinimide and periodate.  This oxidation requires Fe2+ and the resultant PKC is 
constitutively active.  For oxidized cPKCs, Ca2+ and phospholipids are not required for 
this type of activation [43; 85].  Oxidation can also negatively regulate PKC activity.  N-
chlorosuccinimide and hydrogen peroxide reduce phorbol ester binding to PKC, 
indicating oxidation of the C1A domain [86].  Oxidation represents a unique type of 
regulation whereby initial oxidation causes constitutive activity and further oxidation 
causes inactivation [43].   
Yet another mode of activity regulation is nitrosylation.  PKC contains thiol 
residues which may serve as substrates for S-nitrosylation.  PKC disulphide bridge 
formation following nitrosylated thiols result in irreversible inactivation and loss of 
phorbol ester binding.  S-nitrosylation also prevents calpain access to PKC [43; 81; 87; 
88].  It was reported that 100μM peroxynitrite leads to tyrosine nitration of PKCβII and 
PKCα [89]. 
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Steroid hormone binding has also been shown to activate certain PKC isoforms.  
The C2 domain of PKCα binds aldosterone whereas the C2 domain of both PKCα and 
PKCδ bind 17 β-estradiol.  Both interactions result in PKC activation [90].  PKCs α, γ, 
and ε are activated by 1 α,25-dihydroxyvitamin D3.  In this instance, the C1 domain (most 
likely the zinc fingers) is responsible for binding, not the C2 domain.  This interaction 
mediates a steroid hormone rapid “non-genomic” response [91]. 
PKC Intracellular Distribution 
The traditional model of PKC subcellular localization comes from studies of 
PKCα.  In this model, PKCα is cytosolic in the basal state.  Upon activation, it 
translocates to the plasma membrane.  However, this is an oversimplification since PKC 
isoforms are not restricted to these two compartments.  As mentioned above, PKCβII  
translocates from the plasma membrane to the pericentron in a biphasic manner [19].  
PMA induced ceramide (formed from the salvage pathway) prevents translocation of 
PKCβII to the pericentron (a.k.a. juxtanuclear compartment) [92].  PKCs can also 
translocate to specialized membrane compartments such as lipid rafts or caveolae.  Lipid 
rafts and caveolae contain sphingolipids, cholesterol, saturated fatty acids and signaling 
proteins.  The differences between the two are that lipid rafts do not contain caveolin and 
caveolae do not contain glycosyl-phosphatidylinositol-anchored proteins.  Caveola form 
flashlike invaginations in the PM by oligomerization and association with lipid rafts.  
Caveola are detergent-resistant as opposed to lipid rafts.  PKCδ and PKCζ exert their 
signaling effect through these domains.  PKCδ is involved in ceramide production.  
Ceramide is formed in lipid rafts and is involved in raft fusion.  PKCδ activates acid 
sphingomyelinase (ASM) which hydrolyzes sphingolmyelin to ceramide [93; 94; 95].  
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This ceramide accumulation at the plasma membrane leads to recruitment and activation 
of PKCζ [96].  Several cell lines have cPKCs and nPKCs (both activated and resting) 
recovered in the caveolae fraction [19; 97; 98].    
The Golgi complex is another area where PKC can localize.  For example, PKCδ 
and PKCθ (both ceramide activated) induce apoptosis from the Golgi [99; 100].  PKCε 
modulates secretion (via binding to RACK substrate) from the Golgi complex [19; 101].   
Interleukin-3 (IL-3) treatment has been shown to induce PKCβI and PKCβII nuclear 
localization in hematopoietic cells [102].  PKCη localizes to the ER, nuclear membrane 
and the Golgi upon PMA treatment and serum starvation [103].  PKCδ activated by 
phorbol esters causes mitochondrial translocation from the cytoplasm, which causes 
cytochrome c release and subsequent apoptosis in human U-937 myeloid leukemia cells 
[104].  Lastly, PKCβII can localize to the cytoskeleton (F-actin) , which in turn increases 
its autophosphorylation [105].  Clearly, PKC intracellular localization is dependent on 
many factors including isoform, cell type, agonist treatment, etc.  Therefore, their direct 
effect (as well as indirect) would seem to extend to nearly every intracellular organelle. 
PKC Anchoring Proteins and Substrates 
The first anchoring protein discovered that could localize PKC near its intended 
substrate was RACK1 (Receptor for activated C kinase 1).  RACK1 specifically binds 
activated PKCβII with a Kd of 1nM in vitro.  This binding specificity is due to the V5 
region (as well as the C2 domain) of PKCβII which differs from PKCβI (as mentioned 
above).  However, RACK1 is not a substrate for PKCβII.  This interaction allows for 
proper localization and targeting of the substrate [106; 107; 108; 109].    An example of 
altered subcellular localization would be TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin) 
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activation of RACK1 in cerebellar granule cells.  This activation causes RACK1-PKCβII 
association and subsequent PKCβII translocation from the cytosol to membrane fraction 
[110].   
Another important example of PKCβII-RACK1 interaction that has implications 
for insulin signaling is found in CHO cells.  Here, PMA or dopamine D2 receptor agonist 
induced PKCβII activation causes its association with RACK1 and subsequent 
translocation to the Golgi apparatus.  This movement is inhibited by PLC inhibitor 
ET18OCH3 [111].  As mentioned above, PLC is needed to generate DAG and IP3 
(inositol triphosphate) for PKC activation.   
An example of a PKCβII substrate would be lamin B.  During proliferative 
stimuli in human promyelocytic (HL60) leukemia cells, activated PKCβII (via nuclear 
membrane activation factor (NMAF)) translocates to the nucleus and phosphorylates 
lamin B which leads to mitotic nuclear envelope membrane breakdown [112].   Recently, 
PKCβII was shown to phosphorylate substrate MARCKS (myristoylated alanine-rich C-
kinase substrate), perpetuating skeletal muscle cell ISGT (insulin-stimulated glucose 
transport) [113]. 
An example for PKCβII that would include both the anchor and substrate comes 
from cardiac myoctes.  Here, activated PKCβII translocates from the cytosol to the 
plasma membrane as well as the perinucleus where it binds RACK1.  This association 
brings PKCβII near the L-type calcium channels where it can phosphorylate and inhibit 
the channel [114; 115]. Regulation of L-type calcium channels is important for insulin 
release from pancreatic β islet cells [116]. 
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Anchoring proteins regulate PKC distribution but do not necessarily have to bind 
activated PKCs.  Unphosphorylated, phosphorylated but inactive and phosphorylated and 
active PKCs are all targets.  RACKs may bind active phosphorylated PKCs, but CG-NAP 
anchoring protein binds and localizes newly synthesized (unphosphorylated) PKCε to the 
Golgi/centrosome [117].  AKAP (A Kinase Anchoring Protein) position phosphorylated 
inactive PKCs near the substrate [118].  STICKs (Substrates That Interact with C Kinase) 
bind phosphorylated inactive PKCs and then release them following their 
phosphorylation [119].  PICK1 (Protein Interacting with C Kinase 1) has been shown to 
bind activated PKCα positioning it for eventual phosphorylation of GluR2 (AMPA-type 
glutamate receptor subunit 2) which results in GluR2 release from synaptic anchors and 
in receptor transport from the synaptic membrane [120].   
PKCβ Promoter 
Much of the knowledge of PKCβ promoter comes from the work of Hannun lab.  
Here, up to 2200 bp upstream of the human transcriptional start site was analyzed.  The 
region near the start site is very GC-rich (>80%) and lacks identifiable TATA or CAAT 
boxes.  TATA and CAAT elements are found further upstream at -530 and -395, 
respectively.  This is reverse of the normal order.  The most important area for promoter 
activity was -111 to -40.  Some of the factors identified in this study are included in the 
following table (Table 4): 
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Table 4.  PKCβ Promoter Transcription Factors 
Factor Binding site PKCβ promoter location 
Oct BP ATGCAAAT ATGCAAAT (-76) 
Sp1 GGGCGG GGGCGG (-94,-63) 
E12/47 GCAGGTGG GCAGCTGG (-110, -26, 
+18) 
AP2 CCCCACCCC CCCCACCCC (-330) 
CTF/NF-1 GCCAAT CCAAT (-395) 
AP1 TGAGTCA TGAGTGAC (-442) 
TFIID TATAAA TATAAA (-530) 
 
Another important discovery is that phorbol esters transcriptionally up-regulate 
the PKCβ promoter (basal promoter element) in K562 erythroleukemia cells.  Up-
regulation of the PKCβ promoter may be a way for phorbol esters to relieve the negative 
regulation that they have on PKCβ protein down-regulation [121].  The PKCβ promoter 
and its regulators need more illumination.  This is especially paramount given that a 
functional PKCβ promoter polymorphism in humans has been linked to insulin resistance 
with reduced expression of PKCβII [122].   
PKC Inhibitors 
PKCs are attractive targets for therapeutic intervention given their various cellular 
roles.  However, the plethra of interacting proteins and many secondary messenger 
systems coupled with cellular and tissue-specific variability for each PKC isozyme 
renders specific drug targeting difficult.  The following table (Table 5) from Twelves et 
al. represents the main PKC inhibitors in use today [14]: 
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Table 5.  PKC Inhibitors 
Drug Class Admin Specificity Status 
PMA Phorbol ester Intravenou
s 
Non-specific PKC activator; in a 
phase I trial in 
haematological 
malignancy 
Staurosporine Indolocarbazole Intravenou
s 
Poor 
specificity, 
inhibits other 
Ser/Thr and 
Tyr kinases 
Preclinical 
PKC412 
(midospaurin) 
Indolocarbazole Oral PKCs 
α,β,γ,δ,ε,η: 
also inhibits 
Tyr 
pathways 
Potentiates treatment 
with doxorubicin or 
vinblastine; in phase II 
trials 
UCN01 Indolocarbazole Intravenou
s 
cPKCs>nPK
Cs 
Potentiates treatment 
with cisplatin, 
mitomycin C, 
camptothecin or 5FU; in 
phase II trials 
Go6976 Indolocarbazole Intravenou
s 
cPKCs>nPK
Cs 
 
Byrostatin 1 Macrocyclic 
lactone 
Intravenou
s 
Activates 
cPKCs & 
nPKCs 
Acts as 
antagonist in 
presence of 
agonist 
Potentiates treatment 
with cytosine 
arabinoside, paclitaxel, 
tamoxifen or vincristine 
Tamoxifen Nonsteroidal 
anti-oestrogen 
Oral PKCs α,β,γ 
non selective 
 
Bisindoylmalei
mide 
Indolocarbazole Oral  PKCβ Used in treatment of 
diabetic retinopathy 
LY317615 
(enzasautaurin) 
Indolocarbazole Oral PKCβ Potentiates treatment 
with gemcitabine, 5FU, 
cisplatin or radiotherapy 
ISIS3521 
(aprinocarsen) 
Antisense oligo Intravenou
s 
PKCα Phase I and Phase II 
trials 
ISIS9606 Antisense oligo Intravenou
s 
PKCα Not developed further in 
clinic 
 
Other pertinent drugs include Ruboxistaurin (LY333531) which is a macrocyclic 
bisindolymaleimide drug developed by Eli Lilly being being tested for use as therapy in 
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diabetic macular oedema and other diabetic angiopathies, including diabetic retinopathy, 
diabetic peripheral neuropathy and diabetic nephropathy [123].  It is a competitive 
reversible inhibitor of PKCβ [124].  LY379196 is an analog of LY33531 which will be 
used in studies detailed in the RESULTS section.  The following table (Table 6) 
represents the IC50 spectrum for LY379196 [125]: 
Table 6. LY379196 Inhibitor IC50 Spectrum 
Enzyme IC50 (μM) 
PKCα 0.6 
PKCβI 0.05 
PKCβII 0.03 
PKCγ 0.6 
PKCδ 0.7 
PKCε 5 
PKCζ 48 
PKCμ 0.3 
Cyclic AMP Kinase >100 
Ca2+ -calmodulin Kinase 5 
Casein Kinase >100 
Src Tyrosine Kinase 4.4 
 
The other PKC inhibitor used is CGP53353 (4,5-Bis(4-fluoroanilino)phthalimide) 
synthesized by Novartis.  It is a selective inhibitor of both Epidermal Growth Factor 
Receptor (EGFR) as well as PKCβII.  The following table represents the IC50 spectrum 
for CGP53353 [126]: 
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Table 7. CGP53353 Inhibitor IC50 Spectrum 
CGP53353 IC50 (μM) 
EGF receptor intracellular domain 0.7 
v-abl kinase >50 
c-src kinase 50 
c-lyn kinase >150 
c-fgr kinase >150 
Csk >100 
TPK-I1B kinase >150 
Cyclic AMP-dependent protein kinase >500 
Phosphorylase kinase >500 
Protein kinase CK-1 >200 
Protein kinase CK-2 >200 
Cdc2/cyclin B >10 
PKCα 1.9 
PKCβI 3.8 
PKCβII 0.41 
PKCγ 22 
PKCδ >500 
PKCε >500 
PKCζ >500 
PKCη >500 
 
The Mochly-Rosen lab has been working on drugs that disrupt protein interaction 
domains.  First generation drugs were short peptides that bound to specific PKC RACKs 
to disrupt anchoring and subsequent function of PKC isozymes.  Second generation 
peptide design inhibits PKC binding to its substrate.  This is expected to block the 
function related to phosphorylation of that substrate without affecting PKC translocation, 
binding to RACK or phosphorylation of another substrate.  These peptides are 6-10 
amino acids long and are derived from one of the interacting domains thereby blocking 
the association of two proteins.  Even though the binding surface for PKC is large and 
flat, these peptides are highly selective and effective.  They serve as potential drugs in 
treating human disease [26].   
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Glucose Transporter 4 
Glucose is a fundamental source of energy for eukaryotic cells [127].  It is the 
precursor for the synthesis of glycoproteins, triglycerides and glycogen as well as 
providing an important source of energy by generating ATP through glycolysis.  Glucose 
is polar so it does not readily cross the hydrophobic plasma membrane.  Therefore, 
specialized carriers are needed to bring glucose into the cell [128].    The uptake of 
glucose into a cell involves a family of transport proteins called GLUTs (glucose 
transporter) which shuttle sugar across the cell surface [127].  GLUT4 is the major 
insulin-responsive glucose transporter.  GLUT4 is highly expressed in striated muscle 
and adipose tissue.  It is responsible for postprandial removal of glucose from the 
circulation [127; 129].  In the basal state, GLUT4 slowly but continuously cycles 
between the plasma membrane and other intracellular compartments.  Only 5% of total 
GLUT4 is localized at the plasma membrane in the basal state.  Insulin treatment (or 
exercise in the case of skeletal muscle) induces an acute response where within 2-3 
minutes, GLUT4 exocytosis dramatically increases concomitant with a small decrease in 
endocytosis.  At this point, 50% of the GLUT4 have been relocated to the plasma 
membrane.   Removal of the insulin signal subsequently decreases the rate of exocytosis 
and the trafficking of GLUT4 returns to basal status [127; 129; 130; 131].    Exocytosis 
and endocytosis occur without the need for continuing protein synthesis [132].  Insulin-
stimulated glucose transport (ISGT) due to irregularities in GLUT4 trafficking is severely 
disrupted in type 2 diabetes [130]. 
GLUT4, like other GLUTs (13 known), is a 12 transmembrane domain-containing 
protein [133].  Figure 11 shows GLUT insertion structure in the plasma membrane [127].  
 24
GLUT4 is widely dispersed to many organelles throughout the cell.  These include the 
plasma membrane, sorting endosomes, recycling endosomes, the TGN (trans-Golgi 
network) and vesicles that mediate the movement of GLUT4 between these 
compartments [127]. 
Molecular regulation of GLUT4 via insulin involves several discrete steps (Figure 
12) [134].  The first step would be biogenesis of GLUT4 storage vesicles (GSVs).  This is 
where the majority of GLUT4 is found and where the majority of GLUT4 translocates 
following insulin treatment (skeletal muscle and 3T3-L1 adipocytes) [135].  The second 
step would be translocation.  Translocation is thought to involve cytoskeletal elements 
such as actin and microtubules [134].   In 3T3-L1 adipocytes, cortical actin 
remodeling/polymerization and well as actin comet tailing (representative of actin-based 
motility) on GLUT4-containing vesicles was critical for insulin-stimulated translocation 
[136; 137].  Also in 3T3-L1 adipocytes, the kinesin motor (moving toward plus end 
[plasma membrane] of microtubule) was critical for GLUT4 translocation [138].  The 
third step is tethering.  This is a low-affinity interaction between GSVs and the plasma 
membrane arbitrated by a tethering complex [134].  Tethering involves what is referred to 
as the “exocyst complex.”  This complex is responsible for the initial interaction of 
GLUT4 vesicles with the plasma membrane in 3T3-L1 adipocytes.  Exo70, Sec6 and 
Sec8 are some of the recently identified components of the exocyst complex [139].  The 
fourth step is docking.  This is the assembly of the trans SNARE (soluble N-
ethylmalemide-sensitive factor attachment protein (SNAP) Receptor) complex.  It is the 
final committed step before fusion between GSVs and the plasma membrane [134].  In 
3T3-L1 adipocytes, VAMP2 (vesicle-associated membrane protein 2) and 
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VAMP3/cellubrevin represent v-SNARE proteins (protein complexes in the vesicle 
compartment) and syntaxin 4 represents t-SNARE proteins (receptor complex at the 
plasma membrane) [140].  The fifth step is fusion.  This is where the lipid bi-layers of the 
GSV and the PM amalgamate [134].  Frohman et al. has shown that activated PLD1 
(phospholipase D 1) plays a rate-limiting step in insulin-stimulated fusion of GSVs with 
the PM in 3T3-L1 adipocytes [141].  Corroborating this finding is the observation that 
PA (product of PLD1 mediated hydrolysis) serves as an anchor for mammalian 
components of the SNARE complex [142].  PA has also been purported to act as a 
fusogenic lipid by lowering the activation energy for membrane bending during 
generation and expansion of fusion pores [143].  PA is also capable of activating 
phosphatidylinositol 4-phosphate 5-kinase thereby increasing the levels of 
phosphatidylinositol 4,5-bisphosphate, critical for exocytosis [141].  In L6 skeletal 
muscle cells, insulin-stimulated PKCβII causes retention of PLD1 at the PM and 
subsequent fusion of GLUT4 [113].  GLUT4 can translocate and fuse with both caveolae 
and non-caveolar lipid rafts [144].  The sixth step is endocytosis [134].    GLUT4 has 
been shown to be internalized via clathrin-mediated endocytosis (CME).  This has been 
demonstrated in 3T3-L1 adipocytes and L6 myotubes [132].  Interestingly, caveolae 
associated GLUT4 internalized faster than non-caveolar lipid raft after removal of insulin 
[144]. 
3T3-L1 adipocytes have been used as the gold standard for GLUT4 trafficking.   
In these cells, GLUT4 is mostly located in the perinuclear region and the cytoplasm to a 
lesser extent [134; 145].  Insulin induces a 10-fold increase in glucose uptake.  Rat 
adipocytes have an even greater response (20-fold increase in glucose uptake) whereas 
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human adipocytes only respond with a 2-3 fold increase in insulin-stimulated glucose 
uptake.  In L6 myotubes (the only skeletal muscle cell line that expresses GLUT4), 
GLUT4 is expressed mostly in perinuclear regions as well as being dispersed along 
discrete bodies in the cytosol.  Insulin induces a 2-fold increase in glucose uptake in this 
cell line [145]. 
In 3T3-L1, as mentioned above, most GLUT4 reside in GSVs near the TGN.  
Even before GLUT4 is expressed in differentiated adipocytes, there is a reservoir 
compartment (what will eventually be the GSV).  A protein called insulin-responsive 
aminopeptidase (IRAP) is localized to this storage compartment and has very similar 
trafficking to that of GLUT4.  Once GLUT4 is expressed, it enters this storage 
compartment [130].  Regardless of whether insulin stimulation has occurred or not, 
GLUT4 and IRAP are not retained at the plasma membrane.  They are rapidly 
internalized with half times of 3-10 minutes [130; 146].  GSV formation requires Golgi-
localized γ-ear-containing Arf-binding protein (GGA) in order to sort GLUT4 from the 
TGN [147].  Sortilin (also part of the TGN and endosomal membrane) is also necessary 
for GSV formation as well as for GLUT4 protein stability [148].  Sortilin most likely 
serves as the cargo adaptor linking GLUT4 to GGA coated transport vesicles.  Sortillin 
does this by binding to GGA′s VHS cargo-binding domain with its VHS consensus 
binding motif (DxxLL) [129].  In differentiating adipocytes, sortillin is expressed prior to 
GLUT4 [148]. 
The GLUT4 N-terminal FQQI domain and C-terminal LL domain are both 
required for proper trafficking of GLUT4.  The FQQI domain is important in transferring 
GLUT4 away from the endosome system [149].  The LL domain is important in shuttling 
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GLUT4 between the TGN and GSVs [150].  Both domains are required for proper 
endocytosis [130].  Trafficking steps of GLUT4 can be summarized by Figure 13 [130].  
It is important to note that the perinculear reticular GLUT4 storage compartment and 
dispersed vesicular GLUT4 storage compartment are further sub-classifications of GSVs.   
It is also noteworthy to point out that v-SNARE VAMP2 (in addition to IRAP) 
colocalizes with GLUT4 in PR-GSC.  The ratio between the two proteins is kept fairly 
constant in the DV-GSC.  This would suggest a role for VAMP2 in direct fusion with the 
PM [151].  aPKCs have been suggested to serine phosphorylate VAMP2, possibly 
localizing GSVs at sites of actin remodeling and subsequent PM insertion [152]. 
Figure 13 is not a hundred percent accepted model.  There are two main models 
concerning GLUT4 storage and cycling in 3T3-L1 adipocytes [153].  Model 1 (which 
more closely resembles Figure 13) asserts that GLUT4 from every compartment 
eventually reaches the PM in the basal state, GLUT4 intracellular storage is dynamic and 
that GSV is distinct from the transferrin-positive TGN [154].   Model 1 also asserts that 
insulin promotes two routes for GLUT4 mobilization towards the PM.  The direct route 
comes from the GSV.  The indirect route goes from the GSV to the ERC to the PM [153].   
The two routes possible to get to the PM are supported by the presence of VAMP2 in 
insulin-dependent GLUT4 recycling [140; 155].  Model 2 proposes that only a fraction of 
GLUT4 reaches the PM in the basal state, that insulin increases GLUT4 amount available 
for translocation, and that part of the transferrin receptor negative GLUT4 compartment 
interfaces with the TGN [156].  Increasing insulin causes more GLUT4 to accumulate at 
the non-cycling pool, which is then translocated to the PM through a single exit route 
(GSVs to PM).  The non-cycling pool contains few “latent GLUT4 molecules” which are 
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not mobilized in response to insulin.  It is hypothesized that these latent GLUT4 
molecules are synthesized early in cellular life and exhibit non-insulin responsiveness 
[157].  The main differences between the two models are the extent to which GLUT4 
recycles in the basal state, the presence of a static/latent pool of GLUT4,  the TGN being 
a storage site for GLUT4 and the number of routes insulin-stimulated GLUT4 can take to 
get to the PM [153]. 
Akt 
Protein Kinase B (Akt) belongs to a family of ubiquitously expressed 
serine/threonine kinases that was discovered by cloning using a probe specific for PKA 
[158].  Akt shares 65% homology with PKA and 77% homology with PKC.  Three 
mammalian isoforms exist, α (1), β(2), γ(3) (Figure13), which are products of different 
genes [159].    The three isoforms share 90% homology between each other [160].  All 
three isoforms contain an N-terminal PH domain, which is a roughly 100 amino acid 
domain that can bind phosphatidylinositol lipids  (e.g. PIP2) as well as PKC and other 
proteins during signaling [161].  Downstream of the PH domain is the catalytic domain 
and finally the C-terminal domain [159].   Rat Akt3 contains a truncated C-terminal 
domain whereas human Akt3 contains a full-length C-terminal domain [160; 162].  
 Akt was identified as an oncogene early on.  First, Akt1 amplification was 
detected in gastric adenocarcinoma [163].  It was then shown that Akt2 was amplified in 
two ovarian carcinoma cell lines [164].  The breakthrough in Akt research came using the 
PI3K inhibitor, wortmanin.  This led to the discovery that Akt was a downstream target 
of PI3K activated by PDGF and EGF [165; 166].  The lipid-binding PH domain of Akt 
was essential for this PI3K-mediated activation in response to these ligands [166].    
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Binding of the PH domain to lipids is not the only way Akt is activated.   Phosphatase 
inhibitor experiments showed that Akt activity was controlled by reversible 
phosphorylations on both serine and threonine residues [167].  The next step was 
showing that insulin stimulation resulted in Akt phosphorylation at residues T308 and 
S473 [168].  At this point, complete Akt activation necessitates lipid binding via the PH 
domain as well as phosphorylation by at least one upstream kinase.  Previous 
observations indicate that Akt kinase activity requires PI3K and that Akt is potently 
activated by products of PI3K, PIP2 and PIP3.  This led to the discovery of PDK1 (3-
phosphoinositide-dependent protein kinase 1) [169].  This ended up being the kinase 
which is responsible for phosphorylation of Akt at T308.  However, the kinase 
responsible for phosphorylating Akt on S473 has remained controversial and only 
recently been proposed (mTORC2).  Mutation of either T308 or S473 in Akt1 does not 
prevent the other residue from being phosphorylated in response to insulin, suggesting 
the phosphorylations can occur independently [170].  Akt phosphorylated at only the 
PDK1 site has 10% of the activity compared to when it is phosphorylated at both T308 
and S473 [171].  However, the threshold of activity required for substrate 
phosphorylation may differ so that Akt phosphorylated at only T308 may be sufficiently 
active to phosphorylate certain targets [172].  Figure 15 illustrates the mechanism of Akt 
activation [57; 169; 173; 174; 175].  A controversial additional pathway for Akt 
activation has been proposed for skeletal muscle cells.  In this two-step model for Akt 
activation, insulin triggers the assembly of β-arrestin-2, c-Src and Akt.  This allows c-Src 
to phosphorylate Akt on Tyrosine 315 (Y315) and Y326 which is required for 
downstream phosphorylations of Akt at S473 and T308.  This may not apply to fat cells 
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because in muscle and liver, but not fat, β-arrestin-2 expression is reduced ~50% in 
insulin-resistant animal models [176]. 
 As with any kinase, there is a mechanism to turn it on as well as one to turn it off.  
Recently discovered PHLPP proteins put the brakes on Akt and PKC activation.  PHLPP 
is a Ser/Thr-specific phosphatase (PH domain leucine-rich repeat protein phosphatase).  
Once Akt is phosphorylated, its activity no longer relies on secondary messengers.  In 
contrast, PKC is only active when bound to DAG.  Dephosphorylation of PKC would 
promote degradation [177].    PHLPP1 and PHLPP2 specifically dephosphorylate the 
hydrophobic motif (S473) of Akt, resulting in decreased activity.  PHLPP needs the PDZ-
binding motif in order to accomplish this dephosphorylation [177].  PHLPP1 and 
PHLPP2 dephosphorylate the hydrophobic motif of cPKCs and nPKCs but not aPKCs 
because they contain a Glutamic acid at this position [171].  As alluded to earlier, cells 
deficient in the mTORC2 complex have decreased PKC phosphorylation at the 
hydrophobic motif which suggests that this complex contributes to phosphorylation of 
PKC at this site [178].  This possibly puts PHLPP in opposition of mTORC2 [177]. 
There is abundant evidence that Akt plays a role in insulin-dependent glucose 
disposal by directing GLUT4 vesicles to the PM.  Initially it was reported that insulin 
rapidly and persistently activates Akt in traditional target tissues such as muscle and fat 
[179].  The connection between Akt and insulin′s metabolic actions was firmly 
established when constitutively active Akt mimicked insulin in eliciting high levels of 
glucose transport and GLUT4 translocation in adipocytes in the absence of insulin [180].  
More specifically, insulin causes Akt association with GLUT4 vesicles in rat adipocytes 
which results in phosphorylation of associated proteins [181; 182].   Suspected proteins 
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phosphorylated by Akt include sortilin and SCAMPs (secretory carrier-associated 
membrane proteins) which are involved in membrane trafficking and fusion of GLUT4 
[182].  SNARES are also thought to be an important Akt substrate [183].  Inhibiting Akt 
activity by antibodies, substrate peptides and dominant-negative constructs partially 
blocks insulin-stimulated GLUT4 translocation in fat and muscle [184; 185].   
Insulin is responsible for a host of outcomes, besides glucose homeostasis, that 
are mediated at least in part via Akt.  For instance, insulin mediates vasodilation of blood 
vessels promoting peripheral tissue glucose disposal [186].  Akt is able to exert its effect 
here by phosphorylating/activating endothelial nitric oxide (NO) synthase, thus 
increasing NO production [187].    
Insulin mediates protein synthesis in muscle and fat cells by enhancing initiation 
and elongation steps in protein translation.  Evidence suggests that Akt modulates the 
activity of translational components [179].  Constitutively active Akt increases protein 
synthesis in L6 muscle cells and 3T3-L1 adipocytes [188; 189].    Insulin-stimulated 
protein synthesis is blocked by dominant inhibitory Akt mutant in 3T3-L1 adipocytes 
[190].   
Lipogenesis (converting incoming sugar to fatty acids) is an insulin regulated 
event.  Akt is thought to play a crucial role by inhibiting GSK-3 (glycogen synthase 
kinase 3).  GSK-3 normally phosphorylates ATP citrate lyase (decreasing its activity), an 
enzyme that catalyzes the conversion of citrate and CoA to acetyl-CoA and oxaloacetate 
in the cytosol.  This step is a major source for the biosynthesis of fatty acids, cholesterol 
and acetylcholine [191].  In addition, Akt also increases the transcription of fatty acid 
synthase, an enzyme that catalyzes several steps converting malonyl-CoA and acetyl-
 32
CoA to long-chain fatty acids [192].  Constitutively active Akt has been shown to induce 
high levels of lipogenesis in quiescent 3T3-L1 adipocytes [193].  At the same time Akt is 
turning on genes for lipogenesis, it has been reported to help block lipolysis in adipocytes 
by inhibiting hormone-sensitive lipase (HSL).  HSL is activated by PKA 
phosphorylation, and PKA activity is activated by cAMP.  Use of a dominant-negative 
mutant as well as constitutively active kinase showed Akt reduces cAMP concentrations 
by stimulating cyclic nucleotide phosphodiesterase PDE-3B via phosphorylation [193; 
194].   
Insulin promotes glycogen synthesis from the glucose that is driven into the cell.  
It does this by activating glycogen synthase (GS) which adds glucosyl groups to growing 
polysaccharide chains, which is the final step in glycogen synthesis.  Akt is able to exert 
its effect on this pathway.  GS is negatively regulated by C-terminal serine 
phosphorylations by GSK3.  Akt is able to inhibit GSK3, thus relieving the inhibitory 
phosphorylation and activating GS [179].  In adipocytes, a GSK3β mutant that is 
insensitive to Akt results in insulin-stimulated GS suppression [195].  Similarily, 
constitutively active Akt in L6 skeletal muscle dramatically blocks GSK3 activity and 
can activate GS without insulin.  In the same cells type, dominant-negative Akt resulted 
in over 50% inhibition of insulin-stimulated GS activation [189; 196].   
Blood sugar levels are maintained by insulin through promotion of glucose uptake 
as well as suppressing hepatic glucose output.  The liver is the main organ to respond to 
insulin in terms of reducing its glucose production.  Akt is thought play a role here by 
suppressing glycogenolysis but promoting glycogen synthesis (likely similar to skeletal 
muscle and fat).   Akt may exert influence on PEPCK (phosphoenolpyruvate 
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carboxykinase) and G6Pase (glucose-6-phosphatase).  PEPCK catalyzes the early 
committed step in gluconeogensis and G6Pase regulates the terminal step for both 
gluconeogenesis and glycogenolysis before glucose is released from the liver.  There is 
still controversy as to whether Akt really inhibits these genes [179].   Very recently, Akt 
activation was shown to stimulate APPL1 (Adaptor protein, phosphotyrosine interaction, 
PH domain and leucine zipper containing 1), which potentiates insulin-stimulated 
inhibition of hepatic glucose output [197].   In 3T3-L1 adipocytes, the interaction of Akt 
with APPL1 is required for insulin-stimulated GLUT4 translocation, even though insulin 
causes their dissociation [198]. 
A role for Akt in pancreatic cells has also been proposed.  This is because 
pancreatic regeneration is associated with an increase in IRS2 and activated Akt in 
proliferating duct cells [199].  Overexpression of active Akt1 in β cells of transgenic mice 
leads to a significant expansion of β-cell mass (cell number and cell size) [200].  Insulin 
signaling via PI3K and Akt was critical in preventing ER stress and thus β cell 
dysfunction [201].   
As if Akt did not do enough, it has also recently been implicated (Akt1) in 
adipocyte differentiation [202]. Figure 16 summarizes the pivotal role Akt plays across 
various tissues [179]. 
Physiological relevance of Akt in insulin resistance, and thus T2DM, extends 
beyond cell culture.  Akt activity has been found to be reduced in adipocytes [203] and 
muscle [204] obtained from T2DM patients .  However, there have also been 
antagonizing reports that Akt activity is normal from diabetic muscle tissue where PI3K 
activity is reduced [205].  These contradictory findings have also been reported in rodent 
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models of obesity and insulin resistance [179].  Mice with adipocyte insulin resistance 
had been found to have reduced IRS and PI3K activity but normal Akt activity [206].    In 
Zucker rats that were insulin resistant obese, activation of PI3K was much more impaired 
than either Akt1 or Akt2.  In adipocytes, Akt2 activation actually increased slightly [207].  
Etiology of T2DM is not well understood and this may have something to do with the 
heterogeneity of results.  However, targeted disruption of Akt2 (expressed highly in 
muscle and fat) in mice presents a phenotype resembling human impaired glucose 
tolerance [208].  Akt2 knockout mice display severe impairment in whole-body glucose 
disposal [179].  Interestingly, Akt1 knockout mice do not display insulin resistance [209].  
This suggests distinct physiological roles for different Akt isoforms.   
Akt can regulate alternative splicing by acting as an SR protein kinase and 
directly phosphorylating the RS domain [210].  This has a major impact on the insulin 
signaling cascade as Akt can phosphorylate SRp40 [211] thus regulating PKCβ 
alternative splicing.  Akt can also regulate other SR kinases such as Clk/Sty (CDC-like 
kinase 1) (LAMMER family of protein kinases) giving it an even broader role in insulin- 
mediated alternative splicing [212]. 
Insulin Signaling and Involvement of PKC, GLUT4 and Akt 
To give a broad general overview, insulin signaling involves two distinct 
branches.  One defined by the Rho-family GTPase TC10 (also referred to as CAP/Cbl 
pathway) and the other by phosphatidylinositol 3-kinase (PI3K) [213].  Briefly, the 
insulin receptor (IR) is a member of the family of transmembrane receptors with intrinsic 
tyrosine kinase activity [214].  Some or all of the insulin receptor is constitutively bound 
to lipid rafts [215].  The mature IR is composed of two extra-cellular α- and two 
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transmembrane β-subunits disulfide linked into an α2β2-heterotetrameric structure [216].  
Alternative splicing gives rise to two IR isoforms, IR-A and IR-B [216].  IR-A is 
expressed in the developing fetus as well as adult pancreatic β-cells, whereas IR-B is 
expressed in adult muscle, adipose and liver.  IR-A is regulated by IGF-II (insulin-like 
growth factor-II) whereas IR-B is regulated by insulin.  Insulin binds to the extracellular 
α-subunits which induces a conformational change that allosterically regulates the 
intracellular β-subunit tyrosine kinase domain.  Ensuing is a series of intermolecular 
trans-autophosphorylations generating multiple phospho-tyrosine sites [133; 216].  
Tyrosine phosphorylation at the juxtamembrane Y960 is required for binding IRS1-4.  
This is important for propagating the insulin signaling cascade.  Phosphorylation at 
Y1146, Y1150, Y1151 in the kinase activation domain relieves pseudosubstrate 
inhibition further enhancing the tyrosine kinase activity [216].  Other scaffolding proteins 
recruited to the IR are Gab1, Shc, SIRPS, Cbl and APS [133].  IRS2 knockout cells show 
a major defect in insulin-stimulated glucose transport [217].  IRS is able to bind IR via its 
C-terminal PH domain and  phosphotyrosine-binding domain (PTB) [218].  This 
facilitates binding to PI3K, which has a pivotal role in metabolic and mitogenic actions of 
insulin and IGF1 [219].  Because of PI3K′s crucial role in propagating the insulin 
signaling pathway, it deserves further digression.   
PI3Ks catalyze the transfer of the γ-phosphate of ATP to the D3 position of 
phosphoinositides.  PI3Ks can be grouped into three classes based on substrate specificity 
[220].  Only class I PI3Ks have been shown to activate Akt in cells.  In cells, class I 
PI3Ks prefer PtdIns(4,5)P2 as a substrate.    The resulting PtdIns(3,4,5)P3 can then go on 
to give rise to PtdIns(3,4)P2 via 5′ inositol phosphatases.  Class I PI3Ks are heterodimers 
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made up of a roughly 110 kDa catalytic subunit (p110) and an adaptor/regulatory subunit.  
Class I PI3Ks that bind tyrosine kinases and heterotrimeric G-protein coupled receptors 
are referred to as Class IA and Class IB PI3Ks respectively.  Class IA PI3Ks are diverse 
with three catalytic p110 isoforms (p110α, p110β and p110δ, each encoded by different 
genes) and seven adaptor proteins (generated by alternative splicing of three genes: p85α, 
p85β and p55γ) [170].  The p85 adapter subunit, starting from the N-terminus, contains a 
Src homology 3 (SH3) domain, a breakpoint-cluster-region homology (BH) domain 
flanked by two proline-rich regions and two C-terminal SH2 domains spaced by an inter-
SH2 (iSH2) region.  The iSH2 mediates tight binding between p85 to the catalytic 
subunit [221; 222; 223].  The catalytic subunit possesses intrinsic serine kinase activity.  
The regulatory subunit p85α S608 can be phosphorylated by the p110α catalytic subunit 
which reduces lipid kinase activity [224].  P110δ can not phosphorylate regulatory 
subunits but can undergo autophosphoryaltion [224].  As far as insulin stimulation is 
concerned, class IA PI3K activation is accomplished by translocation to the plasma 
membrane and binding with its two SH2 domains (one N-terminal, the other C-terminal) 
to tyrosine-phosphorylated pYMXM and pYXXM motifs on IRS [220; 225].   
As mentioned, PI3K produces PIP3, which binds to the PH domain of a variety of 
signaling molecules altering their activity and/or subcellular localization [226].  
Phosphatidylinositol-3-phosphates regulate three main classes of signaling effectors: the 
AGC family of serine/threonine protein kinases (which include PKCs), guanine 
nucleotide-exhange proteins of the Rho family of GTPases and the TEC family of 
tyrosine kinases.  PI3K might also activate the mTOR/FRAP pathway and be involved in 
PLD1 regulation, which leads to hydrolysis of phosphatidylcholine and increases in PA 
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and DAG [225; 227].  The best characterized AGC target of PI3K is phosphoinositide-
dependent kinase 1 (PDK1), one of the serine kinases that phosphorylates and activates 
Akt.  PDK1 has an N-terminal kinase domain and a C-terminal PH domain which has a 
higher affinity (in vitro) for PtdIns(3,4,5)P3 and PtdIns(3,4)P2 than other PIs such as 
PtdIns(4,5)P2.  Its affinity for PIs is higher than that of Akt [170].  PDK1 was discovered 
for its ability to phosphorylate Akt Thr 308 in vitro [169].  In unstimulated cells, PDK1 is 
mainly cytosolic with relatively little PM localization [228].    With agonist stimulation 
(e.g. insulin) PDK1 phosphorylates Akt1 on T308 and the equivalent residues in Akt2,3.  
This phosphorylation of Akt is enhanced over 1000-fold in the presence of lipid vesicles 
containing miniscule amounts of PtdIns(3,4,5)P3 or PtdIns(3,4)P2 but not PtdIns(4,5)P2 or 
other PIs [169].  Akt binds with its PH domain to  PtdIns(3,4,5)P3 or PtdIns(3,4)P2 which 
alters its conformation so that T308 becomes accessible to PDK1 [170].   
For a long time, there was no consensus as to the identity of the kinase “PDK2” or 
“hydrophobic motif kinase” responsible for S473 phosphorylation of Akt.  Several 
candidates had been proposed including PDK1, integrin-linked kinase (ILK) and Akt 
itself and DNA-PKcs.  However, the identity of the kinase complex responsible has now 
been firmly established as mTORC2 [174; 229].  Due to the pertinence of mTOR in this 
study, it necessitates further digression.   
mTOR is a member of the phosphoinositide 3-kinase-related kinase (PIKK) 
family of proteins [230].  mTOR is a target of rapamycin, a macrolide antibiotic and 
immunosuppresent of the phosphoinositide kinase family.  The mTOR kinase exists in 
two complexes, mTORC1 and mTORC2.  mTORC1 consists of mTOR, mLST8, 
RAPTOR (regulatory-associated protein of mTOR) and PRAS40 (proline-rich Akt 
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substrate 40 kDa).  RAPTOR positively regulates mTOR activity and acts as a scaffold 
recruiting mTORC1 substrates.  PRAS40 negatively regulates mTORC1 activity 
depending on its phosphorylation state. [231]. Activated mTOR can phosphorylate 
PRAS40 relieving mTORC1 of substrate competition [232].  The best known targets of 
mTORC1 include ribosomal protein S6 kinases (S6K1 and S6K2 in mammals) and 
eukaryotic initiation factor 4E (eIF-4E)-binding protein 1 (4E-BP1).  S6K1 is activated 
by phosphorylation and regulates ribosomal protein translation and ribosome biogenesis.  
S6K1 also acts as a feedback inhibitor of insulin induced PI3K-Akt pathway.  It does this 
by directly phosphorylating and inhibiting IRS1 on S270.  Phosphorylation of 4E-BP1 by 
mTOR decreases 4E-BP1 affinity for eIF-4E leading to translation of cap-dependent 
mRNAs [231; 233].   
The mTORC2 protein complex consists of mTOR, RICTOR (rapamycin 
insensitive companion of mTOR), mLST8/GβL (mammalian LST8 /G-protein β-subunit 
like protein), SIN1 (stress-activated-protein-kinase-interacting protein 1) and Protor 
(protein observed with Rictor) (collectively called mTORC2).  Rapamycin acutely 
inhibits mTORC1 but is needed for much longer incubations to have an effect on 
mTORC2 [234].  mTORC2 can phosphorylate Akt S473 in 3T3-L1 adipocytes.  This 
along with phosphorylation of T308 results in fully activated Akt [174; 234; 235].  
mTORC2 also phosphorylates Akt at the turn motif T450 [54; 55].  mTORC2 regulates 
organization of the actin cytoskeleton through phosphorylation of PKCα [236].    SIN1 
maintains mTORC2 complex integrity thereby regulating phosphorylation of Akt S473 
[229; 237].    It is not known how the interaction between mTORC2 and Akt is facilitated 
[238].  Alternative splicing of mSin1 gives rise to at least five isoforms, three of which 
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assemble into mTORC2 to generate three distinct mTORC2s.  Two of these mTORC2s 
are regulated by insulin [239].  mTORC2 is also regulated by two tumor suppressors 
called tuberous sclerosis complex protein 1 and 2 (TSC1 and TSC2).  Within the TSC1-
TSC2 complex, TSC1 stabilizes TSC2, while TSC2 acts as a GTPase activating protein 
(GAP) for the small GTPase Rheb (Ras homolog enriched in brain).  GTP bound Rheb 
activates mTORC1 which is involved in promoting cell growth and proliferation through 
its main substrate ribosomal S6 kinases (S6K1 and S6K2).  The mTORC1 complex is 
inhibited if the TSC1-TSC2 complex is active by stimulating the conversion of Rheb-
GTP to Rheb-GDP.  The TSC1/TSC2 complex activates mTORC2 and thus Akt in a 
manner that is independent of Rheb, mTORC1 and mTORC1-mediated feedback effects 
on PI3K.  Endogenous TSC1 and TSC2 co-immunoprecitate with exogenously expressed 
mTOR [234; 240].  However, the TSC1-TSC2 complex can only associate with 
mTORC2, not mTORC1 [240].  In response to growth factors, Akt phosphorylates TSC2 
directly.  Phosphorylation of TSC2 impairs the ability of the TSC1-TSC2 complex to act 
as a GAP towards Rheb, which allows Rheb-GTP to accumulate and potently activate 
mTORC1.  This will eventually lead to negative regulation of Akt because activated 
mTORC1 will target S6K1/2 which will block insulin signaling as mentioned above 
[234].  DEPTOR (dishevelled, egl-10, pleckstrin (DEP) domains and interacts with 
mTOR) is an mTOR interacting protein whose expression is negatively regulated by 
mTORC1 and mTORC2.  DEPTOR normally functions to inhibit mTORC1 and 
mTORC2 pathways.  However, when overexpressed, it relieves the negative feedback 
inhibition of Akt, thus causing Akt activation [241].   
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Many additional factors converge on mTORC1 (including mTORC2) thereby 
regulating protein synthesis as well as insulin signaling.  Akt phosphorylates TSC2 at 
S939, S981 and T1462.  The serine phosphorylations allow binding of the cystolic anchor 
14-3-3.  This disrupts binding between TSC1 and TSC2.  Akt can phosphorylate PRAS40 
at T246 resulting in dissociation of PRAS40 from mTORC1.  PRAS40 is also a substrate 
of both mTORC1 and mTORC2.  S183 and S221 are phosphorylation residue targets of 
mTORC1 and mTORC2, respectively.   TNFα signaling to Akt, induces IKKα (inhibitor 
of nuclear factor-κB kinase α), which is able to activate Raptor and thus mTORC1.  
IKKβ, also downstream of TNFα signaling pathway, is able to inhibit TSC1 by 
phosphorylation at S487 and S511 [230].  mTOR is able to sense cellular energy levels 
by monitoring cellular the ATP:AMP ratio via AMP-activated protein kinase (AMPK) 
[242].  Cellular stress activates AMPK, especially when AMP levels are high.  AMPK 
(phosphorylated and activated by LKB1) phosphorylates TSC2 at S1345, increasing its 
GAP activity towards RheB-GTP, inhibiting mTORC1.  AMPK can also phosphorylate 
Raptor at S792, leading to 14-3-3 binding and inhibition of mTORC1 [230].  The Wnt 
pathway, involved in cell growth control, is linked to mTORC1 activation.  Wnt signaling 
inhibits GSK3β.  GSK3β phosphorylates and inhibits TSC2 on S1341 and S1337 (after 
priming phosphorylation of TSC2 on S1345 by AMPK).  Akt and RSK (ribosomal S6 
kinase) can also phosphorylate and inhibit GSK3β.  Hypoxic conditions work to inactive 
mTORC1 through hypoxia-inducible factor 1α (HIF1α) and REDD1.  REDD1 competes 
with TSC2 for 14-3-3 binding.  Low nutrient conditions inhibit mTORC1.  Rag proteins 
(Ras small GTPases comprised of four members) are capable of activating mTORC1 in 
an amino acid sensitive manner.  RAG proteins form heterodimers of RAGA or RAGB 
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with RAGC or RAGD.  During conditions where there are sufficient amino acids GTP-
bound RAG complex activates mTORC1, likely by changing the subcellular localization 
of mTORC1 and bringing it into close proximity with RheB.  The Ras-ERK pathway 
activates mTORC1 by phosphorylating TSC2 at S664 and S1798 by ERK and RSK 
(ribosomal S6 kinase), respectively.  RSK can also activate Raptor via phosphorylations 
at S719, S721 and S722.  Some of the many pathways converging on mTORC1 are 
displayed in Figure 17 [230; 242].   
The conversion of PA from PC by PLD1 is integral for both mTORC1 and 
mTORC2 activation.  Structural studies have shown that PA binds to the FRB (FKBP 
rapamycin binding) domain of mTOR.  PA is in competition for this site with rapamycin 
which is associated with FKBP12 (FK506 binding protein 12).   PLD1 through PA 
facilitates formation of mTOR complexes.  mTORC2 binds PA more strongly than 
mTORC1 which explains why higher concentrations of rapamycin are needed to inhibit 
mTORC2 versus mTORC1 [243]. 
Growth factors stimulate mTORC2 activity with some mTORC2 subunits 
undergoing phosphorylation.  The kinases responsible for these phosphorylations are 
unknown.    There is preliminary evidence that Ras may be responsible for some of these 
phoshorylations [238].  mTORC1 and mTORC2 activity can be distinguished based on 
the phosphorylation status of mTOR.  Activated mTOR is phosphorylated between its 
catalytic domain and FATC (Frap, ATM, TRRAP, C-terminal) domain near the C-
terminus at T2446, S2448 and S2481 [61].  T2446 is phosphorylated in response to 
nutrient availability [244].  mTORC1 is predominantly phosphorylated on S2448 while 
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mTORC2 is predominantly phosphorylated at S2481.  S2481 is a rapamycin-insensitive 
autophosphorylation site [61; 245].   
Activated Akt has many target substrates involved in glucose homeostasis.  
SNARE associated protein synip has been identified as an Akt substrate.  
Phosphorylation of synip via Akt might allow for insulin-dependent dissociation of synip 
from syntaxin 4 which would allow SNARE pairing between syntaxin 4 and VAMP2 
thereby facilitating GSV fusion with the PM in adipocytes [246; 247].   A very promising 
Akt substrate was identified using a phosphor Ser/Thr Akt substrate (PAS) antibody.  
This protein was AS160 (Akt substrate of 160kDa), originally named TBD1D4 [246].  
AS160 is abundant in muscle and adipose tissues [246; 248].  There are six putative Akt 
substrate motifs on mouse AS160.  In 3T3-L1 adipocytes, insulin stimulated (likely 
through Akt) phosphorylation in five of the six putative Akt substrate motifs (S318, 
S341, S570, S588, T642, T751) [249].  In muscle cells, insulin, AMPK agonists or 
contractile activity have been shown to cause AS160 and GLUT4 translocation [250].  
AS160 contains two N-terminal PTB domains and a C-terminal Rab-GAP (Rab GTPase-
activating protein) domain.  This led to the hypothesis that Akt-mediated AS160 
phosphorylation (and inactivation) regulates GLUT4 translocation via regulation of GAP 
activity towards Rab proteins [251].   A second Rab-GAP substrate of Akt is TBC1D1 
(tre-2/USP6, BUB2, cdc16 domain family member 1), which regulates insulin-stimulated 
GLUT4 trafficking [252].  RUVBL2 (RuvB-like protein 2) has been identified as an 
AS160 substrate critical for insulin-stimulated phosphorylation of AS160 in 3T3-L1 
adipocytes [253].  The current thinking is that Rab-GAP activity promotes hydrolysis of 
GTP to GDP by Rab proteins on GSVs.  In the inactive form, GDP-bound Rabs are 
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unable to cause GLUT4 translocation to the PM.  However, with insulin treatment, 
AS160 is phosphorylated which leads to inactivity of Rab-GAP.  This would enable 
GSV-associated Rabs to load up on GTP and elicit GLUT4 translocation.   So far, the 
Rab14 isoform has emerged as the most likely Rab responsible for GLUT4 translocation 
in 3T3-L1 adipocytes [252].  Rab 10 has also been implicated in adipose cells [254].  In 
L6 muscle cells, the AS160-substrate Rab8A isoform seems to be involved in GLUT4 
translocation [255].  Rab8A and Rab10 are both able to bind myosin Va and Vb, 
molecular motors responsible for localization of Rabs and GLUT4 translocation [254].  
Munc18c is a putative target of Akt-controlled Rab activity.  Munc18c is a member of the 
Sec1p/Munc18 (SM) family of proteins.  Munc18c is thought to keep syntaxin4 (t-
SNARE) in a closed conformation.  Rab activity causes dissociation of Munc18c from 
syntaxin4 allowing syntaxin4 to interact with VAMP2 (v-SNARE) and SNAP23 (23kDa 
synaptosomal-associated protein) (t-SNARE) [129; 183].  Recent in vitro experiments 
also point to a Mucn18c role in fusion by anchoring VAMP to syntaxin [129].   
  In adipocytes AS160 phosphorylation at Thr642 promotes interaction with 14-3-
3 protein.  This interaction is critical in insulin-stimulated (Akt-dependent) suppression of 
AS160′s inhibitory role in GLUT4 translocation in adipocytes [252; 256].  14-3-3 binding 
to AS160 in L6 cells is not enhanced as a result of insulin-stimulation. However, AMPK-
mediated phosphorylation of AS160 Ser237 did enhance binding [257].   
Using the same PAS antibody mentioned above, phosphoinositide 5-kinase 
PIKfyve (phosphoinositide kinase for five position containing a Fyve finger) was 
identified as a potential Akt substrate.  It is phosphorylated at S318 (inactivated) in 
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response to insulin.  This effect is blocked by wortmannin.  Inactivated PIKfyve is 
associated with enhanced insulin-stimulated GLUT4 translocation [258].   
In addition to Akt and its downstream effectors, PKCλ/ζ is downstream targets of 
PI3K signaling that have been suggested to play a role in insulin-induced GLUT4 
translocation [259; 260; 261].  However, there is some controversy as to PKCλ/ζ′s role in 
insulin-stimulated GLUT4 translocation [262].    After phosphorylation of PKCλ/ζ by 
PDK1, it is recruited to lipid rafts in a TC10-dependent manner via Par3 and Par6.  Par6 
and PKCλ/ζ both contain PB1 (Phox and Bem1) domains required for heterodimer 
complex formation.  Par3 has three PDZ domains that specifically bind to both Par6 and 
PKCλ/ζ [263].    
Before moving on to the other half of the insulin pathway, it should be noted that 
PI3K activation can be attenuated by PIP3 dephosphorylation via 3′ phosphatases such as 
PTEN (phosphatase and tensin homolog) [264] or 5′ phosphatases such as SHIP2 (SH2-
containing 5′-inositol phosphatase 2) [265].  PTEN action on PIP3 yields 
phosphatidylinositol 4,5-bisphosphate whereas SHIP2 action on PIP3 yields 
phosphatidylinositol 3,4-bisphosphate [152].  Both PTEN and SHIP2 can negatively 
regulate insulin signaling [266; 267].  However, in 3T3-L1 adipocytes, PTEN, and not 
SHIP2, is able to inhibit PI3K-dependent insulin signaling [268].  Insulin action can also 
be attenuated by protein tyrosine phosphatases (PTPases) which catalyze 
dephosphorylation of the receptor and its substrates (e.g. IRS).   The most prevalent is the 
cytoplasmic PTP1B.  PTP1B-/- mice are resistant to diet-induced obesity [225].  In L6 
skeletal muscle cells, Ghosh et al. have shown that ceramide-activated protein 
phosphatase (CAPP) is able to dephosphorylate Akt and SRp40 resulting in decreased 
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PKCβII alternative splicing.  The PP1-like CAPP, in this case, is stimulated by TNFα, 
which in turn stimulates de novo and hydrolysis pathways of ceramide generation.  This 
ceramide allosterically activates the CAPP responsible for suppressing PKCβII 
expression [269]. 
 The other pathway critical for insulin-stimulated glucose uptake is the CAP/Cbl 
pathway.  Upon insulin stimulation, Cbl is phosphorylated with the help of APS (adaptor 
protein containing a PH and SH2 domain).  APS has a PH domain required for membrane 
localization and an SH2 domain that interacts with the phosphorylated receptor.   APS 
needs to be phosphorylated in order to recruit Cbl.  It interacts with an atypical SH2 
domain of Cbl.  APS and Cbl are recruited to the receptor as dimers.  Once at the insulin 
receptor, Cbl is tyrosine phosphorylated in the C-terminus.  This tyrosine 
phosphorylation also requires another adaptor protein, CAP (Cbl-associated protein).  
CAP interacts with Cbl through a C-terminal SH3 domain [136; 270].  Once Cbl has been 
phosphorylated, Cbl-CAP dissociate from the receptor and translocate to lipid 
raft/caveolae microdomains in the PM.  This is mediated by interaction of the CAP SoHo 
(sorbin homology) domain with flotillin [271].  Lipid raft-bound Cbl recruits another 
adaptor protein named CrkII.  An SH2 domain of CrkII interacts with phospho-Cbl.  
CrkII forms a constitutive complex with C3G (CRK SH3-binding guanyl nucleotide-
exchange factor (GEF)).  C3G (acting as an insulin-stimulated GEF) catalyzes the 
exchange of GTP for GDP for the G protein TC10 [272].  TC10 has a C-terminal CAAX 
sequence specifying farnesylation and palmitoylation responsible for targeting to lipid 
rafts [273].  TC10 localization to lipid rafts (caveolin positive) is required for insulin-
induced activation [273; 274].  Activated TC10 provides a second signal to GLUT4 in 
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parallel with activation of the PI3K pathway [272].  This may involve stabilization of 
cortical actin, critical for GLUT4 translocation [225].  Rac is the G protein equivalent to 
TC10 in skeletal muscle cells that is responsible for actin remodeling [275].  Several 
effectors of TC10 have been proposed.  One is CIP4 (Cdc42-interacting protein 4) which 
contains 1 FCH domain, 2 coiled-coil domains and 1 SH3 domain.  The FCH domain 
(part of larger F-BAR domain) interacts with microtubules, the F-BAR domain regulates 
membrane curvature and the second coiled-coil domain interacts with GTP-bound TC10.  
In addition, CIP4 interacting proteins include Gapex-5, a RasGAP and VPS9 domain-
containing protein that functions as a guanine nucleotide exchange factor (GEF) for 
Rab31.  Rab31 is a Rab5 subfamily GTPase involved in TGN-to-endosome trafficking.  
Insulin recruits the CIP4/Gapex-5 complex to the PM decreasing Rab31 activity in 3T3-
L1 adipocytes [276].  Rab31 may possibly function in retention of GSVs, therefore, 
inhibition of Rab31 would allow for release of this GLUT4 population [129].  Gapex-5 is 
also part of the TC10/Gapex-5/Rab5 axis that mediates insulin-stimulated production of 
phosphatidylinositol 3-phosphate [PI(3)P].  PI(3)P is an important regulator of GLUT4 
vesicle trafficking, regulating translocation of GSVs to the PM .  To accomplish this 
TC10 (via Gapex-5) must activate Rab5, a multifunctional GTPase that recruits a 
network of effectors regulating internalization of proteins from the cell surface, 
homotypic fusion of early endosomes, formation of clathrin-coated vesicles and motility 
of early endosomes on microtubules.  Phosphoinositide synthesis and turnover are also 
regulated by Rab5 via recruitment of two distinct PI3-kinases, VSP34 and PI3K-p110β as 
well as PI phosphatases including type II PI5-phosphatase and type 1α PI(3,4)P2 4-
phosphatase.   Because spatial and temporal distribution of phosphoinositides is critical 
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for ISGT, Rab5 is a critical regulator of insulin action.  In order to accomplish Rab5 
activation, several upstream processes must occur.  Gapex-5 is bound to Rab31 (active) 
in the unstimulated state which promotes intracellular retention of GLUT4.  Insulin 
activates TC10 which recruits CIP4/Gapex-5 to the PM.  Dissociation of Gapex-5 from 
Rab31 (now inactive) allows for GLUT4 translocation to begin.  At the PM, Gapex-5 
(likely acting as a GEF) activates Rab5 by causing dissocation of Rab5 from RabGDI 
(Rab GDP dissociation inhibitor).  Rab5, which is now GTP loaded (active), can assist in 
ISGT [277; 278].    
TC10 also interacts with Exo70, a component of the exocyst complex.  This is 
important for tethering and docking of secretory vesicles.  Additional components of the 
exocyst complex are Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo84 and the C-terminal of 
a protein called Snapin which binds to the coiled-coil domain of Exo70.  This complex is 
necessary for glucose uptake in 3T3-L1 adipocytes [152; 279].  Other factors important 
for propagating TC10-regulated tethering and docking include SAP97, a MAGUK 
(membrane-associated guanylate kinase) family member.  Sec8 associates with the PDZ 
domain of SAP97 and recruits it to lipid rafts.   SAP97 is expressed in lipid rafts 
(localization not influenced by insulin) and anchors the exocyst complex to lipid rafts 
[215].  The exocyst complex is non-fusogenic.  Fusion involves the SNARE complex 
which is capable of inducing the fusion reaction.  This includes VAMP2 (v-SNARE on 
GSVs) and Syntaxin4 (t-SNARE) and SNAP23 (t-SNARE).  Syntaxin4 interacting 
partners are Munc18c, Synip and Tomosyn, all of which appear to inhibit syntaxin from 
binding VAMP or SNAP.  Insulin-dependent Akt2 phosphorylation of Synip on S99 
leads to dissociation of Synip from syntaxin4, allowing for assembly of SNARE-
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complex.  Activated PKCζ complexes with 80K-H and Munc18c to promote VAMP2 
binding to syntaxin4 that enhances GLUT4 fusion.  This suggests both a negative and 
positive regulatory effect of Munc18c.  PLD1 product, phosphatidic acid (PA) accelerates 
the rate of fusion when incorporated with the syntaxin/SNAP23 acceptor membrane 
[129].   DOC2B (double C2-like domains, beta), a SNARE related protein, is a very 
recent discovery.  It is a positive SNARE regulator of insulin-stimulated GLUT4 fusion.  
It has two C2 domains and translocates to the PM during insulin treatment in a Ca2+ 
dependent manner [280] 
TC10 is also thought to influence actin cytoskeleton dynamics.  3T3-L1 
adipocytes contain cortical actin that lines the surface of the PM.  This cortical actin 
contains punctate filamentous F-actin that emanate from the organized caveolae-rosettes 
where TC10 is segregated.  This F-actin structure is referred to as Cav-actin.  Interference 
with TC10 abolished cav-actin formation.  TC10 is thought to regulate both Cav-actin 
and cortical actin structures [281].  The organization of F-actin is entirely different in 
myotubes, which are present as stress fibers running longitudinally [152].  It is also 
thought that TC10 influences massive actin polymerization in the peri-nuclear regions via 
downstream effector N-WASP protein (neural Wiscott-Aldrich syndrome protein).  
TC10, along with caveolins and flotillin, is detected in the TGN endosomes localized in 
the peri-nuclear regions.  This region (as mentioned above) is implicated as a major 
storage site for GSV in 3T3-L1 adipocytes [282; 283].  TC10 inhibition using c. difficile 
toxin B completely shuts down both cortical actin and peri-nuclear actin rearrangements 
and greatly reduces insulin-stimulated GLUT4 translocation [284].  N-WASP protein 
contains a VCA (Verprolin, cofilin, acidic) domain.  When N-WASP is bound to TC10, 
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the VCA domain is exposed and activates the Arp2/3 complex resulting in de novo actin 
polymerization in response to extracellular stimuli [285].  This actin polymerization 
(actin comet-tails) is the driving force for vesicle movement and is involved in membrane 
trafficking events [286].  Activated TC10 differentially regulates two distinct population 
of F-actin in 3T3-L1 adipocytes.  It depolymerizes cortical F-actin beneath the PM and 
greatly increases F-actin polymerization in the perinuclear region [282]. 
Insulin stimulation causes GSVs to migrate toward cortical actin along 
microtubules.  The kinesin motor thought to be responsible for this is KIF5B (kinesin 
family member 5B).  KIF5B is responsible for transporting GSVs along microtubules in a 
PI3K independent manner in 3T3-L1 adipocytes [287].  Work from several groups has 
helped to bridge the myosin motor, actin cytoskeleton and the exocyst complex as it 
relates to 3T3-L1 GLUT4 translocation to the PM.    After GSVs have migrated along 
microtubules, translocation requires both the actin cytoskeleton and the rapid movement 
of GLUT4 along linear tracks which is likely mediated by molecular motors.  A key 
component of the molecular motor near actin filaments is the unconventional myosin 
Myo1c (Myosin 1c) protein which is present in GSVs.  Myo1c functions independent of 
PI3K and helps control the movement of GSVs to the PM [288].  Myo1c travels along the 
actin cable in order to reach the PM.  This will likely take GSVs to F-actin where TC10 
(and the exocyst complex) is located [136].  GTPase RalA mediates the coordination 
between Myo1c and the exocyst complex.  RalA that is GTP-loaded (via insulin) interacts 
with the exocyst complex.  RalA interaction with Myo1c is GTP-independent.  
Calmodulin binds GSVs and modulates the association between RalA and Myo1c 
through IQ motifs in a manner that depends on calcium-bound calmodulin.  Myo1c may 
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recognize RalA as a cargo receptor on GSVs [289].  CaMKII (calcium/calmodulin-
dependent kinase II)-mediated phosphorylation of Myo1c is necessary for ISGT to 
proceed.  Myo1c phosphorylation is associated with elevated 14-3-3 binding and reduced 
calmodulin binding [290]. Binding of 14-3-3 to Myo1c does not inhibit its ATPase 
activity (which it obtained via phosphorylation).  Insulin causes a calcium influx just 
below the plasma membrane which activates CaMKII.  Interestingly, Rictor associates 
with Myo1c during insulin signaling and may provide a link for the regulated interaction 
of Myo1c and actin [291].  The interaction between Rictor and Myo1c is insulin 
independent.  Their association is necessary for phosphorylation of actin filament 
regulatory protein paxillin and promotes cortical actin remodeling [292].  In addition to 
Myo1c, myosin Va and myosin Vb are also actin-based motors implicated in GLUT4 
trafficking.  Va is phosphorylated by Akt2, enhancing its association with actin [152].  
Vb can bind Rab8A which is critical for localization of Rab8A and GLUT4 translocation 
[254].  How GSVs associate with the cytoskeleton (cortical actin mesh) is not clearly 
known.  A prime candidate is α-actinin 4 (ACTN4).  This protein is found only within 
remodeled actin but not along filaments in unstimulated cells.  Insulin promotes co-
localization of actin filaments, ACTN4 and GLUT4 as well as physical association 
between GLUT4 and ACTN4.  It is thought that insulin-stimulated release of TUG 
(tether, containing a UBX domain, for GLUT4) from GLUT4 enables its interaction with 
ACTN4 [152].  TUG is responsible for sequestration of GLUT4 in GSVs in unstimulated 
3T3-L1 adipocytes [293; 294].     
The preceding insulin signaling cascades as it relates to glucose uptake are 
illustrated in Figure 18 [129; 133; 175; 225; 252; 276; 289; 290; 293; 295]. 
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Peroxisome Proliferator-Activated Recpeptor γ 
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear 
hormone receptor superfamily of transcription factors that exist as three isoforms.  
PPARα is expressed mainly in brown adipose tissue, liver, kidney, heart and skeletal 
muscle and plays a major role in lipid catabolism [296].  PPARδ, expressed in many 
tissues, is involved in lipid metabolism and energy utilization [297].  PPARγ exists as 
two isoforms, PPARγ1 and PPAR2 resulting from alternative promoter usage and 
mRNA splicing.  PPAR1 is more ubiquitously expressed, whereas PPAR2 is to be 
found mainly in adipocytes.  PPAR2 is critical for adipogenesis and regulates genes 
involved in lipid storage and glucose metabolism.  To list a few; acyl-CoA oxidase, aP2, 
PEPCK, malic enzyme, leptin, resistin, lipoprotein lipase and adiponectin [296; 298].   
PPARγ1 has also shown to have some adipogenic action but not as much as PPARγ2 
[299].  PPARγ3 has also been observed.  Its expression seems to be confined to 
macrophages [300]. 
The structure of PPARγ is shown in Figure 19 [297; 301].  At the N-terminal end 
of PPARγ is the AF-1 region which is a ligand-independent activation function (AF-1) 
domain.  The AF-1 domain can functionally synergize with the AF-2 domain [302].  The 
AF-1 region contains serine and threonine residues that can be phosphorylated.  For 
example, MAPK (mitogen-activated protein kinase) family member ERK (extracellular 
signal-regulated protein kinase) can phosphorylate PPARγ at serine112 and cause 
inhibition of transcriptional activation [303].   
After the AF-1 domain is the DNA-binding domain (DBD).  Glucocorticoid 
receptor (GR) DBD is the current model representing the nuclear receptor superfamily.  
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Briefly, DBD folds into a globular domain made up of two nonequivalent zinc-finger 
structures.  Each zinc atom is coordinated by four cyteines.  The zinc-finger structure is 
necessary for DNA-binding activity [304].    Important are two α-helices.  The N-terminal 
helix (P-box) directly interacts with the major groove of each DNA half-site (base 
specific contact).  The C-terminal helix aids in stabilization.  Residues that make up the 
dimmer interface are located in the C-terminal zinc finger (D-box) (Figure 19) [301].  
DNA binding is coupled to structural changes necessary for heterodimer formation.  
Heterodimerization depends on helical unfolding which occurs in the C-terminal 
extension (CTE) of the DBD.  In the case of thyroid receptor (TR), two helices within the 
CTE are crucial for DNA binding and heterodimer assembly.  A helix in the T-box 
completes the heterodimeric interface with the second zinc-finger helix of retinoid X 
receptor (RXR).  A helix in the A-box makes extensive contacts with the DNA [301]. 
Next is the ligand binding domain (LBD).  It is composed of many 12 α-helical 
globular domains.  These domains form three anti-parallel helical sheets that combine to 
make an α-helical sandwich.  The ligand binding pocket is located in the interior of this 
structure.  Binding strength and specificity are based on hydrophobic interactions, 
hydrogen bonding and the steric size and shape of the binding pocket.  For hormone 
receptors, the smaller the size the more discerning the binding pocket is towards ligands 
[301].  PPARγ has a relatively disordered pocket to accommodate different ligands [305].  
At the end of the LBD is the ligand-dependent activation function (AF-2) that can bind 
coactivators.  The coactivator interface of this domain is a hydrophobic groove formed by 
several helices of the LBD including helix 12 (called AF-2 helix).  Coactivators can bind 
this groove through a LXXLL motif [301].  Agonists regulate LBD-coactivator 
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interactions by modulating both LBD and helix 12 conformations.  Non-agonist bound 
PPARγ would inactivate the LBD causing it to exist in many conformations, few of 
which are the active [306].  Corepressor binding to PPARγ can also inhibit coactivator 
recruitment.  Corepressors also contain LXXLL binding motifs enabling them to bind to 
the groove formed by the LBD and helix 12.  However, unlike coactivators, the 
corepressor binding motif forms a long three-turn helix sterically blocking helix 12 from 
obtaining an active conformation [307].  Further stabilization of the LBD-corepressor 
complex occurs via antagonist ligand binding.  This prevents helix 12 from gaining an 
active conformation as well as creates a larger binding surface for the corepressor 
LXXLL motif [301]. 
PPARγ heterodimerizes with RXR alpha (RXRα) to regulate transcription of 
PPARγ-responsive genes.  PPARγ/RXR heterodimers bind to direct repeats (DR) of the 
consensus sequence (AGGTCA) separated by a single nucleotide sequence (DR1) called 
the PPARγ Response Element (PPRE).  PPARγ binds to the 5′ half site while RXRα 
binds to the 3′ half site (polarity) [296; 308]. The PPRE contains an additional AAACT 
motif upstream of the DR1 [309].   Generally, PPREs reside in upstream enhancer 
regions as opposed to the proximal promoter [310].  The heterodimer binds to the PPRE 
in a head-to-tail orientation, allowing them to accommodate small changes in the number 
of nucleotides spacing the two hexanucleotides [301].  In fact, binding of the heterodimer 
pair has been observed in DR0 and DR2 PPRE′s [311].  The heterodimer pair is able to 
bind to DNA without ligand activation.  However, gene activation is inhibited due to the 
binding of corepressors.  Upon ligand binding, corepressors are released and coactivators 
are recruited leading to transcriptional activation [309]. 
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The PPARγ-RXRα complex structure was recently reported.   In PPARγ, the CTE 
forms significant DNA interactions and is followed by two helical segments that reach 
the LBD.  The RXRα CTE forms one of the dimer contacts with the PPARγ DBD.  
Otherwise, RXRα has no secondary structure which may be the reason it can 
promiscuously bind other nuclear receptors.  Both DBDs have α-helices that directly bind 
to the half sites.  Hydrogen-bonding occurs between the DBD and the major groove of 
the half-sites.  The PPARγ LBD and DBD are closely positioned whereas the RXRα LBD 
and DBD are far apart with the space between them being occupied by PPARγ LBD.  
PPARγ LBD is the target of most drugs since it is the centerpiece around which all other 
domains are positioned.   
Polarity (as mentioned above) is mainly determined by the PPARγ CTE′s affinity 
for the 5′ flanking sequence.  Another determinant of polarity is that both receptors have 
tight binding between their DBDs.  Both DBDs have α-helices that can bind with the half 
sites.  Hydrogen-bonding occurs between the DBD and major groove of the half sites.  
PPARγ makes more base and phosphate backbone contacts than RXRα.  The PPARγ 
hinge region also has extensive DNA interactions, binding to the upstream AAACT 
sequence.  Besides the DBD-DBD interface, an additional dimer interface is created by 
the two LBDs.  A third interface occurs between PPARγ LBD and the DBD CTE region 
of RXRα.   
Heterodimerized PPARγ has a “Y′” shaped pocket in its LBD that binds ligands.  
As alluded to before, the active conformation for the PPARγ-RXRα have their helix 12 
properly positioned by ligands thereby facilitating coactivator docking.  Coactivator 
binding is far from other protein-protein interaction sites.  The PPRE is also far from 
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coactivator binding.  This suggests that in order to recruit promoter-specific coactivators, 
PPREs may have to cooperate with other promoter elements [309].  Adding more 
complexity is the fact that an intact PPRE is not required for heterodimer binding and 
subsequent activation for some PPREs [296].  A phenomenon called the phantom effect 
has been reported whereby an RXR ligand can cause dissociation of corepressors and 
recruitment of coactivators.  Here, the binding of a ligand to one receptor can cause a 
similar activating conformational change in the other receptor.  The RXR-RAR (retinoic 
acid receptor) heterodimer has reported to undergo this type of activation [312].  
However, it has not been observed yet for the PPARγ heterodimer. 
 Polyunsaturated fats and their metabolites have been identified as PPARγ ligands 
although none have established physiological relevance.  The best characterized is 15-
deoxy prostaglandin J2 (15-d-PGJ2).  It binds PPARγ with a Kd (dissociation constant) in 
the low micromolar range and can activate PPARγ target genes at concentrations near the 
Kd.  The problems with this ligand are that it has never been shown to exist in vivo and it 
may not be specific to PPARγ [313; 314].  Other natural ligands of PPARγ include 
component of oxidized low-density lipoprotein 9- and 13-hydroxyoctadecadienoic acid 
(HODE) and 12- and 15-hydroxyeicosatetraenoic acid (HETE) [313].  Recently, 
unsaturated nitrated fatty acids (nitroalkenes) have been shown to activate PPARγ.  
Specifically, nitrolinoleic acid (NO2-LA) and nitrooleic acid (NO2-OA) are potent 
PPARγ activators.  They can activate PPARγ-dependent transcription in the nanomolar 
range [315].  The regioisomer 12-NO2-LA was identified as the most potent with an IC50 
(0.41-0.6 μM) comparable to synthetic PPARγ agonist Rosiglitazone (IC50 = 0.25 μM) 
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[316].  Lysophosphatidic acid has also been suggested to be an endogenous PPARγ 
ligand [317]. 
 PPARγ shares many of the same coactivators with other members of the nuclear 
receptor family.  These include CBP/p300, the SRC family, TRAP220, PGC1α etc. [318]. 
Some coactivators, such as PGC1α, can bind in a ligand-independent manner [319].  
Despite this, PGC1α′s activating role for PPARγ displays gene selectivity.  Some of the 
corepressors capable of suppressing PPARγ activity include SMART, NCoR and RIP140 
(nuclear receptor interacting protein1) [318].  The general mechanism for PPARγ 
associated gene regulation is shown in Figure 20 [320].  Ligand bound PPARγ 
heterodimer activates target promoters whereas without ligand activation the heterodimer 
is bound by corepressors that repress target promoters [320].  Another mode of PPARγ-
mediated gene suppression is called ligand-dependent transrepression.  This involves 
repression of pro-inflammatory genes such as nuclear factor-κB (NF-κB).  Here, 
activated PPARγ monomer blocks the clearance of the corepressor complex.  The 
mechanism is not precisely defined but is thought to involve ligand-dependent 
association with PIAS1 (protein inhibitor of STAT1).  PIAS1 binding would induce 
SUMOylation of the PPARγ LBD which would enable it to maintain NCoR (nuclear 
repressor corepressor) on the promoter of inflammatory genes [297].   
 One of the most critical functions for PPARγ is being the “master” regulator of 
adipogenesis.  The adipocyte is at the nexus of energy balance and whole-body lipid 
homoestasis.  PPARγ is induced during the differentiation from fibroblasts to adipocytes 
(both white and brown fat) [298; 318].  Adipose cells can not form without PPARγ.  
PPARγ advances adipogenesis by inducing a transcriptional cascade that includes such 
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members as CAAT/enhancer binding proteins (C/EBP) [318].  Adipogenesis initially 
starts by induction of C/EBPβ and C/EBPδ.  These proteins bind to the PPARγ promoter 
and induce its expression [321].  PPARγ, upon ligand activation, induces expression of 
target genes involved in lipogenesis and adipogenesis.  It also activates C/EBPα which 
can positively regulate PPARγ expression [318].  C/EBPα can not induce adipogenesis 
without PPARγ [299].  Many genes are involved in lipogenesis and insulin sensitivity 
which have PPREs.  Of interest is GLUT4, which is responsible for attaining full insulin 
responsiveness.  Deletion of PPARγ in mature adipocytes leads to lipodystrophy and 
insulin resistance [322].  PPARγ2 deletion in obese and insulin-resistant ob/ob mice leads 
to decreased fat mass, severe insulin resistance and dyslipidemia [323].   
Thiazolidinediones 
Thiazolidinediones (TZDs) are a class of drugs that are used to treat T2DM by 
reversing insulin resistance in target tissues and reduce hyperinsulinemia [324].  Today, 
two members of this drug class, rosiglitazone and pioglitazone, are currently approved by 
the FDA to treat T2DM [318].  Lehmann et al. was the first to discover that TZDs were 
direct ligands for PPARγ [325].  TZDs are believed to increase insulin sensitivity mainly 
through binding PPARγ.  There are three main reasons for this.  First, clinical potencies 
of different TZDs correlate with potency of PPARγ activation [326; 327].  Second, non-
TZD agonists for PPARγ also improve insulin sensitivity [328].  Third, mutations in 
PPARγ in humans are associated with insulin resistance [322; 329; 330].   
 Current evidence suggests that adipose tissue is the consequential tissue target 
responsible for TZD beneficial effects (Figure 21).  The “lipid steal” hypothesis has been 
used to explain the mechanism of TZD.   The rationale is as follows.  Type 2 diabetes 
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correlates with increased plasma free fatty acids (FFA) and their inappropriate deposition 
on liver and skeletal muscle [318; 331; 332].  FFA and triglyceride (TG) accumulation in 
skeletal muscle translates to insulin resistance and compromised systemic glucose 
homeostasis [333].  Nonalcoholic fatty liver disease (NALFD) has a high correlation with 
the metabolic syndrome (which includes insulin resistance) [334].  White fat cell PPARγ 
activation is believed to boost its capacity to store dietary FFAs.  As a consequence, the 
FFAs are turned into fat deposits and partitioned away from tissues thereby enhancing 
peripheral tissue insulin sensitivity.  Consistent with this model, TZDs lower circulating 
FFA levels [335].  It has also been proposed that TZDs exert their anti-diabetic effect 
through modulation of cytokine expression.   
 The “lipid steal” contends that the primary site of TZD action is adipose tissue.  
This is evidenced by a study showing that the presence of white adipose tissue (WAT) is 
necessary for TZDs effects to materialize.  However, in this study, TZDs was still able to 
reduce circulating lipid levels in mice suggesting other sites may play a role in lipid 
removal via fatty acid oxidation etc. [336].  Also, adipose specific PPARγ knockdown 
mice do not respond to TZD treatment.  In this study, TZDs were not able to lower 
plasma FFAs without adipose tissue that expressed PPARγ [322].   Compensatory 
mechanisms such as oxidation may kick in when WAT is not around.   
 Another question that arises from the “lipid steal” hypothesis is whether there is 
adipose hyperplasia or hypertrophy.  In cultured cells, PPARγ agonists induce 
adipogenesis.  Patients taking TZDs tend to gain weight, some of which is attributable to 
an increase in fat mass [337].  This might seem at odds with helping improve insulin 
sensitivity.  However, TZDs simulate fat cell differentiation of smaller, more insulin-
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sensitive adipocytes that promote adipocyte glucose uptake [338; 339].  In addition, the 
added adipocyte load is predominantly in the subcutaneous fat with a slight decrease in 
visceral fat [338; 340].  Individuals with upper-body (central) obesity (excess 
subcutaneous abdominal and especially visceral fat) tend to be have metabolic and 
cardiovascular complications [341].  This can partly be explained due to the fact that 
visceral fat is more lipolytically active.  This means excess FFAs are released from 
triglyceride stores into the circulation.  This is compounded by the fact that visceral fat 
drains directly into the hepatic portal vein, thereby delivering FFA to the liver causing 
hepatic insulin resistance [341].  The excess FFA will also reach skeletal muscle [338]. 
 There is another mechanism by which activated PPARγ can induce whole-body 
insulin sensitivity which does not contradict “lipid steal.”  This involves alteration of the 
adipokines secreted from adipocytes.  One of the most critical is adiponectin.  
Adiponectin is produced exclusively from adipocytes and is a direct target for regulation 
by PPARγ [342].  TZDs induce adiponectin mRNA and plasma protein levels in rodents 
and humans [343].  Further, TZDs induce a preferential switch to the high molecular 
weight adiponectin (as opposed to the low molecular weight type), which is the active 
form responsible for reducing serum glucose levels [344].   In mice, adiponectin 
treatment leads to suppression of hepatic glucose output and improved glucose disposal 
[345].  Mice lacking adiponectin display impaired TZD responses [346].  TZD activation 
of PPARγ can also repress expression of adipokines inversely related to insulin 
sensitivity.  These include tumor necrosis factor (TNF) α and resistin which are thought 
to cause insulin resistance [347].   
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 Skeletal muscle is the largest importer of glucose.  TZD ability to improve overall 
insulin sensitivity must affect skeletal muscle glucose uptake.  However, PPARγ has very 
limited expression levels in skeletal muscle.  This means that the TZD effect is likely 
indirect.  The “lipid steal” hypothesis would explain this through less circulating FFA and 
increased insulin sensitizing adipokines.  Liver also express low levels of PPARγ and its 
activation in liver is associated with steatosis.  However, overall TZD benefits most 
likely outweigh this side effect [318].   
 Another area of PPARγ activation affected by TZDs is macrophages.  Infiltration 
of adipocytes by macrophages is thought to lead to increased inflammatory factors that 
cause insulin resistance such as IL-1β, TNFα and IL-6.  PPARγ is induced during the 
differentiation of monocytes into macrophages and is highly expressed in activated 
macrophages [348].   Macrophages can undergo activation to inflammatory (M1) 
macrophages which are characterized by production of IFN-γ (Interferon) and IL-12.  
They can also undergo alternative activation to anti-inflammatory M2 macrophages 
characterized by the production of arginase I and IL-10 [348].  Macrophage-specific 
PPARγ expression was shown to inhibit inflammation and increase insulin sensitivity 
(muscle and liver) as well as reduce atherosclerotic lesion size [349; 350].   Figure 21 
illustrates the global as well as molecular insulin sensitizing benefits of TZD action on 
the major TZD target tissues.    
Peroxisome Proliferator-Activated Receptor γ Coactivator 1 α 
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) was 
originally identified as the coactivator of PPARγ [319].  PGC1α has since been shown to 
increase the transcriptional activity of PPARγ and variety of nuclear receptor families 
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including oestrogen receptor, retinoid X receptor, mineralocorticoid receptor (MCR), 
glucocorticoid receptor (GR), liver X receptor (LXR), pregnane X receptor (PXR), the 
consititutive androstane receptor (CAR), vitamin D and thyroid hormone receptor 
families [351; 352].  PGC1α can also bind unliganded nuclear receptors such as PPARγ, 
orphan hepatocyte nuclear factor (HNF) 4α, farnesoid X receptor (FXR), and oestrogen-
related receptor (ERR) α [352; 353].  PGC1α also targets non-nuclear receptors involved 
in the insulin signaling pathway including FOXO1 (forkhead box O1), whose activation 
is required for gluconeogensis [354].   Most receptor binding takes place through 
PGC1α′s three LXXLL (L1-L3) motifs (Figure 22).  The L3 motif marks the beginning of 
the negative regulatory (NR) regions which aids in anchoring to PPARγ [352].  Recently, 
Li et al. showed that rosiglitazone-stimulated PPARγ has a preference for the PGC1α ID1 
motif (L1 aa 144-148).  This combined with the fact that PGC1α expression increases 
with Rosiglitazone treatment (via coactivation of PPARγ on the PGC1α promoter), 
suggests that the interaction between PPARγ and PGC1α is critical in mediating TZD 
benefits [355; 356].   After the PGC1α NR region is the central hinge region (amino acids 
400-500), which contains the tetrapeptide DHDY.  This is the host cell factor docking site 
[352].  Of interest, PGC1α has the MADS box transcription enhancer factor (MEF) 2C 
binding site which is required for coactivation of GLUT4 [357].   
 Besides being a powerful transcriptional coactivator, PGC1α can also bind histone 
acetyltransferase (HAT)-containing proteins at their N-terminal such as CBP, p300 and 
SRC-1 [358].   HATs acetylate histones and remodel chromatin allowing access for 
factors of transcription.  Concomitant with recruitment of transcription activators, PGC1α 
is able displace repressor proteins such as histone deacetylase (HDAC) and small 
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heterodimer partner (SHP) [359; 360]. The C-terminal region of PGC1α binds the 
mediator complex (TRAP/DRIP complex) which is responsible for coupling pre-mRNA 
splicing and transcription due to its Ser/Arg-rich domain as well as its RNA binding 
domain [361; 362].  PGC1α′s C-terminal region also has two RS domains (to bind SR 
proteins) and an RRM domain.   Binding to SR proteins influences splice site selection 
during splicing.  The RRM is implicated in the control of translational elongation as well 
as splicing.  Both the RS and RRM synergize with the nuclear localization sequence 
(NLS) in translocating PGC1α to the nucleus [363].     PGC1α is diffusely distributed in 
the nucleoplasm including nuclear speckles, where hypophosphorylated inactive SR 
proteins concentrate [362].  Just like the RS of other proteins (e.g. SRp proteins), those of 
PGC1α harbor several Akt consensus site (RXRXXS/T) [352].  SRp40, for example, 
(which can bind to PGC1α) can be phosphorylated in this manner and participates in 
alternative splicing of PKCβII in an insulin-dependent manner [211; 362].  The ability of 
PGC1α to bind proteins involved in transcription and splicing suggests that it is a key 
mediator of co-transcriptional gene processing [362].  PGC1α affects alternative splicing 
only when it is recruited to complexes that interact with gene promoters [362]. 
 Coactivation of mitochondrial gene transcription factors allows PGC1α (as well 
as PGC1β) to stimulate mitochondrial biogenesis.  Some of the most critical are NRF-1, 
NRF-2, PPARα, PPARδ, ERRα and TR [364].  NRF-1 and NRF-2 are not only targets as 
transcription factors but their genes are subject to regulation by PGC1α.   These genes are 
able to simulate the expression of mitochondrial transcription factor A (Tfam), a 
mitochondrial matrix protein necessary for replication and transcription of mitochondrial 
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DNA [365].  Control of both nuclear and mitochondrial genes leads to increased activity 
in fatty-acid β-oxidation, Krebs cycle, and oxidative phosphorylation (OXPHOS) [364].   
 White fat cells are needed for energy storage while brown fat cells are used for 
energy dissipation.  PPARγ is needed for formation of brown fat and white fat.  TZD 
stimulation has even been shown to promote the differentiation of brown fat [366].    
PGC1α was discovered to turn on adaptive thermogenesis in brown fat.  These processes 
include fuel intake, mitochondrial fatty-acid oxidation and heat production through 
uncoupling protein-1 (UCP1).  PRDM16 is a coregulator necessary and sufficient for 
brown fat cell differentiation.  PRDM16 dramatically increases PGC1α expression, UCP1 
and other brown fat genes.  PGC1α and PGC1β exhibit complementary function during 
brown fat differentiation through genes such as UCP1 as well as mitochondrial 
biogenesis.  However, after development of brown fat, PGC1α and PGC1β do not always 
share complementarity in terms of function.  For instance, PGC1α regulates cold 
inducible UCP1 in mature brown fat, PGC1β does not.  Recently, LRP130 has been 
shown to be critical for the complementary actions of the PGC1′s during brown fat 
development [367].    
 Exercise training promotes switching of muscle type fiber.  It increases the 
number of type I and type IIA muscle fibers which are red in appearance and contain a 
large number of mitochondria, more myoglobin and vascularization than type II B and 
type IIX muscle fibers.  The former muscle type are resistant to fatigue and contract 
slower with a low peak force [368].  Endurance training or strength training both result in 
the release of calcium from the sarcoplasmic reticulum.   This activates several important 
transcription factors such as cyclic-AMP-responsive-element-binding protein (CREB), 
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myocyte-enhancer factor 2C (MEF2C) and MEF2D, and members of the nuclear factor 
of activated T cells (NFAT) family.  These factors lead to an increase in PGC1α which is 
probably involved in modulating metabolic fluxes in skeletal muscle in response to a 
decrease in ATP and altered fuel demands [369; 370].  PGC1α′s interaction with AMP-
activated protein kinase (AMPK) may mediate these metabolic fluxes.  Activated AMPK 
phosphorylates PGC1α and induces de novo synthesis of additional PGC1α [370; 371].  
Transgenic mice encoding PGC1α in skeletal muscle at levels of those in type I muscle 
fibers, show a definite switch towards both typeI and type IIA muscle fiber [372].  These 
fibers are more resistant to fatigue than wild-type mice and are characterized by an 
increase in mitochondrial density and function, increased oxidative metabolism, 
increased expression of myofibrillar proteins characteristic of type I and type IIA muscle 
fibers [372].  PGC1α also increases glucose uptake which leads to an increase in 
glycogen stores post-exercise for future expenditure [373].  Substrate usage for energy 
shifts to fatty-acid oxidation [374].  Mice with skeletal muscle ablation of PGC1α have 
more type IIB and type IIX (glycolytic) muscle fibers and a lower capacity for endurance 
exercise compared with wild-type mice [375].  There is wide variation in the PGC1α 
expression in people′s human muscle.  This may have implications in terms of 
susceptibility to metabolic diseases such as insulin-resistance [376].   
Serine/Arginine-rich Proteins 
Serine/arginine-rich (SR) proteins are splicing factors characterized by their 
arginine/serine (RS) dipeptide rich domain [377].  SF2/ASF was the first SR protein 
identified [378].  The term ′SR protein′ was coined following identification of RS 
domain-containing proteins using the antibody mAb 104.  These SR proteins were bound 
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to active sites of RNA polymerase II transcription [379].  Those SR proteins were SRp20, 
SRp40, SRp55 and SRp75, named after their molecular mass on an SDS/PAGE gel [380].  
SR proteins have a modular structure with one or two copies of an N-terminal RRM 
(RNA recognition motif) that provides RNA-binding specificity (SRp40 has two RRMs).  
The C-terminal RS domain facilitates protein-protein interactions that bring the SR 
proteins to the spliceosome [381; 382].  Once localized to pre-mRNA, SR proteins can 
make contact via the BP (branch point) and the 5′ ss (splice site) [363; 383].  Also in the 
RS domain repertoire is the ability to act as an nuclear localization sequence (NLS) 
which shuttles SR proteins into the nucleus via the SR protein nuclear import receptor, 
transportin-SR [384; 385].   
 Classical SR proteins include SF2/ASF, SC35, SRp20, SRp75, SRp40, SRp55, 
9G8.  The criteria used to define classical SR proteins are structural similarity, dual 
function in constitutive and alternative splicing, presence of a phosphoepitope recognized 
by mAb104 and purification using magnesium chloride [377].  Additional SR proteins 
have been classified as well as SR-related proteins that may have additional roles besides 
splicing such as chromatin remodeling, transcription and cell cycle progression [386].   
 SR proteins are concentrated in nuclear speckles and are recruited to RNA 
polymerase II (RNAP II) during transcription [387].  Interactions between SR-related 
proteins and the CTD (C-terminal domain) of RNAPII have been reported [388].  Also, 
SR proteins are among the hundreds of proteins present in the RNAPII complex [389].  
SC35 has recently been reported to promote RNAP II elongation in certain genes.  This 
demonstrates the potential of SR proteins to couple transcription and splicing, even 
bidirectionally [390].   The importance of the transcriptional machinery in splicing has 
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produced a kinetic co-transcriptional coupling model whereby the rate of transcriptional 
elongation determines splice site selection, and this rate is partially determined by the 
recruitment of splicing factors to the CTD of RNAP II [391].   
 SR proteins influence splicing by binding to ESE′s and ISEs (exonic and intronic 
splicing enhancers) or ESSs and ISSs (exonic and intronic splicing silencers).  Binding of 
SR protein to ESEs prevents exon skipping [392].  Cooper et al. has shown SRp40 binds 
to an ISE downstream of the PKCβII exon and promotes insulin-stimulated PKCβII exon 
inclusion [38].  Two models have been proposed to explain how SR proteins regulate 
exon inclusion.  The ′recruitment model′ proposes that ESE-bound SR proteins recruit 
and stabilize binding of U1 snRNP (small nuclear ribonucloprotein) at the 5′ ss as well as 
U2AF65 at the 3′ss [393].  This is referred to as exon definition [394].  In the second 
model, ′inhibitor model′, ESE-bound SR proteins antagonize activity of hnRNP-ESE 
recognition.  The hnRNP (heterogeneous nuclear RNP) family of proteins binds RNA 
and is known to negatively regulate alternative splicing [377].  In addition to these two 
models, it has been shown that SR proteins can form a network of protein-protein 
interactions spanning the intron boundries early in spliceosomal assembly.  They can also 
bind ISEs at the branch point to promote pre-spliceosomal assembly [363; 383].  SR-
related proteins can recruit U4/U6.U5 tri-snRNP to the pre-spliceosome via the RS 
domain [395]. 
 SR proteins can also function in mRNA processing, mRNA nuclear export, NMD 
(nonsense-mediated decay) and translation [377].  Some of these processes are partly 
aided by nuclear SR proteins localized in nuclear speckles [396].  A subset of SR proteins 
(SF2/ASF, SRp20 and 9G8) are able to shuttle between the nucleus and the cytoplasm 
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that can further progress these processes [396].  Increased expression of SRp40, along 
with others, is implicated in nuclear aspects of NMD [397]. 
 SR protein phosphorylation dynamics have an important part in pre-mRNA 
splicing.  The RS domain of SR proteins is heavily phosphorylated on serine residues 
[377].  This regulates both subcellular localization and activity.  Phosphorylation of the 
RS domain in SF2/ASF stimulates protein-protein binding with other RS domain-
containing splicing factors such as U1-70K [398].  Dephosphorylation of SR and SR-
related proteins is required for the splicing reaction to progress [399].  Insulin-induced 
PKCβII alternative splicing occurs as a result of SRp40 phosphorylation by Akt [211].  
The phosphorylation status of the RS domain is important in post-splicing activities of 
SR proteins.  A hypophosphorylated RS domain is needed for the interaction of 
nucleocytoplasmic shuttling of SR proteins with TAP/NFX1 nuclear export receptor 
[400].    SR protein kinases re-phosphorylate the RS domains enabling reentry into the 
nucleus [401].  Both shuttling and non-shuttling SR proteins associate with the pre-
mRNA when hyperphosphorylated.  Non-shuttling SR proteins are released after initial 
spliceosomal assembly.   Dephosphorylation of the RS domain determines the sorting 
within the nucleus.  Shuttling SR proteins are likely dephosphorylated during the 
transition from prespliceosomal complexes (E and A) to mature spliceosomal complexes 
(B and C).  The shuttling SR protein may remain bound to aid in RNA export.  Shuttling 
SR proteins must be dephosphorylated to be moved to the cytoplasm.    Shuttling and 
non-shuttling SR proteins are recycled via different pathways [402].   
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PU.1/Spi1 
PU.1/Spi1 is a hematopoietic-specific ETS (E26 transformation-specific) family 
member transcription factor involved in the development of all hematopoietic lineages 
[403].  ETS proteins are characterized by a conserved 85-residue domain that binds 
DNA.  This domain recognizes purine-rich sequences containing 5′-(A/T)GGA(A/T)-3′ 
consensus.  ETS proteins can tolerate variation in the flanking bases [404].  PU.1 is able 
to partner with spliceosomal proteins [405].  One such factor is TLS (translocated in 
liposarcoma) which binds PU.1 in vivo.  TLS is an RNA-binding protein that influences 
the choice of alternative splice sites by favoring the selection of the proximal 5′-splice 
site of E1A pre-mRNA.  In, addition the C-terminal region of TLS can bind SR proteins 
which will also influence splicing [406].  The DBD of Spi-1 is able to interact with 
poly(A) + RNAs and homoribonucleotide poly (G) polymers.  However, it does not have 
RNA recognition specificity [405; 407].   
Co-transcriptional Splicing 
Pre-mRNA processing (capping, splicing and cleavage/polyadenylation) can be 
tightly coupled to transcription through RNA polymerase II allowing for much greater 
efficiency, both spatially and energetically [408].  However, co-transcriptional splicing is 
not obligatory.  Introns can not serve as splicing substrates until both the 3′ and the 5′ 
ends are synthesized.  Therefore, the time it takes for RNA pol II to synthesize each 
intron, defines a minimal time and distance along the gene where splicing factors can be 
recruited and spliceosomes formed.  The time that it takes for RNA pol II to reach the end 
of the TU (transcription unit) defines the maximal time that splicing could occur co-
transcriptionally [409].   Introns in the 5′ part of the transcript will likely be co-
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transcriptionally spliced.  However, modulation of RNAP II elongation rates by 
transcriptional activators influences alternative splicing [408].  
 Co-transcriptional splicing occurs due to RNA pol II being able to recruit both 
transcription and splicing factors by acting as a landing pad.  In particular, the CTD of 
RNA pol II plays a central role in the coupling process.  Dynamic changes in CTD 
phosphorylation play a role in RNA processing.  Transcriptional activation of RNA pol II 
results in recruitment of splicing factors to sites of transcription [408].  This does not 
occur if the CTD is mutated [387].    
 Promoter identity is critical in determining alternative splicing.  Factors recruited 
to the promoter affect the type of SR proteins recruited [408].  PGC1α, as mentioned 
before, is a pertinent example because it can bind SRp40 [362].  Promoters, through the 
factors they recruit, also affect RNA pol II elongation rates.  This is important because a 
slower pol II elongation rate or internal pauses favors inclusion of alternative exons 
where there is a weak 3′ ss upstream of a strong 3′ ss [408].   It has been suggested that 
the rate of RNA synthesis affects its secondary structure which in turn affects splicing.  
This model suggests that pre-mRNA is free to fold within a limited timeframe after 
transcription [410].  
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Figure 1.  Proposed effects of protein kinase C activation.  The PKC family influences many pathways.  Some isozymes can be activated by 
several different pathways, such as calcium or DAG production.  Others are activated by one pathway such as ceramide.  Many isozymes have 
overlapping substrate specificities in vitro and thus may interact to control signaling pathways that mediate cell-cycle control, proliferation, 
apoptosis, cellular adhesion and metastasis.  
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Figure 2.  Domain structure of PKC isoforms.  PKCs have a conserved kinase domain (blue) and ATP binding domain (turqoise) and more 
variable regulatory domains.  All PKC regulatory domains (except PKCD,v) have a pseudosubstrate motif (yellow) upstream of the C1 
domain (light blue).  C1 domains bind DAG/PMA in cPKCs & nPKCs. aPKC C1 can not bind DAG/PMA.  C2 domain (dark green) binds 
Ca2+ and phospholipids in cPKCs.  nPKC C2-like domain does not bind Ca2+.  The Hinge region (cPKC, nPKC, aPKC) separates the 
regulatory and catalytic domain and can be cleaved (scissors).  aPKC PB1 (orange) domain is for protein:protein interaction. PKCD PH 
domain (red) is involved in protein:protein interactions. ++ (cPKC C2) represents a basic patch that recognizes PIP2.  W (tryptophan nPKC 
C1B) residue confers high DAG/PMA affinity.  Tyrosine (Y in cPKC C1B) residue can be phosphorylated in place of phosphatidylserine 
binding.       
 
71
V3
V1 V5 V1 V5
V2 V4 V2 V4
C1 C1C4 C4
Zn fingers
Phosphatidyl
serine
DAG
PMA
Calphostin C
C2 C3
Calpain
Ca2+
ATP
Staurosporine
Activation
Pseudosubstrate motifSubstrate
C2
C3
V3
Figure 3.  PKC pseudosubstrate autoinhibition.  Newly synthesized PKC is unfolded with the pseudosubstrate unbound to the substrate 
binding domain.  However, upon phosphorylation, PKC adopts a closed conformation (left).  Signals causing PKC engagement with its C1 
and C2 domains results in pseudosubstrate release, allowing downstream signaling (right). 
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Figure 4.  PKCβ secondary structure.  Rat PKCβ gene structure (top).    Close up of the C-terminal region 
(middle).  The approximate sizes of introns and exons are given. Polyadenylation sites are designated AATAA for 
PKCβII and ATTAAA for PKCβI.  Stop codon (TAA) 159bp into  PKCβII exon.  Possible splice site 2 is shown.  
Close up of PKCβII exon and 3’ UTR (lower).  CATG/GTGACAT and CATG/GTGGCAT define the exon/intron
junction of splice site 1 & 2, respectively.  Polypyrimidine tract (pyr) between ss1 and ss2 is a 30bp pyrimidine-rich 
tract important for spliceosome assembly.  Black dots represent short (10-14bp) purine-rich splicing enhancers.   
Stem loop structure reflects 44bp AUUUA stem loop structure.  SRp40 depicts binding site for phosphorylated
SRp40. Exon Splicing Enhancer (ESE) represents a 38bp purine-rich exon splicing enhancer.  
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Figure 5.  PKCβ alternative splicing and alternative polyadenylation. 4 possible splice variants (I-IV) 
from rat brain are shown.  Splice variant I reflects mature PKCβI mRNA.  Splice variant II reflects  mature 
PKCβII mRNA.  Splice variant III reflects mature PKCβII mRNA with additional splice site.  Splice variant 
IV reflects PKCβII mRNA from alternative polyadenylation selection.  
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C1APS C1B C2 Kinase DomainN C
P P P
500 641 660
Activation loop Turn motif Hydrophobic motif
βII 484    DFGMCKENIWDG-VTTK T FCGTPDYIAPEII  628 NFDRFFTRHPPVL  T PPDQEVIRNIDQS       --- EFEGFS FVNSEFLKPEVKS
α 481  DFGMCKEHMMDG-VTTR T FCGTPDYIAPEII  625 NFDKFFTRGQPVL  T PPDQLVIANIDQS       --- DFEGF S YVNPQFVHPILQSAV
βI 484  DFGMCKENIWDG-VTTK  T FCGTPDYIAPEII  629 NFDKEFTRQPVEL T PTDKLFIMNLDQN     --- EFAGF S YTNPEFVINV
γ 498   DFGMCKENVFPG-STTR  T FCGTPDYIAPEII  642  NFDKFFTRAAPAL   T PPDRLVLASIDQA     --- DFQGF T YVNPDFVHPDARSPTSPVPVPVM
δ 489   DFGMCKENIF-GENRAS   T FCGTPDYIAPEIL 630  NFDPEFLNEKPQL  S FSDKNLIDSMDQT    --- AFKGF S FVNPKYEQFLE
ε 550   DFGMCKEGILNG-VTTT    T FCGTPDYIAPEIL  697  NFDQDFTREEPVL T LVDEAIVKQINQE      --- EFKGF S YFGEDLMP
ζ 394   DYGMCKEGLGPGD-TTS  T FCGTPNYIAPEIL  547 NFDTQFTSEPVQL  T PDDEDAIKRIDQS     --- EFEGF  E YINPLLLSTEESV
η/L 496 DFGMCKEGICNG-VTTA   T FCGTPDYIAPEIL 642 NFDPDFIKEEPVL    T PIDEGHLPMINQD    --- EFRNF  S YVSPELQP
Θ 522 DFGMCKENML-GDAKTN   T FCGTPDYIAPEIL 663 NFDKEFLNEKPRL  S FADRALINSMDQN   --- MFRNF  S FMNPGWSG
ι/λ 387 DYGMCKEGLRPGD-TTS    T FCGTPNYIAPEIL 542 NFDSQFTNEPVQL T PDDDDIVRKIDQS     --- EFEGF E YINPLLMSAEECV
Figure 6.  PKC isoform phosphorylation sites.  Alignment of activation loop, turn motif and hydrophobic motif phosphorylation 
sites in PKC isozymes.   PKCβII structure is shown on top along with residues of phosphorylation.  Below is an alignment of PKC 
isoform phosphorylation sites.  
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Figure 7.  Biphasic cPKC translocation in short- and long-term exposure to agonists.  (A) Activation of either G protein-coupled receptor 
or tyrosine kinase receptor (e.g. insulin receptor) leads to activation of PLC and subsequent hydrolysis of PIP2 to membrane-bound DAG and 
soluble IP3.  IP3 leads to an elevation of Ca2+ which then recruits PKC to the plasma membrane where it binds DAG and PS in the presence of 
Ca2+ and becomes activated.  Activated PKC can then phosphorylate target substrates.  PKCs return to the cytosol within 120s, which 
correlates with the metabolism and loss of DAG and the autophosphorylation of PKC C-terminus. (B) In chronic PKC stimulation, stimulation 
of receptors leads to activation of PLD.  PLD cleaves PC to generate PA and free choline.  PA can be converted to DAG via PAP.  This type 
of DAG (mimicked by long term PMA treatment) is stable in the plasma membrane for over 1 hour and induces prolonged PKC translocation.  
PKC can translocate (among other areas) to a novel juxtanuclear compartment, termed the “pericentron.”
A B
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Figure 8.  Spatial, temporal and conformational regulation of cPKC.   Newly synthesized cPKC associates with PM in an open 
conformation in which the pseudosubstrate (orange rectangle) is dislodged from the substrate-binding cavity on the kinase domain (green 
circle).  The upstream kinase, PDK1 (light blue circle with rectangular PH domain) is docked on the C-terminal tail and initiates 
phosphorylation at the activation loop (Thr 500 in PKCβII).  This is followed by mTORC2 mediated phosphorylation at the turn motif (Thr
641 in PKCβII) and then autophosphorylation of the hydrophobic motif (Ser 660 in PKCβII).  Fully phosphorylated “mature” PKC is released 
into the cytosol in a closed conformation in which the pseudosubstrate occupies  the substrate-binding cavity, thereby inhibiting the kinase
(bottom left).  External signals causing hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP2) cause PKC translocation to the PM.  
Binding of Ca2+ to the C2 domain (red) recruits PKC to the PM via a low-affinity interaction where the C1 (brown) domain binds DAG.  The
C1 domain (post calcium binding) also interacts with PIP2 and phosphatidylserine.  Engagement of both C1 and C2 domains on the PM results 
in pseudosubstrate release allowing downstream signaling to take place.  This membrane translocation is reversible determined by second 
messenger levels.  The membrane-bound PKC conformation is highly sensitive to phosphatases.  Prolonged exposure in this conformation 
results in dephosphoryolation of PKC by PH domain Leucine-rich repeat protein phosphatase (PHLPP) (red) as well as PP2A which can 
potentially lead to degradation.  Binding of Hsp70 (dark yellow) to the dephosphorylated turn motif on the PKC C-terminus causes 
stabilization and the ability to be re-phosphorylated, thus re-entering the pool of signaling-competent PKC.  The phosphorylation step is 
constitutive* and the translocation and dephosphorylation are agonist-induced.  PKC that is not rescued by Hsp70 is ubiquitinated by E3 
ligases (e.g. RINCK) and degraded.
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 Figure 9.  The main pathways of DAG generation and catalysis.  DAG is inside the blue box (dashed).  The principle enzymes involved are 
green.  The enzymes dependent of extracellular signaling are circled.  Groups that are changed during the reaction are shown in red (OH is 
hydroxyl; R, R′ and R′′ are fatty acids; P is a phospho group).  The three-carbon backbone is in black.  AT, acyltransferase; CDP, cytidine
diphosphate; CEPT`, choline/ethanolamine phosphotransferase 1; CPT1, choline phosphotransferase; DGAT, diacylglycerol acyltransferase; 
TAG, triacylglycerol; MAG, monoacylglycerol; LPA, lyso-phosphatidic acid; PLA, phospholipase A; PAP, phosphatidic acid 
phosphohydrolase; LPP, lipid phosphate phosphatase; LPAAT, lysophosphatidic acid acyltransferase; DGK, diacylglycerol kinase; PLD, 
phospholipase D; PLC, phospholipase C; DGK, diacylglycerol kinase; SMS, sphingomyelin synthase; SM, sphingomyelin.
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Figure 10.  Agonist-induced membrane phospholipid degradation for acute and sustained PKC activation.   Phospholipase C is 
responsible for acute DAG production by converting phosphatidyl 4,5 bisphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3).  
Phosphatidylcholine (PC) is the starting material for sustained agonist-induced DAG production.  Phospholipase D converts PC to DAG.  
Phospholipase A2 hydrolysis of PC generates free fatty acids (FFAs) or lysophosphatidylcholine (LysoPC).  These products help potentiate 
PKC activation in the presence of DAG.
Cellular responses
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Figure 11. GLUT family PM insertion structure.  There are 13 GLUT family members.  All span the plasma membrane 12 times with both 
amino- and carboxyl-termini cytosolic.  GLUT4 belongs to Class I GLUTs (1-4) which are glucose transporters.  Class II GLUTs (5, 7, 9, and 
11) are fructose transporters.  Class III GLUTs (6, 8, 10, 12 and HMIT1) are structurally atypical and poorly defined.  This diagram shows a 
homology plot between GLUT1 and GLUT4.  Residues shown in red are unique to GLUT4.  
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Figure 12. GLUT4 trafficking itinerary.  GLUT4 trafficking can be divided into six discreet steps.  1) Budding [biogenesis of GLUT storage 
vesicles (GSVs)], 2) Movement, 3) Tethering, 4) Docking, 5) Fusion and 6) endocytosis.
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Figure 13. Proposed GLUT4 compartments and trafficking.  GLUT4 (purple) and other rapidly recycling proteins such as transferrin
receptors (red) are removed from the plasma membrane in clathrin-coated vesicles and enter the endosome system (1).  Depending on cell-
type, this recycling endosomal system can be both beneath the plasma membrane and perinuclear.  GLUT4 can either enter the endosomal
recycling compartment (2) or be sorted away from tranferrin receptors and shuttled to the perinuclear reticular GLUT4 storage compartment 
[PR-GSC] (3).  The PR-GSC is similar to the Trans-Golgi network (TGN) (5) but has a more restricted population of stored proteins.  GLUT4 
is in constant flux between the PR-GSC and the dispersed vesicular GLUT4 storage compartment [DV-GSC] (4).  The DV-GSC is available 
for quick fusion with the PM.  Newly synthesized GLUT4 from the TGN mostly goes to the PR-GSV.  The PR-GSV can become saturated 
and is available within the endosome system for rapid translocation in response to insulin.  Mutated GLUT4 (alterations in targeting domains) 
are targeted to the late endosomes and lysosomes (6).  Black arrows indicate trafficking steps that lead to GLUT4 storage.  This includes the 
biosynthetic route (TGN) as well as from the PM via the endosome system.  Red arrows indicate probable route from storage to the PM and 
the route stimulated by insulin.  Blue arrows indicate possible route of GLUT4 from storage to the endosomes and to the PM.  Green arrows 
indicate routes mutant GLUT4 might take if it can not be retained in the PR-GSC or endosome compartment.  
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Figure 14.  Domain structure of mammalian PKB/Akt isoforms.  The N-terminal region contains the PH domain. 
The lysine (K) indicates the residue involved in catalysis.  Regulatory phosphorylations in the catalytic and C-terminal 
domain are indicated.  
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extracellular
Figure 15. Mechanism of Akt activation.  Newly synthesized Akt (light blue circle) is phosphorylated on the turn motif (Thr 450 in Akt1) in 
an mTORC2 (dark orange) dependent manner.  Signals generating phosphatidylinositol-3,4,5-triphosphate (PIP3) engage Akt PH domain at the 
PM.  Now the Akt activation loop (Thr 308) is exposed leading to PDK1 mediated phosphorylation and subsequent phosphorylation of 
hydrophobic motif (Ser 473) via mTORC2.  Fully phosphorylated Akt is locked in an active conformation and translocates throughout the cell 
influencing downstream signaling (bottom right).    Signaling is terminated by dephosphorylation of the lipid second messengers (via PTEN) 
and direct dephosphorylation of Akt.  PHLPP (red) directly dephosphorylates the hydrophobic motif.  Protein phosphastase 2 (PP2A) (red) has 
been shown to dephosphorylate Thr 308.  Whether phosphorylation of Thr 308 or Ser 473 comes first is still being debated.  It has recently 
been proposed that Ser 473 precedes phosphorylation of Thr 308.  
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Figure 16.  Functional role of Akt in various tissues.  The role of Akt in liver, pancreas, muscle and adipocyte is shown. Images courtesy of 
iStockphoto.com.
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Figure 17. Mechanism of mTORC activation.  mTORC1 phosphotransferase activity is stimulated by GTP-bound RHEB.  RHEB is 
negatively regulated by the TSC heterodimer complex.  TSC2 converts RHEB to its GDP-bound form (inactive).  Amino acids cause the Rag 
protein complex to be in its GTP (active) form and subsequently activate mTORC1.  The PI3K-Akt, Ras-ERK and IKK pathways converge and 
activate mTORC1 by inhibiting the TSC complex or PRAS40.  RSK kinase and IKKα can activate mTORC1.  The AMPK and GSK3β
pathways negatively regulate mTORC1 by activating TSC2.  AMPK can also directly inhibit Raptor.  Both mTORC1 and mTORC2 can turn
off PRAS40 inhibition of mTORC1.  Activated by growth factors, mTORC2 is the kinase complex responsible for phosphorylating Akt on 
Serine 473 and thus full Akt activation.  However, by activating mTORC1, mTORC2 causes a negative feedback loop that will  blunt the 
PI3K-Akt signaling pathway.  This is because mTORC1 activates S6K1 which will phosphorylate and inhibit IRS1. Downstream targets of 
mTORC1 are components of the translational machinery.  mTORC1 is potently inhibited by rapamycin.  Green arrows indicate activation.  Red 
arrows indicate inhibition.
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Figure 18. Model for insulin signaling.  PI3K and TC10 signaling pathways converge on GLUT4 storage vesicles to cause their 
translocation, docking, tethering and fusion with the PM. Green arrows indicate activation.  Red arrows indicate inactivation.  Black oval 
arrows indicate change in activity level.
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Figure 19.  Generalized structure of PPARγ1 and PPARγ2.   Starting at the N-terminus, the AF-1 domain is a 
ligand-independent transcriptional activation function domain.  Then the DNA-binding domain consisting of two 
highly conserved zinc-finger motifs.  In the middle is a hinge region allowing flexibility for PPARγ to dimerize and 
bind DNA.  Next is the ligand-binding domain (LBD) which has a second dimerization interface.  Finally, the ligand-
dependent activation function domain (AF-2).  Numbers on top indicate amino acid number.  Below is the detailed 
structure of the DBD.
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Figure 20.  Ligand-dependent transactivation and active repression.  PPARγ heterodimerizes with RXRα.  (A) In the presence of ligands 
(natural or synthetic), PPARγ binds to coactivator complexes which result in the activation of target genes.   (B) In the absence of ligands, 
PPARγ associates with corepressor complexes on target genes.  These corepressors that also include histone deacetylases (HDACs) which
lead to active repression of the promoter.
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Figure 21. Improved insulin sensitivity via TZD mediated adipocyte PPARγ
activation.    TZD activation of PPARγ leads to lipid storage in adipose tissue through 
target gene activation.  Adipokine secretion profile (center blue box) is also altered 
leading to increased peripheral tissue insulin sensitivity.  Overall effects of reduced serum 
FFAs and beneficial adipokines include reduced hepatic glucose output and increased 
skeletal muscle glucose uptake.  PPARγ also siphons macrophages towards an anti-
inflammatory M2 phenotype and reduces their infiltration into fat.  Reprinted with 
permission, from the Annual Review of Biochemistry, Volume 77 © 2008 by Annual 
Reviews www.annualreviews.org
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Figure 22.  Human PGC1α protein structure.  The N-terminal region contains the activation domain (AD).  Two of the
LXXLL motifs are present in the AD.  The third LXXLL motif lies in the negative regulatory region.    After L3 there are three 
p38 MAPK phosphorylation sites located within the negative regulatory (NR) region.  Host cell factor (HCB) is in a region that 
binds MEF2C protein.  A novel DEAD box is located in human PGC1α (not mouse or rat).  Directly downstream of the DEAD 
box are two putative casein kinase (CK) phosphorylation sites (CK1 and CK2).  Rat and mouse contain only CK2.  RS protein 
interaction domains followed by a nuclear localization (NL) signal and the RNA recognition motif (RRM).  The C-terminal 
region has been shown to bind the TRAP220 mediator complex, splicing factors (U1-70K) and some transcription factors.  
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EXPERIMENTAL PROCEDURES 
 
Cell Culture 
 
Mouse 3T3-L1 preadipocytes obtained from American Type Tissue Culture 
repository, ATCC (Manassas, VA) were maintained and passaged as preconfluent 
cultures in DMEM high glucose 4.5g/L (Invitrogen, Carlsbad, CA) with 10% newborn 
calf serum (Sigma-Aldrich, St. Louis, MO) at 37oC and 10% CO2.  Once confluent, cells 
were differentiated (day 0) in DMEM high glucose with 10% fetal bovine serum (Atlas 
Biological, Fort Collins, CO), 10μg/mL bovine insulin (Sigma), 1mM dexamethasone 
(Sigma), and 0.5mM isobutyl-1-methylxanthine (Sigma).  On day 2, media was replaced 
with DMEM high glucose, 10% FBS, and bovine insulin.  Day 4 and afterwards, cells 
were cultured in DMEM high glucose plus 10% FBS.  Media was changed every two 
days.  Prior to insulin treatment for glucose uptake or other assay, 4 hour serum 
starvation was accomplished by using DMEM high glucose without FBS. 
L6 rat skeletal myoblasts (obtained from Dr. Amira Klip, The Hospital for Sick 
Children, Toronto, Canada) were grown in αMEM (Invitrogen) with 10% FBS to 
confluence at 37oC and 5% CO2.  Myoblasts were fused into myotubes by changing 
media to αMEM with 2% FBS for 2-4 days post confluence.  Serum starvation was 
accomplished by using αMEM for 6 hours.   
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Rat aortic vascular smooth muscle cells (A10, ATCC CRL 1476) were grown in 
DMEM low glucose with 10% FBS at 37oC and 5% CO2.  Once confluency was reached, 
cell synchronization was achieved by serum deprivation (with 0.5% FBS) for 48 hours.   
HeLa cells (ATCC CCL-2) were grown in MEM (Invitrogen) with 10% FBS until 
confluent at 37oC and 5% CO2.  Serum starvation was achieved by incubation with MEM 
(no serum) for 6 hours.   
Overexpression/Minigene Transient Transfection 
 
 Transient transfection was accomplished using TransIT-LT1 transfection reagent 
(Mirus Bio Corporation, Madison, WI) according to manufacturer′s protocol.  Briefly, L6 
cells were cultured in 6-well plates until 60-75% confluent.   250μL serum-free αMEM 
was mixed with 2.5μL TransIT-LT1transfection reagent per 1μg DNA.  DNA was added 
to this mixture and incubated for 30 minutes at room temperature.  TransIT-LT1 Reagent 
– DNA complex was added to cells (with complete growth medium) and incubated for 
48-72 hours.  Plasmids used were as follows: 
 
Gene of Interest Donor ID # 
pcDNA3.1/myc-His A 
vector control 
Invitrogen V800-20 
PPARγ Addgene Inc., (Cambridge 
MA) 
8895 
PPARγ E499Q Addgene 8896 
PGC1α Addgene 1026 
PGC1α delta CTD Addgene 1030 
SRp40 cDNA Dr. Rebecca Taub PMID: 9199345 
SRp40 (myc) Hercules Apostolatos PMID: 15684423 
HRS (myc) Hercules Apostolatos N/A 
pCMV GFP Addgene 11153 
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siRNA Knockdown in L6 Skeletal Muscle Cells 
 
 L6 skeletal muscle cells were grown in 6-well plates.  Cells were ready for 
transfection at 60-75% confluency.  In one tube (per well), 5μL siPORT NeoFX 
Transfection Reagent (Applied Biosystems/Ambion, Austin, TX) was mixed with 95μL 
αMEM (no serum). This was incubated 10 minutes room temperature.  In another tube, 
RNA and αMEM (no serum) were combined up to 100μL.  Two tubes were mixed and 
incubated 10 minutes.  siPORT NeoFX – RNA solution was added to cells.  αMEM (no 
serum) was added to a final volume of 2.5mL.  After 6-8 hours, media was replaced with 
serum containing αMEM. 
Gene silenced Species 5′ – 3′ Silencer siRNA (Ambion) Sense Sequence 
PPARγ 
(ID#197812) 
Rat GCAUUUGUAUGACUCAUACtt 
PGC1α 
(ID#114748) 
Human GCCAACACUCAGCUAAGUUtt 
SRp40 
(ID#198849) 
Rat GCUCUUUUAUAACUAAACGtt 
Silencer 
Negative 
Control #1 
siRNA (#4611) 
Rat, Mouse, 
Human 
Proprietary 
  
siRNA Knockdown in 3T3-L1 Adipocytes 
 
 Transfection of differentiated 3T3-L1 adipocytes was attempted using DeliverX 
Plus siRNA Reagent Solution (Panomics Inc., Fremont, CA).  Day 8 3T3-L1 adipocytes 
were trypsinized and thinned on a 6-well plate.  Transfection was performed the next day.  
The following is for transfection of 1 well of a 6-well plate.  The siRNA working stocks 
were prepared in one tube by adding siRNA and Buffer-1 up to 50μL.  The DeliverX Plus 
siRNA Transfection Reagent was sonicated (P/N DX0400, Panomics) for 5 minutes 
before usage to achieve a homogeneous solution.  In another tube, 8μL DeliverX Plus 
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siRNA Transfection Reagent and 42μL Buffer-2 were combined.  This second tube was 
vortexed and sonicated for 5 minutes as before.  The two tubes were combined, vortexed 
and incubated at 37oC for 20 minutes.  100μL Buffer-1 and 100μL Buffer-2 were added 
to the siRNA-DeliverX Plus Transfection Reagent mixture.  Just prior to usage, cells 
were washed several times with DMEM high glucose (no serum) to remove traces of 
serum.  300uL mixture was added to each well along with an additional 300μL DMEM 
high glucose (no serum) and incubated for 4 hours.  After, 1mLof DMEM high glucose 
with 10% FBS was added.  Medium was changed the next day.  Knockdown was 
assessed at time points described.  This transfection protocol was also attempted on cells 
not trypsinized (100% confluent) without success. 
Gene Silenced Species 5′ – 3′ Silencer Select siRNA (Ambion) Sense Sequence 
PKCβII Mouse CAAUCAGAAUUCGAAGGAUtt (Custom) 
PKCβII Mouse AGAGCUAAGUAGAUCCGUAtt (Custom) 
Silencer Select 
Negative 
Control #1 
siRNA 
(#4390843) 
Rat, 
Mouse, 
Human 
Proprietary 
 
Oil Red O Staining 
 
 3T3-L1 adipocytes were cultured on chamber slides and fixed with 10% formalin 
in PBS, washed with PBS, and stained for 1 hour at room temperature with 0.15% Oil 
Red O (Sigma) (60:40 mix of isopropanol and water).  Slides were evaluated for the 
accumulation of lipid droplets. 
Cloning the Minigene 
 
 Construction of the PKCβ heterologous minigene was initiated by Hercules 
Apostolatos (H.A.).  PCRs were performed on rat cell DNA extracts to obtain the βII and 
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βI exonic sequence and their flanking intronic sequence (as depicted in Figure 36).  The 
primers (sequences listed with rest of primers) used and the products (visualized in 
Figure 36) obtained are summarized in the following table (performed by H.A.): 
Primer pair Restriction 
Enzymes 
(RE) Inserted 
5′ intronic 
length (not 
including 
RE) 
Exon length 3′ intronic 
length (not 
including 
RE) 
Total size 
BII sense & 
ss1 antisense 
5′ XhoI, 3′ 
BamHI 
103bp 216bp 80bp 399bp 
BII sense & 
ss2 antisense 
5′ XhoI, 3′ 
BamHI 
103bp 216bp 120bp 439bp 
BII sense & 
ss3 antisense 
5′ XhoI, 3′ 
BamHI 
103bp 216bp 346bp 665bp 
BII sense & 
ss4 antisense 
5′ XhoI, 3′ 
BamHI 
103bp 216bp 684bp 1003bp 
BI sense & 
BI antisense 
5′ BamHI, 3′ 
XbaI 
422bp 150bp 7bp 579bp 
BII and BI fragments were digested with BamHI and ligated to produce a BII-BI 
fragment with relevant flanking intronic sequence (H.A.).  These fragments were in turn 
digested with XhoI and XbaI (H.A.).  The pTNT cloning vector (Promega, Madison, WI 
#L5610) was also digested with XhoI and XbaI (H.A.).  The BII-BI fragments, now with 
overhangs were ligated into the pTNT cloning vector (Figure 37)(H.A. and E.K.).  The 
resulting vectors were used by H.A. to perform in vitro transcripion/splicing assays.  For 
use in mammalian cells, the BII-BI fragments would have to be cloned into a vector 
containing a promoter responsive to mammalian cells.  The pCMVTNT vector (Promega, 
#L5620) was used (Figure 38 & 39).  The BII-BI fragments inside the pTNT vector were 
digested with XhoI and XbaI as was the pCMVTNT vector.  The two were ligated.  
pCMVTNT BII-BI ss3 was tested by transfecting it into L6 skeletal muscle cells.  
However, using the CMV_FP1 and CMVRP1 primers (sequence listed below), many 
products were observed (Figure 40) due to the presence of a chimeric intron and T7-SP6-
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β-globin exon within the pCMVTNT vector (Figure 41).  To bypass this obstacle, 
pCMVTNT BII-BI plasmids were cut with BbsI and XhoI (Figure 40).  The BII-BI 
fragments inside the pCMVTNT vector were PCRed out by using BbsI_CMV_F and ss1-
ss4 reverse primers (sequence listed below).  This PCR fragment was digested with BbsI 
and XbaI and ligated to the digested pCMVTNT BII-BI vector (Figure 42).  Of the 
resultant clones pCMVTNT BII-BI ss1 and ss4 (minus the chimeric intron) were tested.  
Both the resultant ss1and ss4 clones were transfected into L6 skeletal muscle cells and 
resulted in appropriate splice products (Figure 43 & 44) using CMV_FP1 & B1R3 
primers (sequence listed below).   The ss4 clone was the most desired clone because it 
had the most intronic sequence thereby allowing for more potential SR protein binding 
analysis.  Because the ss4 splice products were in low abundance, the decision was made 
to use the more responsive ss1 plasmid and reclone the additional splice sites into the ss1 
clone (Figure 45).  pCMVTNT ss4 was PCRed using BbsI_CMV_F & ss4 antisense 
primers to release the BII half of the ss4 fragment.   Before this experiment could 
proceed, an additional BamHI located on the pCMVTNT ss1, had to be eliminated.  This 
was done by starting from scratch and digesting the original pCMVTNT vector with 
BamHI.  This was blunted by Klenow fill-in and blunt ligated.  The ss1 fragment was 
recloned from the pTNT ss1 vector as before (Figures 45).   Now the PCR product and 
the pCMVTNT ss1 (-Chimeric intron) were digested with BbsI and BamHI.  The two 
were ligated.  The resultant vector, pCMVTNT ss4 (-CI, -BamHI), was proven to be 
functional.   
To study the relationship between the PKCβ promoter and gene splicing, the CMV 
promoter was replaced with the human PKCβ promoter (Figure 46).  To do this, PCR was 
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performed using bprom_5 and bprom_AS primers (sequence listed below) on Construct 5 
PKCβ promoter Luciferase vector [121].  The resultant PCR product contained 2243bp of 
the human PKCβ promoter including the transcriptional and translational start site.  The 
PCR product and pCMVTNT ss4 (-CI, -BamHI) were digested with BsrGI and PstI, then 
ligated.  The resultant vector was named Bprom 2243 BII-BI ss4 (Figure 46).  A 
subsequent truncated version was made to study a putative PPRE.  To do this Bprom BII-
BI ss4 was digested with BsrGI and SacI restriction enzymes, then subsequently blunted 
and relegated.  The resultant clone was named Bprom 1143 BII-BI ss4 (Figure 47).  Both 
Bprom clones were verified by restriction digestion and sequencing (Moffitt Cancer 
Center Sequencing Core).  The splice products of Bprom 2243 BII-BI ss4 were compared 
to that of the vector with the CMV promoter by sequencing and were found to be 
identical (Figure 48). 
Mutation of Putative PKCβ Minigene PPRE 
 Mutation of the putative PPRE within the minigene PKCβ promoter was 
accomplished using the QuikChange Lightning Site Directed Mutagenesis kit #210515 
(Stratagene, La Jolla, CA) according to manufacturer manual.  The putative PPRE was a 
DR2 (direct repeat with 2 base pairs separating).  The putative PKCβ promoter DR2 was 
5′ – AGCTCATCAGTTCA – 3′.  This DR2 PPRE was -1848bp upstream of the PKCβ 
transcript start sequence as defined by Vega Human TransView.  The mutagenic forward 
primer named DR2_60_sense had the sequence of 5′ – AAG GCA GGA TGT GGG CTG 
TGA GCT TCC CTT GTG TCA GTT CAA AGG AAA TCT ACT TCA GCA – 3′ (red 
font denoting mutated nucleotides).  The mutagenic reverse primer was named 
DR2_60_anti with a sequence of 5′ – TGC TGA AGT AGA TTT CCT TTG AAC TGA 
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CAC AAG GGA AGC TCA CAG CCC ACA TCC TGC CTT – 3′.   The resultant clone 
was named Bprom 2243 DR2 mut BII-BI ss4. 
RT-PCR 
 
 RNA was extracted using RNA Bee (Tel Test Inc., Friendswood, TX), according 
to manufacturer′s protocol.  Reverse Transcriptase was performed using Omniscript RT 
kit (Qiagen, Valencia, CA, #205113) according to manufacturer′s protocol.  PCR was 
performed using rTaq PCR kit (#R001A, Taqara Bio Inc., Japan).  Primers used for PCR 
reactions were as follows: 
Gene of 
Interest 
Species  Primer 
Direction 
5′ – 3′ Primer Sequence Overhang 
PKCβII & 
PKCβI 
(endogenous) 
Rat Forward GGC GTA TCC CAA GTC CAT GTC 
TA 
 
PKCβII & 
PKCβI 
(endogenous) 
Rat Reverse GGG TTA GTA TAC GAG AAG CCA 
GC 
 
PKCβII only 
(endogenous) 
Rat  Forward ATG AAA CTG ACC GAT TTT AAC 
TTC CTG 
 
PKCβII only 
(endogenous) 
Rat Reverse  CGG AGG TCT ACA GAT CTA CTT 
AGC TCT 
 
PGC1α Rat Forward CCC ACG ACT CCT CCT CAT AAA 
GC 
 
PGC1α Rat Reverse GGC GCT CTT CAA TTG CTT TCT 
GC 
 
PPARγ Rat Forward GGC CCA CCA ACT TCG GAA TCA 
GC 
 
PPARγ Rat Reverse CCG CCA ACA GCT TCT CCT TCT 
CG 
 
SRp40 Rat Forward CGC AGA CCT CGA AAT GAT AGA 
CG 
 
SRp40 Rat Reverse CGC CAC CCA CTT GAA GGA TAC 
TAC C 
 
PKCβ 
promoter 
Human Forward TTC TGT ACA GTT TAA CAG TAT 
CTG GAA C 
 
PKCβ 
promoter 
Human Reverse TTA CTG CAG GGG CTG TCA CTC 
GCC CAG CTG CTG  
 
GFP  Forward CGT GCA GTG CTT CAG CCG CTA  
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CC 
GFP  Reverse CGG CGG CGG TCA CGA ACT CCA 
GC 
 
GATA 2 Mouse Forward CCG GGC TCT CCT GGT GTC TCT 
TAC 
 
GATA 2  Mouse  Reverse GGC GGG CAC ATA GGA GGG ATA 
GG 
 
RUNX1 Mouse Forward CGG CCT CTC GCT ACC ACA CCT 
AC 
 
RUNX1 Mouse Reverse TCA GCT CAG TAG GGC CGC CAC 
AC 
 
HnrnpG Mouse Forward CCG GGA AAC CAA CAA ATC AAG 
AG 
 
HnrnpG Mouse Reverse CGT GGT GGA CCC CCG TAG CTA 
TC 
 
MZF1 Mouse Forward GCT TTG CCC ATG CCC TTG TAC 
TC 
 
MZF1 Mouse Reverse CGC CAC ACA CGA ACG GTC TCT 
C 
 
Nkx2-5 Mouse Forward GGG CGG ATA AAA AAG AGC TGT 
GC 
 
Nkx2-5 Mouse Reverse TGG GGT AGG GGT AGG CGT TGT 
AG 
 
Prrx2 Mouse Forward GCT CGC CGT GTC AAC CTC AGT 
G 
 
Prrx2 Mouse Reverse GAT GGA GAA AAG GCA CGG GAG 
AG  
 
AP2α Mouse  Forward CCC CGC CCT ACC AGC CTA TCT 
AC 
 
AP2α Mouse  Reverse TTC CGC CAC CGT GAC CTT GTA C  
GATA 1 Mouse  Forward CGC CCA CTG ACC ATG AGG AAA 
G 
 
GATA 1 Mouse  Reverse CCG GTG GGG AAG GAG GTT GTA 
G 
 
GATA 3 Mouse Forward CGG CCA CTC CAG TCC TCA TCT C  
GATA 3 Mouse  Reverse CGG GTC TGG ATG CCT TCT TTC 
TTC 
 
SpiB Mouse Forward GGG GGA TGT GTG GCA GAG GTA 
TG 
 
SpiB Mouse Reverse CGG CCA GGG CTA CAC AGA GAA 
AC 
 
Spi1 Mouse Forward TTC CAG TTC TCG TCC AAG CAC 
AAG 
 
Spi1 Mouse Reverse GGG CGA CGG GTT AAT GCT ATG 
G 
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FOXC1 Mouse  Forward TGC CCC GGA CAA GAA GAT CAC 
TG 
 
FOXC1 Mouse  Reverse CCG TTC TCC GTC TTG ATG TCC 
TG 
 
GAPDH Mouse Forward GAT GAT GGA GGA CGT GAT GG  
GAPDH Mouse  Reverse GGC TGC AGG AGA AGA AAA TG  
GLUT4 Mouse  Forward CGG TTC CTC ATT GGC GCC TAC 
TC 
 
GLUT4 Mouse  Reverse CGA CTC GAA GAT GCT GGT TGA 
ATA G 
 
β-actin Rat Forward GTG GGC CGC TCT AGG CAC CAA  
β-actin Rat Reverse CTC TTT GAT GTC ACG CAC GAT 
TTC 
 
β-actin 
promoter 
Mouse Forward AGC CAC AAA CCA AAG AGA GGG 
AC 
 
β-actin 
promoter 
Mouse Reverse GTC AAT CAC CTT ACC TGG CTT 
AC 
 
PKCβ 
promoter -
7091 
Mouse Forward GTG TTA GCT TGC TTG AGG GTG 
TC 
 
PKCβ 
promoter -
6903 
Mouse Reverse GGA AAG GTA CCA CAA CTA AAA 
CAG 
 
PKCβ 
promoter -
4384 
Mouse Forward GTG TTG CCT GCA TTG GAG AGT 
AC 
 
PKCβ 
promoter -
4183 
Mouse Reverse CAC AAA CAA CAA AGC AGA ATA 
GC 
 
PKCβ 
promoter -
1440 
Mouse Forward GAC CGA ATG AGA CAG TGC ACA 
AG 
 
PKCβ 
promoter -
1271 
Mouse Reverse CCT GGT GTT GAG TTT AGC ATC 
TG 
 
PKCβ 
promoter -676 
Mouse Forward TCC GGA TGA GTG ACA ATG AAA 
GC 
 
PKCβ 
promoter -492 
Mouse Reverse CCA GCA ATG ACC AAA CGC CTA 
AG 
 
PKCβ C4B2 Mouse Forward TTA TAA ACC AAA AGC TTG TGG 
GCG 
 
PKCβ B2i Mouse Reverse GGA GGG ATT CCC TCT AGG GCA 
AAG CAG CC 
 
PKCβ B1 Mouse Reverse GGG AGT CAG TTC CAC AGG CTG 
CC 
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Minigene 
primers 
    
BII sense  Rat  Forward GGG CTC GAG GAA AAA CCA CAC 
CCG GTT CC 
XhoI 
Ss1 antisense Rat  Reverse CTA GAG TGG CCA TGT TTC AGT 
GAT CAA AT 
BamHI 
Ss2 antisense Rat  Reverse GTT TGG AGC CAT CTT CGA GGT 
GAT CAA AT 
BamHI 
Ss3 antisense Rat Reverse CAT TCT TCC ACC TTC CCG GCT 
GAT CAA AT 
BamHI 
Ss4 antisense Rat  Reverse CAT TTG GCA CTG TTC TTA GAT 
GAT CAA AT 
BamHI 
Bbs_CMV_F pCMV
TNT 
Forward GCG AAG ACT CTT GCG AAA AAC 
CAC ACC CGG TTC C 
BbsI 
BI sense Rat Forward CTC GGA TCC ACA GGC GTT GTC 
ATT GAG TT 
BamHI 
BI antisense Rat Reverse CAT TAA TGT GTA GGT GAA TGT 
CTA GAC CA 
XbaI 
Bprom_5 Human Forward TTC TGT ACA GTT TAA CAG TAT 
CTG GAA 
BsrGI/ 
Bsp1407I 
Bprom_AS Human Reverse TTA CTG CAG GGG CTG  PstI 
CMV_FP1 pCMV
TNT 
Forward AGC TTT ATT GCG GTA GTT TAT C  
T7flgFP5 pCMV
TNT 
Forward CAC CTG CAG AAG TTG GTC GTT 
AGG CAC TGG G 
 
CMV_RP1 pCMV
TNT 
Reverse GGC CGC CCG GGT CGA CTC TAG  
B1R3 Rat Reverse AGT TTG TCA GTG GGA GTC AG  
  
Silver Staining  
 
 6% polyacrylamide (using 40% Acrylamide/Bis  cat# 1610146 from Bio-Rad 
Laboratories, Hercules, CA) gel was prepared.  Samples were run on gel and put in 10% 
ethanol (Fisher) for 3 minutes.  The ethanol was replaced with 1% nitric acid (Fisher) for 
3 minutes.  Gel was then rinsed three times with water and soaked in 0.1% silver nitrate 
(Sigma) for 10 minutes.    After a quick wash with water, gel was developed using 6% 
sodium carbonate (Fisher) with 0.2% formaldehyde 37% solution (Fisher).  Reaction was 
terminated with addition of 10N glacial acetic acid (Fisher).   
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Agarose Gel 
 
 1% agarose gel (Fisher Scientific, Agarose Molecular Biology Grade cat#  
 
BP1356) was made with ethidium bromide to detect nucleic acids. 
 
Western Blot Analysis 
 
Cell lysates were combined with 2X Laemmli Buffer (Bio-Rad Laboratories) with 
additional SDS up to 8%.  Lysates were subjected to 10% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE).  Gel proteins were electrophoretically transferred to 
Hybond-C Extra nitrocellulose membranes (Amersham, Piscataway, NJ).   Membranes 
were blocked with Tris-buffered saline (Bio-Rad), 0.05% Tween 20 (Bio-Rad) containing 
5% nonfat dried milk, and then incubated with primary and secondary antibodies.  The 
only exception was when probing for PKCβII, where pig gelatin (Bio-Rad) was used for 
the blocking (3%), primary (1%) and secondary (1%).  Detection was performed using 
SuperSignal West Pico Chemiluminescent substrate (Pierce Biotechnology, Rockford, 
IL).  Antibodies used are as follows:  PKCγ C-19, PKCζ C-20, PKCδ C-17, PKCβI C-16, 
pPKCβII/δ Ser660,  pPKCζ Thr 410, Akt1/2/3 H-136, pAkt1/2/3 Thr308, GLUT4 sc1608 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), PPARγ 81B8, pIRβ Tyr 1150/1151, 
PKCα #2056, phospho mTOR Serine 2481, PGC1α 3G6, PU.1 9G7, pAkt Ser473 #4058, 
Adiponectin C45B10 (Cell Signaling,  Boston, MA), GLUT4 C-Terminus 07-1404 
(Millipore, Billerica, MA), β-actin A5441, anti-flag M2 (Sigma).  PKCβII (NH2–(GC) 
EGFSFVNSEFLKPEVKS-COOH), SRp40 (NH2-(GC) EVTFADAHRPKLNE-COOH), 
and SRp55 NH2-(GC) GERVIVEHARGPRRDRD-COOH) were raised by BioSynthesis 
Inc. (Lewisville, TX) and purified using Nab Protein A Plus Spin Kit (Pierce #89948).  
Film bands were quantified using UnScan software (Silk Scientific, Orem, UT). 
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Co-immunoprecipitation 
 
 3T3-L1 adipocytes were harvested with Cell Lysis Buffer (Cell Signaling #9803) 
with added protease inhibitors (SigmaFast Protease Inhibitor Tablet, Sigma).  500μg cell 
lysate was pre-cleared with 50μL Protein A Magnetic Beads #S1425S (New England 
Biolabs, NEB, Ipswich, MA) for 1 hour 4oC with rotation.  This step eliminated non-
specific binding of protein to magnetic beads.  Lysate was separated from beads using 
Magnetic Separation Rack (#S1506S, NEB).  5μg PKCβII antibody (sc-210, Santa Cruz) 
or GLUT4 (sc-7936, Santa Cruz) was incubated with pre-cleared lysate O/N 4oC with 
rotation.  Lysates were now incubated with 50μL Protein A Magnetic Beads for 1 hour 
4oC.  Magnetic field was applied to separate beads from unbound lysate.  Beads were 
washed three times with cell lysis buffer.  75μL 2X Laemmli Buffer (Bio-Rad) with DTT 
was added to the beads.  Samples were boiled for 10 minutes and loaded onto a 10% SDS 
PAGE gel.   
Real-time PCR 
 
Real-Time PCR reactions were performed using TaqMan Universal PCR 
MasterMix (Applied Biosystems (AB) Inc., Foster City, CA, #4304437) according to 
manufacturer′s protocol.  Vic-labeled mouse β-actin was the endogenous control (AB, 
#4352341E).  PKCβII primers and probe were custom made from AB.  Forward primer 5′ 
- GGAGATTCAGCCACCTTATAAACCA - 3′.  Reverse primer 5′ - 
GGTGGATGGCGGGTGAAAA - 3′.  Fam-labeled probe (PKCβ2/PKCβ1 junction) 5′ - 
TTCGCCCACAAGCTT - 3′.  Real-Time PCR was analyzed on the ABI PRISM 7900HT 
Sequence Detection System (AB). 
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Glucose Uptake 
 
[3H]2-deoxyglucose uptake into differentiated 3T3-L1 cells was measured in six-
well plates [411].  Briefly, cells were serum starved with DMEM high glucose for 4 h.  
Media was then changed to 1mL Krebs-Ringer HEPES (121mM NaCl; 4.9mM KCl; 
1.2mM MgSO4; 0.33mM CaCl2; 12mM HEPES, pH 7.4) ± CGP53353 (Novartis, Basel, 
Switzerland) for 30 min ± 100nM pig insulin (Sigma) for 15 min.  [3H]2-deoxyglucose 
(1μCi per well) was added for another 4 min.  The reaction was terminated by addition of 
KRH with 25mM D-glucose (Sigma) containing 10μM cytochalasin B (Sigma).  Cells 
were washed, lysed with 0.1% sodium dodecyl sulfate, and radioactivity was counted 
using a Beckman Coulter LS 6500 Multi-Purpose Scintillation Counter.  Carrier-specific 
uptake was obtained by subtracting nonspecific diffusion of [3H]2-deoxyglucose into the 
cells in the presence of 10μM cytochalasin B.  Counts were normalized to protein 
concentration using the BCA protein assay (Pierce). 
Subcellular Fractionation  
 
Subcellular fractionation was performed essentially by the method of Elmendorf 
et al. [412].  Three 25cm plates of cells were used per condition in order to generate 
enough protein yield for the PM fractions.  After treatment, cells were rinsed with 
HEPES-EDTA-sucrose (HES) buffer.  All subsequence steps were performed at 4oC.  
Each plate was scraped in 2mL HES buffer with 1X protease (Sigma) and 1X 
phosphatase (Sigma) inhibitors.  This was followed by dounce homogenizing with 50 
strokes using a Potter-Elvehjem grinder.  The homogenate was centrifuged at 19,000 g 
for 20 min.  The resulting supernatant was centrifuged at 41,000 g for 20 min.  The high-
density microsomal fraction (HDM) pellet was resuspended in HES buffer.  The 
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supernatant was centrifuged at 180,000 g for 75 min, yielding the low-density 
microsomal (LDM) fraction pellet.  The pellet from the initial 19,000 g spin was layered 
onto 1.12M sucrose cushion in HES buffer and centrifuged 100,000 g for 60 min.  This 
yielded a white band at the interface [plasma membrane (PM) fraction] and pellet 
consisting of nuclei/mitochondria (M/N fraction).  The PM fraction was resuspended in 
HES buffer and pelleted at 40,000 g for 20 min.  Protein levels in each fraction were 
quantified using the BCA protein assay (Pierce).   
Plasma Membrane Sheet Assay 
 
3T3-L1 cells were differentiated to day 8 on BD BioCoat Collagen Type I 8-well 
CultureSlides.  PM sheets were obtained using a modified protocol of Olson et al. [140].  
Cells were swelled with three rinses of hypotonic buffer (23mM KCl, 10mM HEPES, 
2mM MgCl2, 1mM EGTA [pH 7.5]).  Swollen cells were sonicated and washed two 
times with sonication buffer (70mM KCl, 30mM HEPES, 5mM MgCl2, 3mM EGTA, 
1mM dithiothreitol, 0.1mM PMSF [pH7.5]).  PM sheets were fixed with 2% 
formaldehyde (70mM KCl, 30mM HEPES (pH7.5), 5mM MgCl2, and 3mM EGTA) at 
room temperature 20 min.  Fixed membranes were quenched 15 min at 25oC in 100mM 
glycine-PBS (pH7.5).  PM sheets were rinsed three times PBS and blocked 5% donkey 
serum (Sigma) 4oC O/N.  They were then incubated with GLUT4 C-20 (Santa Cruz 
#1608) 1 hour, washed three times in PBS and incubated with donkey anti goat Alexa 
Fluor 488 secondary antibody (Molecular Probes).  PM sheets were washed three times in 
PBS and incubated 15 min with Deep Red Cell Mask Plasma Membrane Stain 
(Molecular Probes) as an internal marker of membrane amount.  Stained PM sheets were 
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visualized with Leica SP2 laser confocal microscope and analyzed using Leica Confocal 
Software (Leica Microsystems Wetzlar GmbH, Germany).   
GLUT4 Exofacial Loop Translocation/Fusion Immunofluorescence Assay 
 
 3T3-L1 cells were differentiated to day 8 to day 12 on BD BioCoat Collagen 
Type I 8-well CultureSlides.  This experiment was modeled after that of Yashamoti et al. 
[413].  After treatment, cells were washed quickly with PBS buffer and fixed with 4% 
formaldehyde 15 minutes room temperature.  Cells were washed three times with PBS 
and incubated O/N 4oC with goat GLUT4 N-20 antibody (sc-1606 , Santa Cruz) diluted 
in 3% donkey serum.  Cells were washed three times with PBS and incubated 45 minutes 
with donkey anti-goat Alexa Fluor 594 (Molecular Probes) diluted in 3% donkey serum.  
Cells were washed three times with PBS, dried completely and mixed with Vectashield 
mounting media with DAPI (Vector Laboratories, Inc., Burlingame, CA) just before 
coverglass application.  Cells were imaged and analyzed as mentioned in the plasma 
membrane sheet assay.   Experiment was also attempted by incubating live cells with 
primary antibody immediately after treatment for 30 minutes (with or without Cell Mask 
Plasma Membrane Stain, Molecular Probes), fixing 15 minutes after treatment and then 
incubating with secondary.  This was done because even without detergent, GLUT4 
antibody was penetrating the plasma membrane.  However, even with these modification, 
GLUT4 antibody was still able to penetrate the plasma membrane.   
Immunofluorescence Measure of pAkt Ser473 
 3T3-L1 cells were differentiated to day 8 through day 12 on BD BioCoat 
Collagen Type I 8-well CultureSlides.  After treatment, cells were washed quickly with 
PBS buffer and fixed with 4% formaldehyde 15 minutes room temperature.  Cells were 
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then blocked 60 min 1% BSA blocking solution with 0.05% saponin.  Cells were then 
incubated with pAkt Serine 473 Antibody (#4058, Cell Signaling) in blocking buffer 4oC 
O/N.  After washing three times with PBS, cells were incubated with combination of anti-
rabbit Alexa Fluor 568 Secondary Antibody (#A11011, Molecular Probes), TO-PRO-3 
nucleic acid stain (Molecular Probes) and RNase A (#19101, Qiagen) 45 minutes, room 
temperature in the dark.  The RNase A digested the RNA so only the DNA (thus the 
nucleus) will show.  Cells were washed five times for five minutes with PBS.  
Vectashield mounting media without DAPI (Vector Labs) was applied.  Approximately 
10 arbitrary fields were pictured per condition.  Experiment was repeated four times.  
Images in figure were processed using Image J software.  Z-stack series from each field 
were stacked and shown as Z projection with maximum intensity.   
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RESULTS 
 
TZDs and Alternative Splicing (A) Hela Cells 
 
TZDs are a class of drugs used for the treatment of non-insulin dependent 
diabetes mellitus.  The molecular target of these drugs is PPARγ.  The main tissue target 
is adipose, which has robust PPARγ expression.  PPARγ activation in this cell type leads 
to overall increased insulin sensitivity in peripheral insulin sensitive tissues.  Insulin 
resistance occurs despite qualitatively and quantitatively normal insulin receptors.  
Therefore, the mechanism for increased glucose disposal lies downstream of the insulin 
receptor [414].  Initial experiments focused on determining whether there was a link 
between TZD treatment and increased alternative splicing of PKCβII, which had been 
shown to be involved in mediating insulin-stimulated glucose uptake in skeletal muscle 
cells [36; 40; 113].  The HeLa cervical cancer cell line was first tested.  Cells were grown 
to confluency and serum starved for 6 hours.  Cells were either treated with 50nM of 
bovine insulin or 1μM Pioglitazone for 24 hours.  Pioglitazone was able to mimic the 
effects of insulin (30 min) on PKCβ alternative splicing.  Relative to control, both insulin 
and Pioglitazone treated cells were able to regulate PKCβ such that PKCβI mRNA 
decreased concomitant with increased PKCβII mRNA expression (Figure 23).  This was 
also novel in that it showed that HeLa cells expressed insulin receptors and that they were 
insulin responsive.   
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TZDs and Alternative Splicing (B) Vascular Smooth Muscle Cells 
TZDs increase insulin sensitivity in insulin-resistant patients and animal models.  
However, they also beget other benefits that may not be mutually exclusive to one 
another.  These benefits include lower blood glucose, decreased circulating free fatty 
acids and triglycerides, lower blood pressure, reduced inflammatory markers, and 
reduced atherosclerosis [313].  PPARγ is expressed in vascular endothelial cells and 
vascular smooth muscle cells (VSMCs).  Proliferation and migration of VSMCs are 
essential in the progression of atherosclerosis.  Inflammation is considered a key 
stimulator of this proliferation and migration.  PPARγ activation can suppress the 
expression of TNFα-induced expression of inflammatory genes such as VCAM-1, MCP-
1 and fractalkine via inhibition of NFκB [415].   Yamamoto et al. has shown that PKCβII 
expression is associated with decreased VSMC proliferation [41].  A possible link 
between TZDs and PKCβII mediated effects on VSMCs was examined.  Figure 24 shows 
A10 rat VSMCs treated with 1μM Pioglitazone for 26 hours increased the mRNA 
expression of PKCβII while decreasing the mRNA expression of PKCβI.  However, A10 
cells proved difficult to culture and synchronize.  The focus turned to L6 rat skeletal 
muscle cells which represent the main insulin responsive tissue responsible for glucose 
disposal.  These cells divide and differentiate rapidly making them an ideal cell line.   
TZDs and Alternative Splicing (C) L6 Skeletal Muscle Cells 
 Skeletal muscle represents a major insulin-reponsive tissue where most glucose 
disposal occurs.  TZDs result in improved whole-body glucose disposal which includes 
skeletal muscle [416].  However, it is unclear whether this effect on skeletal muscle is a 
result of indirect actions such as lowering FFAs or TZDs can actually exert effects on 
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skeletal muscle signaling.  Thus, a possible link between TZDs and skeletal muscle 
signaling was explored.  Using L6 cells, 1μM Pioglitazone for 24 hours was able to 
mimic 100nM bovine insulin for 30 minutes in terms of PKCβII mRNA expression 
(Figure 25).  When Pioglitazone and insulin were combined, there was a synergistic 
increase in PKCβII mRNA expression.  Protein expression of PKCβII revealed a similar 
trend whereby 1μM Pioglitazone was able to mimic 45 or 60 minutes of 100nM bovine 
insulin (Figure 26).  SRp40 overexpression was also able to increase PKCβII expression.  
Three SRp40 constructs were used.  After this experiment, only the construct donated by 
Dr. Rebecca Taub was used.  This data is in concurrence with previous Cooper lab data 
showing SRp40 enhancement of PKCβII alternative splicing [37; 38; 211].  RT-PCR 
detection of PKCβI using primers for both PKCβI and PKCβII was sporadic and not 
reliable. 
PKCβII mRNA Regulated by Overexpression of PPARγ, PGC1α and SRp40 
 Since the main target of TZDs is PPARγ, overexpression of PPARγ was next 
assessed along with overexpression of PGC1α and SRp40.  PGC1α expression favors the 
slow twich, oxidative muscle fiber type [372] and this fiber type has increased insulin-
stimulated glucose uptake [417].  Possible regulation of PKCβ via PGC1α would explain 
the enhanced ability for glucose uptake muscles obtain during TZD treatment.  As shown 
in Figure 27, overexpression of PPARγ, PGC1α and SRp40 and combinations of the three 
resulted in increased mRNA expression of PKCβII compared to control.  The 
combination of all three constructs may have been too much and thus created an 
imbalance.  This is maybe why there is a slight decrease in PKCβII levels compared with 
combinations of two constructs.   
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Functionality of PGC1α C-terminal Domain 
 PGC1α upregulation of PKCβII mRNA necessitated the question of which 
domain was critical in mediating this effect.  The C-terminal domain was thought to be 
the critical effector because it provided the bridge between nuclear receptors and the 
mediator complex as well as serving as a landing pad for splicing factors [361].  In fact, 
SRp40 has been confirmed to bind PGC1α [362].  Figure 28 shows that overexpression of 
CTD mutant PGC1α led to a decrease in PKCβII mRNA expression (compared with 
control) versus wild-type PGC1α which resulted in an expected increase in PKCβII 
mRNA in L6 cells.  
TZDs Influence PKCβ Expression Level and Alternative Splicing  
  Since PGC1α is able to participate in both transcription and splicing, it seemed 
reasonable that TZD treatment may work in a similar mechanism in relation to the PKCβ 
gene.  L6 cells were treated with either 1μM Pioglitazone or Rosiglitazone for 24 hours.  
Both TZDs were able to increase the protein expression of PKCβII while keeping PKCβI 
relatively constant (Figure 29).  This suggested TZDs could influence transcription and 
splicing preferentially selecting the PKCβII isoform.  Rosiglitazone seemed to perform 
even better than Pioglitazone in terms of PKCβII induction.   
Hypothesis #1: TZDs Co-transcriptionally Regulate PKCβ Gene Expression 
 Data obtained up to this point led to the hypothesis that TZDs were able to co-
transcriptionally regulate the PKCβ gene, thereby mimicking the insulin signaling 
cascade (Figure 30).  This would result in increased transcription as well as increased 
alternative splicing that would favor the PKCβII isoform.  This phenomenon would come 
to fruition via TZD-mediated activation of PPARγ.  PGC1α would bind PPARγ.  Even 
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though PPARγ does not have to be active to bind PGC1α, PPARγ activation would be 
required for PKCβ promoter activation.  PPARγ-bound PGC1α C-terminal domain would 
serve as a landing pad for splicing factors that have a positive regulatory effect on 
PKCβII exon inclusion.  These splicing factors would eventually be dropped off to the 
CTD of RNA polymerase II.  Selective SR protein recruitment (e.g. SRp40) would result 
in RNA polymerase II pausing at the weak PKCβII 3′ splice site (intronic sequence just 
before PKCβII exon).  This pause would result in enhanced recognition of the weak 
splice site and thus greater PKCβII exon inclusion.  TZD treatment could regulate factors 
downstream of the insulin signaling pathway, bypassing upstream insulin signaling that 
may be dysfunctional in the insulin-resistant or diabetic state. 
Role of Overexpressed PPARγ on PKCβ Protein Levels 
The ability of PPARγ overexpression to induce PKCβ co-transcripional splicing 
was assessed.  1 or 3μg PPARγ cDNA construct was transfected into L6 cells for 72 
hours.  Figure 31 shows that PPARγ overexpression (regardless of dosage) was able to 
increase protein expression of both PKCβI and PKCβII isoforms.  However, this is not 
the same mechanism of control as compared with TZD treatment.  PPARγ expression 
appears to exert more of a transcriptional effect on the PKCβ gene since PKCβI is 
increased too.  The ligand-dependent AF2 transcriptional activator domain appears to be 
necessary for the increase in PKCβII protein levels.  Overexpression of an AF2 mutated 
PPARγ construct resulted in an increase in PKCβI protein expression but no increase in 
PKCβII protein expression (Figure 32). 
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Role of Overexpressed PGC1α on PKCβ Protein Levels 
PGC1α overexpression was utilized to determine whether it could more closely 
mimic the effects of TZD treatment in terms of PKCβ co-transcriptional splicing in L6 
cells.  As shown in Figure 33, PGC1α overexpression (both 2 and 4μg) mimicked TZD 
treatment and resulted in increased PKCβII protein expression while PKCβI protein 
expression was little changed.  Establishing PGC1α overexpression was difficult.  The 
flag antibody did not work for this tagged protein and the endogenous PGC1α antibody 
could barely be detected.   
Effect of siRNA Knockdown of PPARγ, PGC1α and SRp40 on PKCβII mRNA 
A knockdown strategy using 24 hour transfected siRNA was next employed to 
determine whether endogenous levels of PPARγ, PGC1α or SRp40 are influential in 
generating PKCβII.  In Figure 34, knockdown of PPARγ and PGC1α resulted in reduced 
PKCβII mRNA levels.   In the case of PPARγ knockdown, PKCβII mRNA levels went 
further down with 24 hour treated 1μM Rosiglitazone. However, this may be due to 
experimental design.  Since the drug was added near the time of transfection, the 
transfection reagent may have reacted with Rosiglitazone causing a change in L6 
signaling.  Rosiglitazone treatment could not rescue PKCβII mRNA levels in PGC1α 
knockdown cells.  Figure 35 shows that SRp40 is necessary for PKCβII alternative 
splicing.  This had been predicted based on earlier Cooper lab data but had not been 
shown with SRp40 siRNA.  Again, Rosiglitazone treatment was unable to rescue PKCβII 
mRNA levels most likely because of the same experimental design flaws described 
above.   Even Rosiglitazone with scrambled siRNA had no effect on PKCβII, suggesting 
inhibition of the drug by the transfection reagent. 
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Generation of Heterologous PKCβ Promoter-driven PKCβ Minigene 
To determine whether PPARγ had a direct effect (via binding) on the PKCβ 
promoter, a heterologous PKCβ minigene was created as outlined in the Experimental 
Procedures section and illustrated in Figures 36-48.  This ultimately resulted in a 
minigene that had the BI and BII exons with sufficient flanking intronic sequences.  In 
addition, the minigene was under the control of 2243bp of the human PKCβ promoter.  
Figure 48 shows that this PKCβ minigene was functional since transcriptional products 
mimicked those of the CMV promoter construct.  The BI and BII mRNA products were 
confirmed by sequencing .  The minigene was also shown to be responsive to 2nM 
phorbol ester treatment (Figure 49).  TPA activated the promoter and increased both BI 
and BII products.  GFP expression is used to assess transfection efficiency because its 
expression is not governed by TPA treatment.   
Effect of TZD on PKCβ Minigene 
 TZD treatment results in co-transcriptional splicing of endogenous PKCβ.  To 
assess if this effect was related to a direct effect on the PKCβ promoter, the minigene was 
transfected for 48 hours and concomitantly the cells were treated with 1μM Pioglitazone 
for 24 hours as seen in Figure 50.   Pioglitazone was able to directly affect the PKCβ 
promoter and increase alternative splicing.  The result is dramatically increased BII 
minigene product.   
PPARγ-mediated PKCβ Transcriptional Regulation: Direct vs. Indirect? 
 Logical progression led to co-transfection of the minigene and PPARγ to assess 
whether PPARγ may be able to bind to a putative PPRE on the PKCβ promoter.  The 
minigene construct without the PKCβ promoter co-transfected with PPARγ had no effect 
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on either the BI or BII minigene products.  Conversely, the minigene construct with the 
PKCβ promoter co-transfected with PPARγ had a dramatic effect on both minigene 
products (Figure 51).  The only caveat of this experiment is that vector control was able 
to increase the BI minigene product.  This may be due to unintended effects of the control 
vector on the PKCβ promoter.  Still, PPARγ overexpression was able to elicit expression 
of the BII minigene product.  Compared with vector control, PPARγ decreased minigene 
BI expression.  This data indicates that PPARγ affects the PKCβ promoter and regulates 
alternative splicing as well as transcription.   
 To test whether there was a direct binding between PPARγ and the PKCβ 
promoter, the truncated PKCβ promoter minigene construct was utilized.  Within the 
upstream region of the PKCβ promoter insert, there is a putative DR2 PPRE as described 
in Experimental Procedures.  From bioinformatic analysis (Nuclear Hormone Receptor 
Scan software), this putative PPRE was the most promising of the 2243 PKCβ promoter 
sequence.  The truncated PKCβ promoter construct lacked this DR2 PPRE.  PPARγ was 
co-transfected with both PKCβ promoter constructs.  Figure 52 revealed that PPARγ was 
not acting through this putative DR2 PPRE.  Either PPARγ was acting on a more distal 
PPRE or PPARγ was affecting the PKCβ promoter indirectly through regulation of other 
transcription factor or coactivators.   
Role of TZDs in 3T3-L1 PKCβII Expression 
 It was determined that the mouse 3T3-L1 pre-adipocyte cells might be a better 
system for examining effects of TZDs on PKCβ co-transcriptional splicing in 3T3-L1 
mouse pre-adipocyte cells.  This cell model seemed a good candidate because during 
differentiation into adipocytes, they express high levels of PPARγ which is the target of 
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TZDs [418; 419; 420].  In addition, 3T3-L1 cells synthesize PPARγ agonists such as 15d-
PGJ2 [421] and a yet to be identified potent ligand that materializes at the onset of 
differentiation, lasts 48 hours, then disappears [422].  Figure 53 a-d demonstrated 3T3-L1 
differentiation (day 0 to day 6) using phase contrast microscopy.  Figure 53 e-h depicted 
accumulation of lipid droplets (red) from day 4 to day 6 via Oil Red O staining.  Oil Red 
O is a fat soluble dye (lysochrome) that stains triglycerides.  The purpose of this stain 
was to confirm differentiation protocol before proceeding to further experimentation. 
 The first experiment in 3T3-L1 cells focused on establishing a link between TZD 
treatment and PKCβ co-transcriptional splicing based on the experiments performed in 
L6 skeletal muscle cells.  As depicted in Figure 54, differentiating 3T3-L1 cells at day 4 
and 6 were chosen for TZD treatment.  It was known that by day 4, copious amounts of 
PPARγ were expressed.  Because culture conditions had not yet been completely 
established, both low and high glucose media were used.  1μM rosiglitazone for 24 hours 
activated PPARγ.  The evidence of this is that the level of PPARγ (both 1 and 2) decrease 
with Rosiglitazone treatment.  PPARγ activation via TZDs increased PPARγ proteasomal 
degradation.  This effect is not necessarily dependent on transcriptional activation but is 
dependent on the AF2 domain [423].    PPARγ activation had no discernable effect on 
either PKCβI or PKCβII protein levels on day 4 or day 6.  However, there was a dramatic 
change in the expression of PKCβ isoforms during the span of these two days.  From day 
4 to day 6, PKCβII expression increased over 6.6 fold while PKCβI expression was 
reduced roughly 1.5 fold.  This data was consistent with a report stating that the 
expression of PKCβ (no isoform distinction) increased at least 10 fold from pre-
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adipocytes to adipocytes [419].  This appeared to be a novel finding which represented 
developmentally regulated PKCβ co-transcriptional splicing. 
Discovery of Novel Differentiation-regulated PKCβ Alternative Splicing in 3T3-L1 
Cells 
 The experiment was repeated but included more days of differentiation.  Figure 
55 shows that again, 1μM Rosiglitazone failed to change the ratio of PKCβ isoforms 
during differentiation even though PPARγ was being activated.  But it was clear that 
PKCβII was heavily induced during differentiation while PKCβI was concomitantly 
decreased.  PPARγ and GLUT4 both served as markers of adipocyte differentiation.  This 
experiment was again repeated (without TZD treatment) but probed for additional 
proteins of interest.  Figure 56 spans from day 0 to day 12.  PKCβ was regulated as 
before.  PKCβII expression peaks at day 8 and then expression plateaus.  PKCδ has a 
similar expression pattern as PKCβII with very low levels at day 0, peaks at day 8 and 
then plateaus.    Longer exposures of the PKCδ blot revealed possible additional splice 
variants.  Seven splice variants have been reported in mice testis [424].  From the 20 sec 
exposure, four putative PKCδ splice variants were visible.  From the 15 min exposure, 
the remaining three putative PKCδ splice variants were visible.  Phospho PKCβII/δ 
antibody probing was very interesting.  This antibody detects the phospho epitope of 
PKCβII S660 and PKCδ S662.  The band displayed was almost certainly that of phospho 
PKCδ.  PKCβ was not expressed on day 0 and should not be phosphorylated regardless of 
the day in the absence of external stimuli such as insuln.  PKCδ has been reported to 
undergo biphasic serum-mediated phosphorylation in fibroblasts [425].  PKCα peaked at 
day 2 then tappers off.  This was consistant with the literature which states that PKCα is 
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downregulated during adipogenesis [426].  PKCγ also has a similar expression pattern to 
that of PKCβII.  However, its expression was very low in the early days with a dramatic 
jump from day 6 to day 8.  After day 8, there was a precipitous fall in PKCγ expression.  
Initially, PKCγ was reported to be only in the brain and spinal cord  [11].  However, a 
recent paper has described PKCγ expression in 3T3-F442A cells [48].  We believe this to 
be the first report of PKCγ expression in 3T3-L1 cells.  PKCζ expression steadily 
increased during adipogenesis peaking at day 6, afterwhich is precipitously drops.  This 
pattern is similar to that described by Ways et al.[426].  PPARγ, GLUT4 and adiponectin 
are used as markers of differentiation.  β-actin indicates relatively equal loading.   
Real-Time PCR Confirms PKCβII Adipogenesis Protein Expression Patterns 
 Real-Time PCR following the mRNA expression pattern of PKCβII during 
adipogenesis revealed a similar expression profile to protein with a peak at day 6 then 
plateauing (Figure 57).  Real-Time PCR was also performed using primers specific for 
PKCβI but this was unsuccessful.  Hence, PKC isozyme-specific expression, with peaks 
of PKCβII, PKCγ and PKCδ, were a hallmark of adipocyte differentiation. 
Use of Distal PKCβII polyA Tail During 3T3-L1 Differentiation 
The PKCβII mRNA transcript has two possible polyA tails to use as reported 
[427] and illustrated in Figure 5.  To determine which polyA tail was used by adipocytic 
PKCβII, RT-PCR was performed with indicated primers (Figure 58) that distinguish 
polyA tail usage.  RNA was collected from both day 0 and day 8 3T3-L1 cells.  Only the 
PKCβII transcript containing the distal polyA tail showed up.  GAPDH is a housekeeping 
gene used as a loading control and PPARγ indicates adipocyte differentiation.   
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Hypothesis #2: PKCβII Can Regulate GLUT4 Expression 
 Previous Cooper lab data had shown that knockdown of PKCβII in L6 skeletal 
muscle cells resulted in reduced GLUT4 protein expression levels (unpublished).  In 3T3-
L1 cells, PKCβII and GLUT4 expression appear at roughly the same time.  It was thought 
that PKCβII may regulate GLUT4 expression. 
 To test this hypothesis, knockdown of PKCβII would be necessary.  Transfection 
of one of two PKCβII specific silencer select siRNA was attempted using siRNA 
transfection reagents from Ambion (siPORT NeoFX), Mirus Bio (TransIT-TKO) and 
Panomics (DeliverX Plus).  In the case of DeliverX Plus, this reagent is supposedly 
tailored for differentiated 3T3-L1 adipocytes.  However, none of the above reagents gave 
any significant knockdown of PKCβII (Figure 59).    Further research into the literature 
revealed that differentiated 3T3-L1 adipocytes are notoriously difficult to transfect if not 
impossible [428; 429].  Electroporation is also not feasible for this cell line with very low 
efficiency and low cell survival.  Lentiviral transduction has been reported to have 
success [430].  However, there is only one available construct for the PKCβII.  Due to 
this uncertainty, this aim was put on hold.  
Regulation of PKCβ Promoter During 3T3-L1 Differentiation 
 Differentially regulated PKCβ alternative splicing suggests an important role for 
PKCβII in adipogenesis and adipocyte function.  Therefore, the factors that regulate this 
differential alternative splicing necessitated further inspection.  The mouse PKCβ 
promoter was examined for putative transcription factors that also had expression 
patterns similar or opposite (for negative regulators) to those of PKCβII during 
adipogenesis.  Figure 60 shows RT-PCR of RNA samples from day 0 to day 6 for factors 
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that had their respective consensus binding sites on the PKCβ promoter.   AP2, also 
known as fatty acid-binding protein 4 (FABP4), is responsible for fatty acid transport in 
adipocyte.  It is a marker of terminal adipocyte differentiation.  It can also influence 
transcription.  Interestingly, FABP4 can cooperate with PPARγ to regulate gene 
expression [431].  GATA1 is a transcription factor that can inhibit PU.1 transcriptional 
activity [432].  GATA2 (assayed for later) and GATA3 are transcription factors known to 
inhibit adipocyte differentiation [433].  Surprisingly, GATA3 expression goes up even 
though it is supposed to inhibit differentiation.  hnRNP G can influence alternative 
splicing [434] and is downregulated at least ten fold from the pre-adipocyte to adipocyte 
stage [419].  RUNX1 is a transcription factor that was reveal by a chromatin 
immunoprecipitation screen to bind the human PKCβ promoter [435].  MZF-1 is a 
transcription factor belonging to the Kruppel family of zinc finger proteins [436]. 
Figure 61 shows RT-PCR and protein expression of PU.1.  PU.1 was considered 
the most promising transcription factor due its many putative consensus binding sites 
blanketing the PKCβ promoter as well as its confirmed role in bridging transcription and 
splicing [405].  PU.1 has been reported to inhibit the differentiation of 3T3-L1 cells in 
concert with GATA2.  However, this was done using overexpression systems which may 
indicate threshold dynamics.  In this same paper, PU.1 mRNA and protein expression 
were shown to increase over the course of differentiation which is consistent with data 
shown in Figure 61 [437].  Also shown in Figure 61 is the protein expression of SRp40, a 
splicing factor that could possibly contribute to PKCβ alternative splicing during 
adipogenesis based on its role in L6 skeletal muscle cells [37; 38; 211].  SRp55, another 
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splicing factor that is regulated by insulin [38], may influence PKCβ alternative splicing 
(unpublished).   
 Using the Chromatin Immunoprecipitation assay, PU.1 is shown to bind the 3T3-
L1 PKCβ promoter at various spots at both day 0 and day 8.  SRp40 seems to also display 
affinity for the PKCβ promoter (Figure 62).  This led to a third hypothesis. 
Hypothesis #3: Developmental Regulation of PKCβ Splicing by PU.1 
PU.1 would be able to bind the PKCβ promoter during the course of 3T3-L1 
adipocyte differentiation and influence the developmental regulation of PKCβ alternative 
splicing.  It would accomplish this by recruiting coactivators (while simultaneously 
displacing corepressors), which would then bind splicing factors such as SRp40 that 
would ultimately result in the PKCβII exon inclusion.   
The next step would have been to knockdown PU.1 during differentiation and 
assess PKCβ mRNA and protein levels.  However, due to the extreme difficulties in 
transfecting differentiated 3T3-L1 cells (as mentioned above), this aim was postponed.   
Linking PKCβII with 3T3-L1 Adipocyte Insulin-stimulated Glucose Transport  
 At the same time, the possibility of PKCβII regulation of glucose uptake in 3T3-
L1 adipocytes, was being explored.  Previous studies show that PKCβII was critical in 
mediating glucose uptake in skeletal muscle cells, another insulin-sensitive tissue [40].  
CGP53353 is an inhibitor of cPKCs with greatest affinity for PKCβII (see Table 7).  It 
was anticipated that the inhibitor might provide evidence of a role for PKCβII in 3T3-L1 
adipocyte ISGT.  Figure 63a is a dose curve showing 50μM CGP53353 attained an 85% 
inhibition of ISGT compared to insulin alone in 3T3-L1 adipocytes day 8 to day 12.  
Figure 63b shows this 50μM dose within a complete experiment with control and drug 
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control.  CGP53353 inhibited ISGT over 6 fold compared to insulin alone.  Drug alone 
had no effect on basal glucose uptake levels compared with control.  In addition to this, 
LY379196, another PKCβ selective inhibitor, was used.  Figure 64a is a dose curve 
showing that LY379196 (with insulin) can inhibit ISGT at 50μM.  Next, both 25 and 
50μM LY379196 were able to significantly inhibit ISGT (3 fold and ~4.3 fold 
respectively) with no effect on basal glucose uptake (Figure 64b).   
CGP53353 Specificity 
A kinase assay via western blot was next pursued to affirm that CGP53353 was 
specifically inhibiting PKCβII and not other critical insulin signaling effectors.  Figure 65 
shows that insulin caused phosphorylation of both PKCβII S660 and insulin receptor 
Y1150/1151.  Only PKCβII S660 phosphorylation is inhibited with drug.  The antibody 
targeting PKCβII also targets phospho PKCδ S662 (thick lower band).  Phospho PKCδ 
migrates at 78kDa on the gel whereas phospho PKCβII migrates at 80kDa on the gel.  
Large gels were run longer in order to obtain reasonable separation between the two 
bands.  The phosphorylation status of PKCδ, PKCζ and the insulin receptor were 
unaffected by the drug.  Total PKCβII levels remained constant.  This led to the last 
hypothesis. 
Hypothesis #4: PKCβII Regulates 3T3-L1 Adipocyte ISGT in Part via GLUT4 
Trafficking or GLUT4 Fusion 
PKCβII′s ability to regulate ISGT in adipocytes was likely due to an effect on 
GLUT4 translocation or late-stage GLUT4 fusion.  The rationale behind this was a report 
demonstrating the ability of PKCβII to phosphorylate Akt at S473 [438].  Fully active 
Akt is required for late stage GLUT4 translocation [184].  Also, in 3T3-L1 adipocytes, 
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PLD1 mediates GLUT4 fusion to the PM [141].  PKCβII (not PKCβI) has been shown to 
bind and activate PLD1.  PLD1 activity caused PKCβII (not PKCβI) to translocate to a 
juxtanuclear subset of recycling endosomes (presumably where GLUT4 is located) [439].  
In skeletal muscle cells, PLD1 membrane localization is regulated via insulin-stimulated 
PKCβII [113]. 
Subcellular Fractionation Points to a Role for PKCβII in GLUT4 Translocation 
To test whether GLUT4 translocation was being affected by CGP53353 
inhibition, subcellular fractionation assays were performed.  As shown in Figure 66, 
insulin caused a redistribution of GLUT4 from the low-density microsomes (LDM) to the 
plasma membrane (PM).  Without insulin stimulation, GLUT4 remained in the LDM.  
Addition of CGP53353 dramatically blocked insulin-stimulated GLUT4 translocation to 
the PM.   Cytoplasmic fractions were also western blotted and probed for β-actin to show 
that protein concentrations measured by the BCA protein assay were accurate.  It also 
shows that cell death was not responsible for the trends observed.  Numerous other 
proteins were tested as internal controls of protein loading.  For the PM fraction, insulin 
receptor, TNFα Receptor 1 & 2, APMAP (adipocyte plasma membrane associated 
protein) were tested.  For the LDM fraction, IRS1 levels were tested.  However, insulin 
and/or CGP53353 treatment affected the expression and/or stability of these proteins and 
thus they could not be used as controls.  In addition to cell surface GLUT4, 
phosphorylated GLUT4 was assessed by probing the PM fraction for pGLUT4 S488 
(Santa Cruz).  Earlier reports indicated that PM GLUT4 C-terminal phosphoserine is 
reduced in insulin-stimulated rat adipocytes.  This has led to speculation that 
phosphorylation of the GLUT4 C-terminus may actually inhibit its intrinsic activity 
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[440].  We were interested to see if PKCβII inhibition altered GLUT4′s phosphorylation 
status and likely its folding/binding partners.  However, we were unable to detect any 
phospho GLUT4.   This was also the case in whole cell lysate.  Other methods are needed 
to increase antibody sensitivity. 
PM Sheet Assay Affirms a Role for PKCβII in GLUT4 Translocation 
 A second method was sought to definitively link PKCβII to GLUT4 translocation.  
The PM sheet assay (Figure 67) reveals a similar trend to that of subcellular fractionation 
in 3T3-L1 adipocytes day 8 to day 12.  Insulin treatment illuminated GLUT4 staining 
(Figure 67b).  However, this staining was abrogated (~3.8 fold) when treated with 
CGP53353 (Figure 67d).  Staining with Deep Red Cell Mask Plasma Membrane Stain 
shows relatively equal PM protein content (Figure 67e-h).  The merger of insulin-
stimulated GLUT4 can be seen with PM proteins (Figure 67j).  Hence, PKCβII is likely 
regulating adipocyte ISGT through regulation of GLUT4 translocation.   
 In addition to regulating GLUT4 translocation, PKCβII was believed to regulate 
GLUT4 fusion to the PM.  This was because PKCβII can bind and activate PLD1 which 
is responsible for insulin-stimulated GLUT4 fusion to the PM [19; 141].  
Immunofluorescence was used to measure GLUT4 that had fused to the PM.  When 
GLUT4 is fused to the membrane, there is a large exofacial N-terminal loop that 
protrudes into the extracellular space (Figure 11).  Santa Cruz Biotechnology has an 
antibody that recognizes this exofacial loop.  The protocol for this experiment was based 
on that performed by Fulcher et al. [413] (Experimental Procedures).  Formaldehyde 
fixed cells were incubated with the antibody with no permeabilizing detergents.  
However, the antibody was still able to penetrate the PM and stain the entire cell.  
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Despite this, there was a suttle trend.  Insulin was often able to aggregate GLUT4 near 
the nucleus, possibly the perinuclear region where GLUT4 resides before translocating to 
the PM in an insulin-dependent manner (Figure 68b).  CGP53353 treatment prevented 
this formation resulting in a more dispersed localization around the nucleus (Figure 68d).  
PKCβII (and possibly other cPKCs) may have a role in basal state and insulin-stimulated 
GLUT4 intracellular trafficking.  Bioinformatic analysis of GLUT4 protein sequence 
revealed a putative PKC phosphorylation site beside the C-terminal insulin-responsive 
motif (IRM), LXXLXPDEX(D/E).  The GLUT4 IRM has been shown to be crucial for 
insulin-stimulated GLUT4 redistribution to the PM [441].  Another attempt to use 
immuno-fluorescence was made by first incubating the live pre-formaldehyde fixed cells 
with the GLUT4 antibody followed by fixation (fixation was also attempted after 
secondary antibody).  The antibody was still able to penetrate the PM.  Primary or 
secondary antibodies that are bulkier must be made in order to perform this assay.  The 
GLUT4 exofacial loop can be glycosylated (Figure 11).  N-glycosylation at this site 
(possibly mediated by Golgin-160) may be necessary for ISGT [442].  It is possible that 
the antibody was made to recognize only the unglycosylated loop.  This would mean a 
new antibody that recognizes that glycosylated loop would have to be raised and 
developed.    
PKCβII Regulation of Akt Activity 
 As mentioned earlier, activated Akt is required for GLUT4 translocation [184].  
PKCβII has been shown to regulate Akt S473 (S473) phosphorylation in a cell and 
stimulus-specific manner [438].  To that extent, we investigated whether PKCβII could 
regulate Akt activity in 3T3-L1 adipocytes.  Insulin treatment induced the dramatic 
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appearance of T308 and S473 phosphorylation (Figure 69).  CGP53353 treatment 
decreased S473 phosphorylation over 17 fold.   Phosphorylation of T308 remained 
relatively constant with CGP53353 treatment.  This was consistent with the literature 
where T308 is regulated by PDK1 (via insulin) and S473 is regulated by a separate PDK2 
(possibly PKCβII) and that S473 phosphorylation is not dependent on T308 
phosphorylation [174; 175; 229].   It is important to note that PKCβII may be regulating 
phosphorylation of mouse Akt1 at S473, Akt2 at S474, Akt3 at S472 or any combination 
thereof since this antibody recognizes the phosphorylated hydrophobic motif of all three 
Akt isoforms.   From here on, Akt phosphorylation at the hydrophobic motif will be 
referred to as Akt S473 since the antibody was labeled as phospho Akt S473.   
Immunofluorescence Confirms Role for PKCβII in Phosphorylation of Akt S473 
 To confirm PKCβII as a possible PDK2 that regulates Akt S473 phosphorylation, 
immunofluorescence was performed on 3T3-L1 adipocytes from day 8 to day 12.  Insulin 
stimulated dramatic staining of phospho Akt S473 (Figure 70b) as expected.  PM staining 
as well as intracellular aggregation staining near the nucleus was apparent.    Treatment 
with CGP53353 eliminated staining of phospho Akt S473 (Figure 70d).  DAPI staining 
for nuclei could not be used because the short wavelengths caused high background 
fluorescence of CGP53353 drug.  TO-PRO3 was used to avoid this problem with an 
emission spectrum around 633nm.  TO-PRO3 stains nucleic acid, DNA and RNA.  In 
order to select for DNA (nucleus), incubation of TO-PRO3 was performed along with 
RNaseA treatment (Figure 70e-h).     
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PKCβII Downstream of mTORC2 but Upstream of Akt 
 The mTORC2 complex was shown by Sarbassov et al. to regulate 
phosphorylation of Akt S473 [174].  Phosphorylation of mTOR kinase at S2481 
distinguishes activated mTORC2 from mTORC1 [61].  However, it is known that 
mTORC2 is also responsible for phosphorylation of PKCβII/PKCα at the turn motif 
which allows the kinases to undergo autophosphorylation at the hydrophobic motif [54; 
55].  This suggested that PKCβII is activated by mTORC2 and then goes on 
phosphorylate Akt S473, thus fully activating Akt.   Figure 71 shows insulin stimulated 
mTORC2 activation via phosphorylation of mTOR S2481.  Insulin has been shown to 
similarily activate mTORC2 in HEK293 cells [61].  CGP53353 treatment did not alter the 
phosphorylation status of mTOR S2481.  This indicated that PKCβII was likely 
downstream of mTORC2.   
 Integrating the role of mTORC2 represented a more mechanistic overview of how 
PKCβII was exerting its effects.  Before mTORC2 was pursued, another promising 
putative PKCβII substrate was examined.  PLD1 is critical in 3T3-L1 adipocyte ISGT by 
enabling fusion of GLUT4 to the PM [141].  PKCβII is capable of phosphorylating and 
activating PLD1 [19].  Using two commercial antibodies for both PLD1 and phospho 
PLD1, detection was attempted by western blotting whole cell lysates, western blotting 
PM and cytosolic fractions and immunofluorescence.  An in vitro PLD1 activity assay 
(Amplex Red, Invitrogen) was also performed.  None of these experiments could detect 
PLD1 or its activity.  This could have been due to low abundance of PLD1 or low PLD1 
anitgenicity or low stoichiometric activity.   
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Insulin-stimulated Binding of PKCβII to mTORC2  
 Data from Figure 71 showed that PKCβII (using Santa Cruz antibody for IP 
which is different than the custom made PKCβII antibody used in Figures 56 & 65) was 
likely being activated by mTORC2 before having the capability to phosphorylate Akt 
S473.  Co-immunoprecipitation showed that insulin stimulated direct binding between 
PKCβII and mTORC2 (Figure 72 lane 3).  This binding was dramatically reduced by 
CGP53353-mediated inhibition of PKCβII (lane 5).  Immunoblotting for PKCβII with the 
same antibody used for co-immunoprecipitation was unsuccessful.  Several additional 
antibodies were utilized without success including a mouse PKCβII antibody (Sigma 
P2584) and a mouse PKC antibody (PKC A-9 Santa Cruz #17804) that recognizes all 
PKC isoforms.  Perhaps PKCβII is extremely sensitive to degradation or antigenicity is 
severely reduced upon cell lysis. 
Insulin-stimulated Binding of PKCβII to Akt  
 Figure 73 provides preliminary evidence that PKCβII is able to bind Akt.  PKCβII 
co-immunoprecipitates with Akt that is phosphorylated at S473 suggesting that PKCβII 
could be the kinase that directly phosphorylates Akt at S473.  The membrane was 
reprobed with PKCβII.  This was unsuccessful due to reasons discussed.  The conditions 
for the reverse co-immunoprecipitation are being worked out. 
Co-immunoprecipitation Between PKCβII and GLUT4 
 Co-immunoprecipitation was performed to assess possible binding of PKCβII to 
GLUT4.  As mentioned earlier, bioinformatic analysis indicated multiple PKC substrate 
sites spanning murine GLUT4.  Akt had been shown to bind GLUT4-containing vesicles 
and then phosphorylate their component proteins in response to insulin [182].  It was 
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hypothesized that PKCβII could act in a similar fashion.  Figure 74 shows that IP with 
PKCβII resulted in increased GLUT4 band intensity compared to rabbit IgG control.  
However, probing for PKCβII (after IPing with PKCβII) yielded nothing, which was 
expected.  IP with GLUT4 antibody was able to pick up PKCβII and this was stimulation 
independent.  GLUT4 band intensity for this was weak but still slightly higher than IgG 
control.  Whole cell lysate probing for GLUT4 using the specified antibody was 
unsuccessful.  This was unexpected for GLUT4 and is probably due to using an antibody 
different than the one used on other blots.  Repeating this assay yielded similar results.  
This experiment still leaves open the possibility that PKCβII is able to directly influence 
insulin-stimulated GLUT4 trafficking, possibly through phosphorylation of vesicle 
component proteins in addition to regulating Akt activity.  
Figure 23.  TZD Pioglitazone mimics insulin’s effect of increased 
PKCβII exon inclusion in HeLa cells.  HeLa cells were grown as 
described and serum starved for 6 hours.  Cells were treated with 
either 50nM bovine Insulin (15 or 30 minutes) or 1μM Pioglitazone
22 hours.  Total RNA was extracted followed by RT-PCR using the 
endogenous PKCβII-PKCβI primers (compatible with rat).  Samples 
were run on a PAGE gel and silver stained.  Experiment was 
repeated twice.
I0       I15     I30 
PKCII
PKCI
Pio RT-PCR:
 
131
Pio - +
PKCII
PKCI
Figure 24.  Pioglitazone increases PKCβII exon
inclusion in A10 vascular smooth muscle cells.  A10 cells 
were grown as described and serum starved for 48 hours.  
26 hours prior to harvesting, cells were treated ± 1μM 
Pioglitazone 26 hours.  Total RNA was extracted followed 
by RT-PCR using the endogenous PKCβII-PKCβI primers 
or β-actin primers.  Samples were run on a PAGE gel and 
silver stained.
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Figure 25.  Pioglitazone combined with insulin synergistically increases PKCβII exon
inclusion in L6 skeletal muscle cells.  L6 skeletal muscle cells were grown as described and 
serum starved 6 hours prior to treatment with 100nM bovine insulin (15 or 30 minutes).  For 
wells treated with 1μM Pioglitazone 24 hours, treatment began 24 hours before harvesting.  
Pioglitazone was re-added to appropriate wells during serum starvation.  (a) Total RNA was 
extracted followed by RT-PCR using the endogenous PKCβII-PKCβI primers (compatible with 
rat).  Samples were run on a PAGE gel and silver stained.  (b) Graphical representation of 
PKCβII mRNA expression in arbitrary scan units derived from pixels.  Experiment was repeated 
twice. 
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Figure 26.  Pioglitazone treatment and SRp40 overexpression mimic insulin’s upregulation of PKCβII protein 
levels.   (a) L6 skeletal muscle cells were grown as described and serum starved for 6 hours.  Cells were either treated 
with 100nM bovine insulin (15, 30, 45 or 60 minutes), treated with 1μM Pioglitazone 24 hours (re-added after serum 
starvation) or transfected with 1.6μg SRp40 (constructs).  Protein was harvested and western blot performed.  (b) 
Graphical representation of PKCβII protein levels in arbitrary units. 
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Figure 27.  Overexpression of PPARγ, PGC1α and SRp40 individually or in combination are 
able to increase PKCβII protein expression.  (a) L6 skeletal muscle cells were transfected with 
2ug of either PPARγ, PGC1α or SRp40 (name construct for SRp40) for 48 hours.  Total RNA was 
extracted followed by RT-PCR using PKCβII only primers or β-actin primers.  Samples were run 
on a PAGE gel and silver stained.  (b) Graphical representation of PKCβII protein levels in 
arbitrary units.
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Figure 28. CTD of PGC1α is necessary for PKCβII exon inclusion.  L6 cells were transiently transfected with 
transfection reagent alone, 2μg PPARg, PGC1-a, or PGC∆CTD for 48 hours as indicated above. (a) Total RNA was 
extracted followed by RT-PCR using endogenous PKCbII specific primers. PCR for b-actin serves as an internal 
control.  (b) Graphical representation of PKCβII mRNA expression in arbitrary units.
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Figure 29.  TZDs Rosiglitazone and Pioglitazone stimulate PKCβ co-
transcriptional splicing.   (a) L6 skeletal muscle cells were treated with either 
DMSO vehicle control, 1μM Rosiglitazone or 1μM Pioglitazone for 24 hours.  
Protein was harvested and western blot was performed. Experiment was repeated 
two times.  (b) Graphical representation of PKCβII/PKCβI protein levels in arbitrary 
units.
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Figure 30.  Hypothetical model of TZD mechanism.  Pioglitazone would activate PPARγ, allowing it to bind to the PKCβ PPRE.  
PPARγ would recruit PGC1α which would then serve as a landing pad for SRp40 and other splicing factors, thereby influencing the 
alternative splicing of PKCβ.
 
138
PKCβII
PKCβI
β-actin
PPARγ - - 1      3
VC   - +       - -
Figure 31.  PPARγ overexpression increases both PKCβI and PKCβII protein levels.  (a) L6 skeletal 
muscle cells were transfected with either 3μg vector control, 1μg PPARγ, or 3μg PPARγ for 72 hours.  Whole 
cell lysate was run on gel for western blot detection.  Experiment was repeated two times.  (b) Graphical 
representation of PKCβII/Actin protein levels in arbitrary units.  (c) Graphical representation of PKCβI/Actin
protein levels in arbitrary units.
Co
ntr
ol VC g 1
PP
AR
g 3
PP
AR
0.0
0.5
1.0
1.5
PK
C
II
/A
ct
in
Co
ntr
ol VC
PP
AR
g 1
mg
PP
AR
g 3
mg
0.0
0.5
1.0
1.5
2.0
PK
C
I/
Ac
tin
(a)
(b) (c)
IB:
 
139
Figure 32.  Ligand-binding domain is necessary for PPARγ mediated upregulation of PKCβII protein levels.  
(a) L6 skeletal muscle cells were transfected with either 2μg vector control, PPARγ or mutant PPARγE499Q for 
72hrs.  Protein was harvested and western blot was performed.  PPARγE499Q is a mutant in the AF2 domain. It 
binds PPARγ ligands with comparable affinity as wild-type, but no ligand-dependent transcriptional activation.  (b) 
Graphical representation of PKCβII/Actin protein levels in arbitrary units.  (c) Graphical representation of 
PKCβI/Actin protein levels in arbitrary units. 
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Figure 33.   PGC1α overexpression mimics TZD stimulation of PKCβII co-transcriptional 
splicing.  (a) L6 skeletal muscle cells were transfected 72 hours with 4μg vector control, 2 or 
4μg PGC1α.  Whole cell lysate was run on gel for western blot detection.  Experiment was 
repeated two times.  (b) Graphical representation of PKCβII/PKCβI protein levels in arbitrary 
units. 
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Figure 34.  PPARγ or PGC1α knockdown reduces basal PKCβII mRNA.  L6 skeletal muscle cells were  transfected
with 10nM of either scrambled siRNA, PPARγ siRNA or PGC1α siRNA for 24 hours and concomitantly treated ± 1uM 
Rosiglitazone for 24 hours.  (a) Total RNA was harvested followed by RT-PCR using specified primers.  PKCβII was 
detected using primers that detected endogenous PKCβII & PKCβI.  (b) Graphical representation of PKCβII protein 
expression levels in arbitrary units.
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Figure 35. SRp40 knockdown results in lower basal PKCβII protein levels. L6 skeletal muscle cells were 
transfected with 10nM scrambled siRNA or SRp40 siRNA for 24 hours and concomitantly treated ± 1uM Rosiglitazone
for 24 hours.  (a) Total RNA was harvested followed by RT-PCR. PKCβII was detected using primers that detected 
endogenous PKCβII & PKCβI.  (b) Graphical representation of PKCβII protein expression levels in arbitrary units.
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Figure 36.  PCR on rat genomic DNA. PCR yielded the PKCβII and PKCβI exons with their respective flanking intronic
sequences.
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Figure 37.  The BII-BI fragment digested and inserted into the pTNT cloning vector.
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Figure 38.  pCMVTNT vector used for mammalian cell expression.
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Figure 39.  BII-BI fragments cloned into pCMVTNT vector for mammalian cell expression.
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Figure 40.  Multiple minigene products.  L6 skeletal muscle cells were transfected for 48 hours 0.7ug GFP or 2ug CMVTNT BII-
BI ss3 (Mss3) and treated ± 100nM bovine insulin for indicated time points.  RNA was extracted followed by RT-PCR using 
CMV_FP1 and CMV_RP1 primers.  Product prediction to the right represents best guess.  BII* represents a possible BII product with 
an additional splice site(s) or has a cryptic splice site.
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Figure 41.  Chimeric intron removed.  Chimeric intron removed from the CMVTNT BII-BI clones via digestion.
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Figure 42.  PCR generates BII-BI fragment with different overhangs. PCR was performed on CMVTNT BII-BI clones 
to lift out the BII-BI fragments with BbsI restriction site on the 5′ end and a XbaI restriction site on the 3′ end.  These were 
then inserted into the CMVTNT vectors missing their chimeric introns.  
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Figure 43.  Predicted splicing events from CMVTNT BII-BI ss1 clone (-CI). Two main hypothetical products, BII (top right) and 
BI (bottom right) are shown from CMVTNT BII-BI ss1 clone without chimeric intron (-CI).
 
151
Figure 44.   Products observed after transfection of CMVTNT BII-BI clones.  L6 skeletal muscle cells were 
transfected with 0.7ug GFP ± 1.5ug pCMVTNT (-CI) BII-BI ss1 (Mss1) or pCMVTNT (-CI) BII-BI ss4 (Mss4).  In 
addition each well was serum starved and treated with 100nM bovine insulin 60 min. Total RNA was extracted 
followed by RT-PCR using CMV_FP1& B1R3 primers.  54oC or 52oC was used as the annealing temperature.
GFP
BI
BII
unknown
1Kb+            Mss1 Mss4- Mss1 Mss4-
GFP
54oC 52oC
 
152
pCMVTNT
βII βI
ss4
BbsI
BamHI
βII
CMV TnT
BamHI
βII βIBP BP
AMPr
CMV 
promoter
P
oly-A
5’ss 3’ss3’ss 5’ss
Figure 45.   Cloning ss4 fragment into ss1 vector.  BamHI site was removed from the original pCMVTNT vector.  BII-
BI ss1 was re-cloned into the pCMVTNT vector, again losing the chimeric intron.  Now, the ss4 fragment was lifted out 
via PCR and inserted into the pCMVTNT BII-BI ss1 vector.   
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Figure 46.  Replacing CMV promoter with human PKCβ promoter.  Human PKCβ promoter was lifted 
out from another a Luciferase vector using PCR and then cloned into the pCMVTNT (-BamHI, -CI) BII-BI 
ss4 vector.
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Figure 47.  Truncation of full length PKCβ promoter.  The full length PKCβ promoter was truncated via digestion and blunt ligation.
 
155
βII βI5’UTR 3’UTR
βI5’UTR 3’UTR
CMV Beta
Figure 48.  PKCβ promoter-driven expression of BII and BI minigene products.  L6 skeletal 
muscle cells were transfected with either 2μg CMVTNT (-)BamHI BII-BI ss4 or βprom 2243 BII-
BI ss4 for 48 hours.  RNA was harvested and RT-PCR was performed for both PKC beta minigene
products using CMV_FP1 and CMV_RP1 primers.  Product legend is shown to the right.  Product 
identity was confirmed by sequencing.
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Figure 49. TPA induces transcription of PKCβ promoter minigene. L6 skeletal muscle cells were 
transfected with GFP expression vector ± βprom 2243 BII-BI ss4 vector for 48 hours.  Additionally, one 
plate was treated for 24hrs with 2nM TPA (phorbol ester) dissolved in ethanol.  (a) Total RNA was 
extracted followed by RT-PCR using T7flgFP5 & CMV_RP1 primers. PCR for GFP shows transfection
efficiency.  (b) Graphical representation of BII expression in arbitrary units.  (c) Graphical representation of 
BI expression in arbitrary units.
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Figure 50. TZD induces co-transcriptional splicing of minigene.  L6 skeletal muscle cells transfected with βprom 2243 BII-BI ss4 vector 
for 48 hours and were treated with either DMSO solvent control (24hrs) or 1uM Pioglitazone (24hrs).  (a) RNA was harvested followed by 
RT-PCR using CMV_FP1 & B1R3 primers.  GFP was a measure of transfection efficiency.  (b) Graphical representation of BII expression 
in arbitrary units.  (c) Graphical representation of BI expression in arbitrary units.
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Figure 51.  PKCβ promoter responsive to PPARγ overexpression.  L6 skeletal muscle cells transfected 48 
hours with 0.5μg GFP ± either 2.5μg CMVTNT BII-BI ss4 or 2.5μg Bprom 2243 BII-BI ss4  ± 1μg PPARγ or 
1μg vector control.  RNA was harvested followed by RT-PCR using CMV_FP1 & B1R3 primers.
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Figure 52. PPARγ does not target putative DR2 on PKCβ promoter of minigene.  L6 skeletal muscle 
cells were transfected with GFP, ± βprom 2243 BII-BI ss4 or βprom 1143 BII-BI ss4 ± 2μg PPARγ. (a) 
Total RNA was extracted followed by RT-PCR using CMV_FP1 & B1R3 primers. GFP shows transfection
efficiency.  (b) Graphical representation of BII expression in arbitrary units.  (c) Graphical representation of 
BI expression in arbitrary units.  
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Figure 53.  3T3-L1 differentiation.   (a-d) Phase contrast of 3T3-L1 differentiating cells from day 0 to day 6.  (e-h) Oil red O 
staining of 3T3-L1 differentiating cells from day 0 to day 6.  
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(e) (f) (g) (h)
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Figure 54. PKCβ splicing is developmentally regulated.  3T3L1 pre-adipocyte cells were cultured in 
DMEM high (4.5g/L) or low (1g/L) glucose for 4 or 6 days and treated ± 24 hours with 1μM Rosiglitazone. 
(a) Whole cell lysate was extracted followed by Western blot analysis. (b) Graphical representation of 
PKCβII protein expression in arbitrary units.  (c) Graphical representation of PKCβI protein expression in 
arbitrary units.
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Figure 55: Rosiglitazone has no effect on developmentally regulated 
PKCβ splicing.  3T3L1 pre-adipocyte cells were cultured in DMEM low 
glucose (1g/L) for 0 to 8 days treated ± 24hrs with 1μM Rosiglitazone.   
Whole cell lysate was extracted followed by Western blot analysis.
Day   0    2   2    4   4    6    6   8
Rosi - - +    - +   - +    -
PKCβII
PKCβI
PPARγ2
PPARγ1
GLUT4
β-actin
IB:
 
163
GLUT4
PKCβI
PKCβII
β-actin
PPARγ1
PPARγ2
Day     0       2      4    6      8     10     12
(a)
PKCα
PKCδ 5 sec
PKCδ 20sec
PKCδ 15min
PKCγ
pPKCβII(Ser660)/δ(Ser662)
PKCζ
Adiponectin
IB:
0 2 4 6 8 10 12
0.0
0.5
1.0
1.5
2.0
*
*
* *
**
Day
PK
C
II
/A
ct
in
(b)
0 2 4 6 8 10 12
0.0
0.5
1.0
1.5
PK
C
I/
Ac
tin
*
*
* * * *
Day
(c)
Figure 56.  3T3-L1 PKCβ (and other PKC isoform) protein expression during differentiation. (a) 3T3-L1 pre-adipocytes were 
differentiated from day 0 through day 12. Whole cell lysates (50μg protein) from each day were run on an SDS-PAGE gel and probed with 
the indicated antibodies via western blotting.  Experiments were repeated three times.  (b) Graphical representation shows PKCβII/actin, 
where * represents a statistically significant increase in PKCβII protein level as compared with day 0 using arbitrary units.  (c) Graphical 
representation of PKCβI/actin, where* represents a statistically significant decrease in PKCβI protein level as compared with day 0 using 
arbitrary untis.    Unpaired t-test (p<0.05) was performed using Prizm5 (GraphPad Software, Inc., LaJolla, CA, USA). 
 
164
Figure 57.  Differentiating 3T3-L1 PKCβII mRNA expression mimics protein expression. 3T3-L1 pre-
adipocytes were differentiated from day 0 through day 10.  2μg from each day was used for reverse 
transcription.  Real Time analysis was performed using arbitrary units as described in Materials and 
Methods.  * represents a statistical significance in terms of fold change of PKCβII/actin mRNA compared to 
day 0 using unpaired t-test, p<0.05.   Experiment was repeated three times. 
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Figure 58. Differentiating 3T3-L1 adipocytes use distal polyA tail for PKCβII alternative splicing. RNA of 3T3-L1 pre-adipocytes
(Day 0) and 3T3-L1 adipocytes (Day 8) were extracted.  RT-PCR from 2μg RNA was performed using indicated primers. C4B2 indicates 
the forward primer spanning the C4 exon – PKCβII exon junction.  B2i indicates the reverse primer binding on the intronic sequence 
downstream of the PKCβII exon but upstream of the proximal polyA tail.  B1 indicates the reverse primer that binds on the PKCβI exon.  
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Figure 59. Differentiated 3T3-L1 adipocytes not transfectable.  Day 5 3T3-L1 adipocytes
were transfected with 10nM siRNA targeting PKCβII and harvested on Day 8.  Lysates were 
run on SDS-PAGE gel and immunoblotted with indicated antibodies.
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Figure 60.  3T3-L1 transcription factor mRNA expression during adipogenesis.  3T3-L1 cell RNA was harvested 
on the indicated day of differentiation.  2μg RNA was used for RT-PCR using primers for the gene indicated on the 
right side.    
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Figure 61.  PU.1 expression through adipocyte differentiation.  Day 0 through 
Day 10 adipocytes were harvested for RT-PCR.  Day 0 through Day 12 
adipocytes were harvested for Western Blot analysis.  2μg RNA was used for 
RT-PCR with primers for the product specified.  50μg protein was loaded on 
SDS-PAGE and probed with indicated antibodies.
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Figure 62.  ChIP of mouse PKCβ promoter.  Day 0 pre-adipcoytes and Day 8 adipocytes
were harvested for ChIP analysis as mentioned in Materials and Methods.  Antibodies 
corresponding to the names given at the top of the figure were used to assess transcription 
factor binding.  Left Y axis numbers represent the forward and reverse primer positions 
relative to the PKCβ1 transcript start as defined by Vega Mouse TransView (Mouse 
Genome Informatics, MGI).  All PCRs were performed with the same amount of cycles, 
primers and template.
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Figure 63.  PKCβII inhibition via CGP53353 attenuates adipocyte glucose uptake. Day 8 to day 12 3T3-L1 adipocytes were serum 
starved for 4 hrs, ± 30 min 50μM CGP53353, ± 15 min 100nM insulin.  Glucose uptake assay was performed as described in Methods 
and Materials.  (a) Dose curve shows the percentage decrease in glucose uptake when comparing insulin vs. drug with insulin.  (b) 
Graphical representation of 50μM treatment where * represents a statistically significant decrease (using arbitrary units) in glucose 
uptake comparing insulin vs. drug with insulin, using unpaired t-test, p<0.05.  Experiments were repeated three times. 
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Figure 64. PKCβ inhibition via LY379196 attenuates adipocyte glucose uptake. Day 8 3T3-L1 adipocytes were serum starved for 4 
hrs, ± 30 min 25 or 50μM LY379196, ± 15 min 100nM insulin.  Glucose uptake assay was performed as described in Methods and 
Materials.  (a) Dose curve shows the effect of increasing drug concentrations on glucose uptake comparing insulin vs. drug with insulin.  
(b) Effect of 25 or 50μM drug concentrations on glucose uptake.  In both graphs, * represents a statistically significant decrease in 
glucose uptake (using arbitrary units) comparing insulin vs. drug with insulin, using unpaired t-test, p<0.05.  Experiments were repeated 
three times. 
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Figure 65.  CGP53353 specifically targets PKCβII phosphorylation. Day 8 3T3-L1 adipocytes were serum starved for 4 hrs, ± 30 min 
50μM CGP53353, ± 15 min 100nM insulin.  (a) Whole cell lysates were run on an SDS-PAGE gel and probed with respective antibodies.  
(b) Graphical representation shows the ratio of pPKCβII/pPKCδ, where * is a statistically significant decrease comparing insulin vs. drug 
with insulin using unpaired t-test, p<0.05.  Experiments were repeated three times. 
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Figure 66.  GLUT4 translocation is blocked by PKCβII inhibition. Day 8 3T3-L1 adipocytes were serum starved for 4 hrs, ± 30 min 
50μM CGP53353, ± 100nM insulin 15 min.  Subcellular fractionation was performed as described.  5μg for each sample of each fraction 
(a,b,c) was loaded onto a SDS-PAGE gel and immunoblotted.  Graphical representation of  PM GLUT4 (d) and LDM GLUT4 (e), where * 
represents a statistically significant change (using arbitrary units) comparing insulin vs. drug with insulin using an unpaired t-test, p<0.05.  
Experiments were repeated on three occasions with similar results. 
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Fig ure 67 .  PM sheet assay confirms PKCß II role in GLU T4 translocation.   Day 8 to day 12  3T3-L1  adipo cytes were serum starved  for 4 
hrs, ± 3 0 min  5 0µM CG P5 3353,  ± 100n M insulin 15 min .  PM sh eets were obtained as  described in Ex per imental Pro cedu res .  (a-d) Green 
staining  represents  GLU T4.  (e-h) Red s taining rep resents PM.  (i-l) Co localization (yello w) is  the merger of GL UT4 and  PM stainin g.  Five 
to  ten arb itrary fields per cond ition were obtained , the average being show n.  Images sho wn h ere are the representative sing le optical section 
from z-series sectio ns taken at averag e 0 .2 µm step .  (m) Graphical representat io n show s a s tatis tical ly sig nificant  decrease (using arbitrary 
units) in GLUT4 o ver PM stain ing co mparing  insulin  vs. d rug with in sulin us ing an u npaired t -test (*,  p<0.05).  E xperiment  was repeated 
th ree t imes.  
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Figure 68.  PKCβII may affect organization of GLUT4.  Day 8 – Day 12 3T3-L1 adipocytes were treated ±
50uM CGP53353 30 min ± 100nM pig insulin 15 min.  Cells were fixed and stained as described.  Red staining 
represents N terminal GLUT4.  Blue (DAPI) staining represents the nucleus.  
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Figure 69.  Effect of PKCβII inhibition on Akt phosphorylation.  Day 8 3T3-L1 adipocytes were serum starved for 4 hrs, ± 30 min 
50μM CGP53353, ± 100nM insulin 15 min.  (a) Whole cell lysates were run on an SDS-PAGE gel and probed with respective antibodies.  
(b) Graphical depiction of pAkt/total Akt, where black bars represent pAkt Serine 473 / total Akt and white bars represent pAkt Threonine
308 / total Akt.  * represents a statistically significant inhibition (using arbitrary units) of phosphorylation of Akt at Serine 473 comparing 
insulin vs. drug with insulin using unpaired t-test, p<0.05.  Experiments were repeated three times. 
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Figure 70. PKCβII inhibition abolishes phosphorylation of Akt Serine 473 and its subcellular locations.  
Day 8 – Day 12 3T3-L1 adipocytes were treated ± 50μM CGP53353 30 min ± 100nM pig insulin 15 min.  Cells 
were fixed and stained as described.  (a-d) Red staining represents pAkt 473.  (e-h) Blue staining indicates DNA.  
(i-l) Colors were merged.
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Figure 71.   CGP53353 treatment does not alter mTORC2 activation.  Day 8 3T3-L1 adipocytes were treated ± 50uM CGP53353 30 min 
± 100nM pig insulin 15 min.  (a) Lysate were run on a SDS-PAGE gel and western blotted with indicated antibodies.  (b) Graphical 
representation of two independent experiments (measured using arbitrary units) using unpaired t-test, p<0.05. 
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Figure 72.   Insulin-dependent binding of PKCβII with activated mTORC2.  Day 8 3T3-L1 adipocytes were 
treated ± 50uM CGP53353 30 min ± 100nM pig insulin 15 min.  Lysate was harvested under non-denaturing 
conditions and co-immunoprecipitated with antibody listed.  Co-immunoprecipitated proteins were  combined with 
Laemmli’s buffer and boiled.  Samples were run on a SDS-PAGE gel and western blotted with indicated antibody.  
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Figure 73.   Insulin-dependent binding of PKCβII with phospho Akt S473.  Day 8 3T3-L1 adipocytes
were treated ± 50uM CGP53353 30 min ± 100nM pig insulin 15 min.  Lysate was harvested under non-
denaturing conditions and co-immunoprecipitated with antibody listed.  Co-immunoprecipitated proteins 
were  combined with Laemmli’s buffer and boiled.  Samples were run on a SDS-PAGE gel and western 
blotted with indicated antibody.  
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Figure 74.   Co-IP of GLUT4 and PKCβII.  Day 8 3T3-L1 adipocytes were treated ± 50uM CGP53353 30 min ±
100nM pig insulin 15 min.  Lysate was harvested under non-denaturing conditions and co-immunoprecipitated with 
antibodies listed.  Co-immunoprecipitated proteins were  combined with Laemmli’s buffer and boiled.  Samples were run 
on a SDS-PAGE gel and western blotted with indicated antibodies.  
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DISCUSSION 
  
 The major findings of my research are: 1) TZDs may be able to regulate co-
transcriptional splicing of PKCβ in rat L6 skeletal muscle cells; 2) PGC1α also seems to 
be able to mimic TZD’s effect on PKCβ co-transcriptional splicing; 3) the PGC1α C-
terminal domain is necessary for bridging PKCβ transcription and splicing; 4) 3T3-L1 
cells developmentally regulate PKCβ expression where PKCβII increases during 
adipogenesis and PKCβI decreases during adipogenesis; 5) PU.1 binds to the PKCβ 
promoter in 3T3-L1 adipocytes and may be responsible for developmental switching 
between the two isoforms; 6) PKCβII is critical for ISGT by regulating GLUT4 
translocation; and 7) PKCβII (being downstream of activated mTORC2) regulates 
GLUT4 translocation by directly phosphorylating and fully activating Akt at Serine 473. 
 Thiazolidinediones have been used since 1997 to treat hyperglycemia in type 2 
diabetes.  Currently, Pioglitazone and Rosiglitazone are the only compounds licensed for 
type 2 diabetic patients. [443].  TZDs work by decreasing insulin resistance.  To elicit 
their insulin-sensitizing effects, TZDs directly activate PPARγ.  They seem to do this by 
primarily working on adipose tissue even though the major effect on insulin-sensitization 
occurs in skeletal muscle.  This is in part due to altered free fatty acid supply.  By 
activating adipocyte PPARγ, TZDs promote differentiation of adipose tissue that is 
smaller and more responsive to insulin, pre-dominantly subcutaneously.  In addition, 
TZDs reduce the output of inflammatory TNFα and FFAs while increasing output of 
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adiponectin which increases peripheral insulin-sensitivity [338].    TZDs have also shown 
benefit to the vasculature.  Rat VSMCs undergo reduced migration and proliferation in 
response to TZD treatment [444].  Yamamoto et al. showed that PKCβ isoforms have 
opposing functions in A10 VSMCs.  PKCβI was associated with accelerated cell 
doubling time and increased S phase cell population whereas PKCβII was associated with 
attenuation of cell doubling time and delayed entry into S phase [41].   Patel et al. showed 
that acute hyperglycemia, which aggrevates cardiovascular tissue injury, post-
transcriptionally destabilizes PKCβII mRNA [445; 446].  Here, we show that TZD 
treatment is able to regulate alternative splicing, favoring the PKCβII isoform (Figure 
24).  PPARγ expression in VSMCs is associated with growth inhibition and 
differentiation through a GATA-6 dependent transcriptional mechanism [447].  Whether 
PPARγ is mediating the observed effects on VSMC PKCβ alternative splicing, remains to 
be seen.   
 L6 cells represent a good model to study insulin signaling because skeletal muscle 
accounts for the majority of post-prandial glucose disposal [420].  24 hour treatment of 
1μM Pioglitazone mimicked insulin′s effect on PKCβII exon inclusion, even synergizing 
when combined with insulin stimulation (Figure 25).  Western blotting confirmed that 24 
hours 1μM Pioglitazone was able to stimulate PKCβII protein expression to a similar 
extent as insulin (Figure 26).  This is significant because the mechanism, in which TZD 
benefits skeletal muscle signaling, as it pertains to glucose disposal, remains unknown 
[448].  PKCβII is a critical regulator of L6 ISGT [40; 113].   TZD treatment could 
possibly bypass a defective upstream insulin signaling pathway to upregulate PKCβII 
expression.  Since TZD treatment is supposedly ineffective at lowering serum glucose 
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levels in the absence of insulin [414], TZDs could enhance L6 insulin sensitivity by 
priming cells with PKCβII.  This may lower the threshold of insulin signaling required 
for full PKCβII activation and thus ISGT.  It is even possible that some alternatively 
spliced PKCβII, as a result of TZD stimulation, could become activated by another 
pathway in the absence of insulin and therefore clear serum glucose in the basal state.  
Non-insulin stimulated PKCζ (another PKC isoform involved in GLUT4 translocation) 
activation and basal glucose uptake were increased in adipocytes with Rosiglitazone 
treatment [449].  Rosiglitazone has been shown to enhance acute 5′AMP-Activated 
Protein Kinase mediated glucose uptake (insulin independent) in muscle and adipose 
tissue of high-fat fed rats [450].  Contraction-stimulated muscle glucose uptake is normal 
in type 2 diabetics and signals through the AMPK pathway.  AMPK (stimulated by 
muscle contraction as well as hypoxia, ischaemia, heat shock, decreased pH, glycolysis 
inhibition, and by uncouplers of oxidative phosphorylation) can stimulate skeletal muscle 
glucose uptake in the absence of insulin and through a PI3K independent pathway.  
aPKCs have been shown to have a role in AICAR (aminoimidazole carboxamide 
ribonucleotide)-stimulated glucose uptake in both L6 cells and in isolated rat muscle 
[451].  PKCα has been ruled out as a possible mediator of contraction-mediated glucose 
uptake in mouse skeletal muscle cells.  However, due to the fact that cPKC inhibitors 
inhibit contraction-stimulated glucose uptake [452], other cPKC isoforms such as PKCβII 
can not be ruled out.   It is possible that TZDs could synergize with skeletal muscle 
contraction-mediated glucose uptake in part by having PKCβII bioavailability which 
could be a downstream target of AMPK.   
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 Overexpression of PPARγ, PGC1α and SRp40 all resulted in increased PKCβII 
mRNA and protein levels (Figures 26, 27, 31, 33).  Knockdown using siRNA further 
stressed the importance of these factors in PKCβII exon inclusion (Figure 34-35).  
Overexpression of the PPARγ E499Q mutant resulted in reduced PKCβII protein 
expression with no effect on PKCβI levels (Figure 32).  This PPARγ mutant can bind 
ligands with affinity equal to wild-type but can not undergo ligand-dependent 
transcriptional activation.  However, PKCβI expression is unaffected which suggests that 
basal transcriptional activity in this case is independent of PPARγ ligands.  The most 
plausible explanation for this is that the overexpressed PPARγ is becoming 
transcriptionally active via its AF1 domain.  PPARγ activation depends on the 
conformation of its C-terminal AF2 helix.  Ligands such as TZDs lock the AF2 in an 
active conformation.  The active AF2 conformation forms a charge-clamp pocket that 
interacts with the LXXLL motif of coactivators.  On the other hand, PPARγ in known to 
have high basal ligand-independent activity [453].   Fibroblast overexpression of PPARγ 
without a functional ligand binding domain was still able to drive adipogenesis.  It is 
possible that when PPARγ was overexpressed, there is a threshold that when crossed may 
relieve the requirement for ligand activation [454].   There is no evidence of PPARγ 
ligands being produced in cultured skeletal muscle cells; although it can not be ruled out 
(different medium could make a difference).  Even in adipose tissue, which abundantly 
expresses PPARγ, endogenous ligands remain poorly characterized [455].  The structure 
of ligand-free PPARγ assumes both active and inactive conformations.  The active 
conformation may be favored by increased amounts of PPARγ coactivators, such as 
PGC1α, which can bind PPARγ in the absence of ligands [453].  To explain why the 
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PPARγ E499Q mutant prevented PKCβII expression even though the ligand binding is 
likely not needed for transcriptional activation of the PKCβ promoter, the mutation must 
affect the ability of coactivators to bind PPARγ.  Coactivators such as SRC-1/NCoA-1, 
CBP/p300, pCAF, TRAP220 and PGC1α can activate PPARγ in a ligand-dependent as 
well as ligand-independent manner.  These coactivators dock on PPARγ on the AF2 or 
helix 12 region of the LBD and this binding shows sequence conservation [456].  
Without exogenous ligands, skeletal muscle cell PPARγ is required for normal rates of 
fatty acid uptake [457] suggesting that forced PPARγ expression will be active.  It is 
possible that either the mutant PPARγ disrupts the sequence recognition of the 
coactivator or it alters the folding/conformation of PPARγ such that it can not bind 
certain coactivators or oscillate between the active-inactive conformations.  In either 
case, this would prevent it from binding coactivators that might potentially recruit 
splicing factors to influence PKCβ alternative splicing.    
 Hypothesis #1 asserted that PPARγ would influence PKCβ alternative splicing by 
directly binding to a PPRE located on the PKCβ promoter.  In order to test this, we 
devised a heterologous PKCβ minigene transcriptionally regulated by 2243bp of the 
human PKCβ promoter (Figures 36-48).  Initial experiments showed promising results 
whereby PPARγ was able to influence both BI and BII exon inclusion when the plasmid 
had the PKCβ promoter as opposed to the CMV promoter (Figure 51).  However, 
deletion of the putative DR2 proved to have no effect on overexpressed PPARγ′s 
influence on the PKCβ promoter (Figure 52).  It is possible that other putative PPREs that 
were overlooked might have been better candidates.  This is unlikely because the other 
candidates were inverted repeats or everted repeats which are not standard PPREs.  
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PPREs have been known to be located far away from the transcriptional start site [455].  
The PKCβ promoter insert may have been too short and would therefore not harbor the 
actual PPRE.   To make matters more complicated, PPARγ exhibits promiscuity in 
binding to the PPRE as opposed to RXRα which can not tolerate deviation from the 
consensus sequence.  The first three bases of the 5′ half site appear to be more critical 
than the last three for PPARγ recognition [296].   The 2243bp of the human PKCβ 
promoter insert may contain more putative PPREs (possibly even DR1s) if the emphasis 
was put on only the 3′ half site.   
PPARγ is still possibly a major player in regulating the PKCβ promoter in skeletal 
muscle cells.  Despite being detected by RT-PCR (Figure 34), PPARγ expression is 
notoriously low in skeletal muscle.  In addition, PPARγ does not account for all skeletal 
muscle benefits via TZD treatment.  Muscle-specific PPARγ deficient mice that are 
insulin resistant still respond to TZD treatment [457].  The coactivators and other 
activators present in skeletal muscle may alter the stoichiometry of PPARγ such that very 
little is needed.  An interesting point discussed by Lefterova et al. is that in some genes, 
PPARγ is constitutively associated with coactivators, leading to high levels of 
transcription [455].  Overexpressed PPARγ in skeletal muscle cells may be constitutively 
bound to a coactivator on the PKCβ promoter causing constitutive co-transcriptional 
splicing.   
One experiment that would have given a more complete picture is PPARγ 
overexpression combined with TZD treatment.  The combined TZD treatment would 
ensure PPARγ activation.  However, one caveat with this is that PPARγ may not be 
activated in the same manner.  TZD is considered a full agonist [300].  For argument′s 
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sake, we′ll ascribe PPARγ overexpression as a partial agonist.  A partial agonist is a 
compound that at saturating concentrations produces activity below that of saturating 
concentrations of a full agonist.  It is important to note that partial agonists do not 
increase the interaction of PPARγ with corepressors.  Depending on the level of 
activation, PPARγ will differentially bind coactivators.  By causing PPARγ to become 
selective in terms of the coactivators it recruits, partial agonists will allow the induction 
of some but not all PPARγ target genes.  This is the concept behind “selective PPARγ 
modulators” (SPPARγM).  This is the idea that future PPARγ agonists will modulate the 
metabolic genes necessary and sufficient for insulin sensitization while not affecting 
genes involved in fat accretion and other side effects (e.g. edema) associated with TZD 
treatment [300].  PA-082 was a novel partial agonist of PPARγ which selectively 
recruited PGC1α.  This drug was able to prevent Rosiglitazone-driven triglyceride 
accumulation in mouse stem cells.  At the same time, PA-082 was also able to induce 
mRNAs of insulin signaling components and adipogenic differentiation pathways [458].  
The point of this is that TZD activation of overexpressed PPARγ may have caused 
PPARγ to associate with competing coactivators which may have hindered its ability to 
stimulate PKCβ alternative splicing.  Overexpressed PPARγ on its own may be able to 
bind coactivators, without competition, that promote PKCβ alternative splicing.   
The benefits of TZDs in skeletal muscle are largely independent of PPARγ [443].    
A much more tantalizing prospect is TZD mediating its skeletal muscle effect through 
PGC1α.   PGC1α overexpression is able to closely mimic TZD treatment in terms of its 
effects on PKCβ co-transcriptional splicing in muscle.  1μM Rosiglitazone and 
Pioglitazone for 24 hours were able to increase overall transcription yet select the PKCβII 
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isoform through alternative splicing (Figure 29).  PGC1α was able to elicit a similar trend 
(Figure 31), keeping PKCβI constant while increasing PKCβII exon inclusion.  Although 
PGC1α protein expression was very difficult to detect by western blotting, it is said to be 
expressed heavily in skeletal muscle [459].  This problem with detection could be due to 
the L6 cell line.  PGC1α protein expression in rat skeletal muscles is highly correlated 
with mitochondrial density and oxidative capacity.  Muscles that express PGC1α switch 
from a type IIb (fast twitch) muscle fiber type to a fast twitch type IIa and type I (slow 
twitch) which contain more mitochondria and exhibit higher rates of oxidative 
metabolism [376; 459].  In addition, PGC1α expression increases muscle glycogen stores 
via increased glucose transport (also involves increased GLUT4 expression), suppression 
of glycolytic flux and by inhibition of glycogen degradation pathway (down-regulation of 
glycogen phosphorylase levels and activity).  Muscles with forced expression of PGC1α 
(similar to exercise-induced expression of PGC1α) energize by fatty acid oxidation 
instead of glycolysis [357; 373].   Of interest here is the fact that PGC1α controls glucose 
uptake.  This could provide an explanation as to why PGC1α would regulate PKCβ co-
transcriptional splicing.  PKCβII is crucial in L6 insulin signaling.  C-terminal deletion 
PKCβII mutant expression as well as pharmacological inhibition using PKCβII-specific 
CGP53353 (1μM) revealed that PKCβII was crucial for insulin-stimulated glucose uptake 
[40].  PKCβII mediates these effects through MARCKS phosphorylation, increased 
membrane PLD1 and cytoskeletal remodeling [113].  If TZD stimulation in skeletal 
muscle cells were exerting their effect through PGC1α, it could do so either through 
increased expression (coactivation) or increased activity/disabling repression.  The 
former has been demonstrated in mouse primary brown adipocytes and 3T3-L1 
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adipcoytes.  This regulation occurs via PPARγ-mediated transcriptional activation on the 
PGC1α promoter PPRE [356].  Even though PPARγ in L6 cells is expressed in small 
quantities, it is still possible that TZD-mediated PPARγ transcriptional activation could 
induce increased PGC1α expression.  Or TZD stimulation in skeletal muscle may activate 
other transcription factors (which may even be coactivated by PGC1α) that will lead to 
increased PGC1α protein levels.  TZDs may also alter the activity of PGC1α.  p38 stress-
activated MAPK phosphorylates PGC1α at three residues (T262, S265, and T298) in the 
negative regulatory domain.  These phosphorylations lead to dissociation of repressor-
bound p160MBP.  Ultimately, PGC1α becomes more stable with increased half-life as well 
as possessing increased transcriptional activity [353; 460].  TZDs are capable of 
activating p38 independent of PPARγ in rat GN4 liver epithelial cells [461].  Glucose 
uptake in insulin resistant skeletal muscle cells in restored by TZD treatment in part by 
activation of p38 [462].  PGC1α activity can be regulated by means other than 
phosphorylation.  Methylation via PRMT1 (protein arginine methyltransferase 1) has 
been shown to positively regulate PGC1α transcriptional activity [463].  Acetylation 
(nicotinamide-induced) has been reported to negatively regulate PGC1α transcriptional 
activity (albeit in liver cells) [464].   TZD-induced PGC1α activation may affect co-
transcriptional splicing of PKCβ.  It is important to mention that the PGC1α and TZD 
effect on splicing needs to be confirmed showing RNA data from both PKCβI and 
PKCβII isoforms.  Until then, it is possible that both treatments increase only PKCβII 
mRNA translation.  In that scenario both PKCβ transcripts could be transcriptionally 
upregulated while splicing remained unaffected.  Although unlikely, it is even possible 
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that the treatments aid in selectively stabilizing the PKCβII mRNA versus the PKCβI 
mRNA. 
 PGC1α′s cited involvement in alternative splicing is another reason why it is an 
attractive PKCβ modulator.  Monsalve et al. evinced the role of PGC1α CTD in bridging 
transcription and splicing.  The CTD contains two RS domains and an RRM domain 
(Figure 22).  The RRM is required for induction of target genes.  In the basal state, 
PGC1α co-localizes with SR proteins at nuclear speckles.  PGC1α, through its RS 
domain is able to bind SR proteins, most prominently SRp40.  Upon activation 
(phosphorylation), both PGC1α and SR proteins alter their intracellular location within 
the nucleus to sites of active mRNA synthesis.  These proteins end up being part of the 
hyperphosphorylated RNA polymerase II complex.  It was shown that PGC1α (via CTD 
deletion) was able to modulate splicing of a fibronectin minigene [362].  The CTD of 
PGC1α is critical in mediating its effect on PKCβ alternative splicing (Figure 28).  Co-
overexpression of PGC1α and the PKCβ minigene would provide more insight as to 
PGC1α′s role in PKCβ alternative splicing.  SRp40 overexpression in another Cooper lab 
PKCβ minigene (BII exon only) stimulates insulin-induced exon inclusion [37].  In vivo, 
insulin induces Akt-mediated SRp40 phosphorylation which stimulates PKCβII exon 
inclusion (assayed by RT-PCR) by direct binding to a SRp40-binding motif [38; 211].   
Here, we further demonstrate that SRp40 overexpression leads to increased PKCβII 
protein expression (Figure 26) and knocking down SRp40 decreases PKCβII exon 
inclusion (Figure 35).  It should be noted that the degree of SRp40 knockdown would 
more closely mirror the knockdown of PKCβII if the number of SRp40 PCR cycles were 
reduced.  As far as hypothesis #1 is concerned (Figure 30), it is possible that TZD 
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treatment activates PGC1α which recruits SRp40 (would likely have to be 
phosphorylated) via PGC1α′s CTD.  SRp40 would then associate with the RNAPII CTD 
and influence splice site selection of the nascent PKCβ pre-mRNA.  However, the 
transcription factor that would initially bind PGC1α to the promoter is even less certain.  
With respect to the minigene, it is possible that not enough SRp40 was available even if 
PPARγ was bound to the minigene PKCβ promoter or even if PGC1α was able to 
coactivate the minigene PKCβ promoter.  It is also possible that some sort of stimulation 
that promoted endogenous SRp40 hyperphosphorylation may be needed for translocation 
and coactivator docking.  Overexpression of SRp40 may induce its phosphorylation by 
increasing the probability of interacting with an SR kinase such as Akt or Clk or possibly 
increasing splicing of certain SR kinase genes (personal speculation).  This could explain 
why combined overexpression with either PPARγ or PGC1α resulted in higher 
endogenous PKCβII mRNA levels than when overexpressed alone (Figure 27).   
 Work on skeletal muscle signaling has revealed PGC1α as the most promising 
potential target of TZDs.  Both PGC1α and PKCβII expression are associated with 
enhanced skeletal muscle ISGT.  Future experiments would focus on establishing 
whether PGC1α is able to associate with the endogenous PKCβ promoter in skeletal 
tissue (via ChIP assay).  Assessing PGC1α’s activity levels with TZD treatment would 
also give insight into whether its coactivation ability was enhanced as well as its ability to 
bind SR proteins (e.g. phosphorylated RS domain).  Knocking out PGC1α expression 
(via siRNA transient transfection) and then treating with TZDs would reveal whether 
PGC1α is necessary for the TZD effect on PKCβ co-transcriptional splicing.  
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Additionally, performing a ChIP assay with the PGC1α antibody would confirm indirect 
binding of PGC1α to the PKCβ promoter. 
 3T3-L1 pre-adipocytes were next used to assess possible TZD-mediated PKCβ 
co-transcriptional splicing.  When differentiated properly, 3T3-L1 cells become 
adipocytes.  Differentiation technique was verified by phase contrast microscopy as well 
as oil red O staining.  A conscious effect was made to avoid DMSO in dissolving the 
differentiation compounds Dexamethasone and IBMX (insulin was dissolved in water).  
This is because the action of DMSO is associated with increased expression of PKCβ, α, 
γ isoenzymes and alternative splicing [121; 465].  For reasons that are apparent in the 
results section, use of DMSO could have called into question the observed effects of 
differentiation-regulated PKCβ alternative splicing (as well as differentiation-regulated 
transcription of PKCα and γ).  Ethanol was instead used to dissolve the two compounds 
mentioned.    
 Glucose concentrations in the media were also examined.  Most papers use high 
glucose media to culture and differentiate 3T3-L1 cells.  But because we were looking at 
PKCβII expression, this presented a potential problem.  Patel et al. had reported that 
hyperglycemia can post-transcriptionally destabilize PKCβII mRNA (but not PKCβI 
mRNA) in A10 VSMCs and primary human aorta cultures [466].  This is the reason why 
both low and high glucose DMEM media was tested initially.  If high glucose 
destabilized PKCβII expression, then low glucose media would be opted for.  However, 
neither media had an effect on 3T3-L1 adipocyte PKCβII expression during development 
(Figure 54-55).  Therefore, we chose to stick with the mainstream culture media. 
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 The 3T3-L1 cell line is an ideal model for studying fat cell development and 
signaling since results in 3T3-L1 adipocytes have repeatedly been confirmed in mouse 
models [467].  During differentiation, many genes are programmed to initiate or cease.  
cDNA microarray analysis of 3T3-L1 cells show PKCβ expression at least ten fold higher 
in 3T3-L1 adipocytes versus 3T3-L1 fibroblasts [419].  This suggested a role for PKCβ in 
adipogenesis and other adipocyte metabolic functions.  Our results confirm that PKCβ is 
regulated during 3T3-L1 differentiation (Figure 56-57).  However, Guo et al. did not 
address which PKCβ isoform was upregulated over ten fold.  We believe this to be the 
first example of differentiation-regulated PKCβ alternative splicing, whereby PKCβI 
starts off as the predominant 3T3-L1 pre-adipocyte isoform and is later replaced during 
differentiation with the PKCβII isoform.  This form of regulation is almost certainly 
disparate from the type of PKCβ alternative splicing that occurs in L6 skeletal muscle 
cells within 15 min of insulin treatment [39].   The fact that PKCβII protein expression 
peaks at day 8, the same time when robust lipid droplets can be observed under the 
microscope, suggests that PKCβII could be involved in adipogenesis.  This could explain 
why protein and mRNA levels of PKCβII dip after peaking.  PKCβII may be critical for 
terminal differentiation.  Once this occurs, PKCβII may be needed in lesser amounts.  As 
far as the mRNA of day 8 and day 10 falling below day 4, this could be explained by the 
fact that a single PKCβII mRNA strand may be more frequently translated after terminal 
differentiation.  As to why PKCβII mRNA peaks at day 6 (Figure 56) and PKCβII protein 
peaks at day 8 (Figure 57), this could be explained by differences in technique 
sensitivities or other factors such as microRNAs regulating protein translation.  Figure 58 
indicates that the distal polyA tail (located downstream of the PKCβI exon) is used for 
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both PKCβI and PKCβII mRNA expression.  This may add stability to the mRNA 
transcript.  The expression pattern of PKCα and ζ (Figure 56) were congruent with 
expression patterns reported by McGowan et al. [426].  PKCζ′s expression pattern is a 
non-sequitur for a kinase confirmed to play a major role in 3T3-L1 adipocyte insulin 
signaling [127; 129; 133; 145; 153; 283].  It is possible that heightened PKCζ expression 
is needed for adipogenesis and then returns to a level that can still support insulin-
stimulated GLUT4 translocation.  PKCδ (with all its possible isoforms) may also function 
in promoting adipogenesis based on its expression pattern.  PKCδ′s function in skeletal 
muscle primary cultures suggests that it could provide a negative feedback to insulin 
receptor tyrosine kinase activity [468].  The expression pattern of PKCγ, to our 
knowledge, has not been reported in this cell line.  It too could be involved in 
differentiation but its expression rises and falls so precipitously from day 6 to day 8 and 
then from day 8 to day 10 respectively, that it may only be needed for the terminal phase 
of adipogenesis.  PPARγ2 and PPARγ1 (which can compensate if PPARγ2 is deficient) 
are essential for adipogenesis [455] and their presence confirms proper adipogenesic 
signaling.  Adiponectin is also a marker of adipocytes.  GLUT4 protein expression 
(Figure 56) signals the beginning of insulin responsiveness.  PKCβII and GLUT4 protein 
expression are very similar.  Based on previous data from the Cooper lab in which 
PKCβII knockdown resulted in reduced GLUT4 protein expression, it was hypothesized 
(#2) that PKCβII could affect GLUT4 expression/stability.   
 Our inability to transfect 3T3-L1 adipocytes prevented this hypothesis from going 
any further.  Factors that could influence differentiation-regulated PKCβ alternative 
splicing were next examined.   As mentioned in the Results section, PU.1 was the lead 
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candidate because it had consensus binding sites covering the PKCβ promoter as well as 
being a factor that could regulate alternative splicing.  PU.1 interacts with proteins 
containing RNA binding motifs.  One of these proteins is TLS/FUS, whose C-terminal 
domain contains three RNA recognition motifs (RRMs) and two arginine glycine-rich 
regions (RGGs). The RGG2-3 domain is capable of recruiting SR proteins [469].  We 
hypothesized that if PU.1 bound the PKCβ promoter during differentiation, it could select 
the SR proteins, and therefore the PKCβ isoform, based on coactivator recruitment.  ChIP 
assays revealed that PU.1 is likely associated with the PKCβ promoter.  It was bound to 
several spots on the promoter, although usually stronger on day 0 than on day 8.  Several 
possibilities exist as to PU.1′s function on the promoter.  First, it could be a stimulator or 
repressor of PKCβ alternative splicing depending on which site it occupies.  Second, even 
though PU.1 overexpression has been shown to inhibit overall 3T3-L1 differentiation, it 
could be transcriptionaly repressive with respect to most adipogenic genes (allowing for 
adipogenesis) but active with respect to PKCβ.  This would explain why 3T3-L1 
adipocytes continue to express PU.1 (Figure 61) even though it has anti-adipogenic 
properties when overexpressed [437].  Also, as mentioned in the Results section, 
overexpression of PU.1 in 3T3-L1 must be interpreted with caution as this may have 
caused PU.1 to cross a threshold expression level to where it became anti-adipogenic.  
PU.1 may behave like PPARγ.  By this I mean that the binding of PU.1 to the PKCβ 
promoter (whether day 0 or day 8) may be the same for a given site but its activation may 
change due to differentiatial coactivator recruitment or post-translational modifications.  
This change in activity may not be possible at day 0 due to the lack of a certain factor that 
can only be expressed when the proper adipogenic signals are present. 
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To our surprise, SRp40 precipitated with the PKCβ promoter.  There were 
noticeable differences between day 0 and day 8 depending on the region.  Regardless, 
association with the PKCβ promoter upstream of the transcriptional start site poses the 
possibility that SRp40 is recruited via transcription factors and coactivators during 
transcription.  According to the literature, this is possible as long as SRp40 is serine 
phosphorylated prior to arrival [470].  GATA2, like PU.1, is also a known anti-
adipogenic protein.  Its expression could not be verified using RT-PCR, however, it did 
appear in the ChIP assay showing binding preferences based on whether it was day 0 or 
day 8.  Of interest, from -4384 to -4183, GATA2 was bound strongly on day 0 and not 
day 8.  Perhaps, PKCβ needs this site to be free of GATA2 in order to accomplish 
alternative splicing.  GATA1 and AML1 did not bind in this assay, even though AML1 
did bind in a previous assay.  AML1/RUNX1 has been confirmed to bind the human 
PKCβ promoter in U937 cells [435].  Perhaps the AML1 antibody had lost potency or 
minute changes in cell culture conditions altered intracellular signaling to the point where 
AML1 could no longer bind the PKCβ promoter.   
Due to difficulties in transfecting 3T3-L1 adipocytes, PU.1 could not be knocked 
down so we could not test directly whether PU.1 is needed for PKCβ alternative splicing 
(hypothesis #3).  Despite this, we moved on to test the physiological relevance of PKCβII 
with respect to ISGT.  Establishing a connection between PKCβII and ISGT would be 
very significant.  Adipose tissue accounts for only a fraction of glucose disposal after a 
meal (~10-15%) with muscle accounting for much of the remainder.  However, global 
glucose homeostasis depends on adipocytes.  This is not only based upon increased or 
decreased adiposity but on the GLUT4 signaling inside the adipocyte [420].  Adipocyte 
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GLUT4 signaling has effects on circulating serum adiponectin, an adipokine crucial for 
peripheral insulin sensitivity [471].  Adipose–specific overexpression of GLUT4 has 
been reported to reverse insulin resistance and diabetes in mice lacking muscular GLUT4 
[472].  Adipose-selective targeting of the GLUT4 gene in mice impairs insulin action in 
muscle and liver [473].  Regulation of adipocyte GLUT4 affects not only adipocyte 
glucose uptake but global glucose homeostasis.  The fact that PKCβII is critical in 
skeletal muscle ISGT begs the question as to whether it holds a similar role in adipocytes.  
Several lines of independent experimentation support the notion that insulin-dependent 
GLUT4 translocation is similar or identical in skeletal muscle and adipocytes [474; 475].  
In both cases, insulin-dependent GLUT4 translocation is PI3K dependent [476].   
To establish this connection, experiments were modeled after Chalfant et al. using 
PKCβII pharmacologic inhibition and [3H]2-deoxyglucose uptake [40].   50μM 
CGP53353 was able to significantly inhibit adipocyte ISGT (Figure 63).  25μM 
LY379196 was also able to significantly inhibit adipocyte ISGT (Figure 64).  Use of both 
inhibitors has culminated in a narrow list of possible glucose uptake effectors.  According 
to the IC50 spectrum (in nM) of CGP53353, 50μM will inhibit PKCβII (IC50=0.41), 
PKCβI (IC50=3.8), PKCα (IC50=1.9), PKCγ (IC50=22) and EGFR (IC50=0.7) [126].  
Beyond 50μM, CGP53353 will not inhibit any other PKC isoform including PKCζ which 
is considered the predominant PKC isoform involved in 3T3-L1 adipocyte ISGT [127].  
Glucose uptake assays were performed on day 8 or later.  At this point there is virtually 
no PKCβI protein expression relative to day 0 (Figure 56).  It is unlikely that it plays a 
significant role in glucose uptake.  In addition, there is no documented role for PKCβI in 
insulin-stimulated glucose uptake in any cell line [40; 477].  CGP53353 at 20μM is able 
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to inhibit ISGT by roughly 45%.  Combined with the reality that intracellular 
concentrations of the drug are likely much lower than 20μM, PKCγ can be ruled out as a 
major drug target.  Use of the LY379196 did not help to further eliminate cPKC 
isoforms.  However, the fact that 25μM was able to significantly inhibit ISGT confirmed 
that there may be a novel PKC isoform involved in ISGT other than PKCζ (IC50=48μM).  
LY379196 also helped to eliminate EGFR from possible CGP53353 effectors since 
LY379196 does not inhibit this protein [125].  EGFR is downregulated during 3T3-L1 
differentiation and was not considered to be a factor in ISGT [478].  PKCδ (IC50=0.7) 
would also be inhibited by LY379196.  However, inhibition of PKCδ activity does not 
inhibit glucose transport in 3T3-L1 adipocytes [479].  Both drugs inhibit PKCα with 
IC50s close to that of PKCβII and for this reason, PKCα can not be completely excluded.  
On the other hand, PKCα has been shown to negatively regulate the insulin receptor 
tyrosine kinase activity by interacting with IRS1 [480].  Angiontensin II inhibits insulin-
induced Akt activation through PKCα in VSMCs [481].  Hence, it would explain why 
3T3-L1 cells downregulate PKCα during the course of adipogenesis and it is thus 
unlikely that CGP53353 is mediating its effects through PKCα [426].  This leaves 
PKCβII as the best candidate.   
 Hypothesis #4 asserted that PKCβII would regulate adipocyte ISGT through 
GLUT4 translocation or GLUT4 fusion.  In L6 cells, Chappell et al. showed that 
CGP53353 at 1μM, a dose specific for PKCβII, was able to prevent GLUT4 fusion by 
isolating PM fractions [113].  This result hinted at the possibility that PKCβII regulated 
vesicle fusion but it was also assumed that this effect was due to inhibition of GLUT4 
translocation.  It is worth while to address the issue that the role of PKCβII in ISGT is 
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controversial.  Several papers have been published for and against a role for PKCβII in 
ISGT regulation.  The use of C-terminal mutant PKCβII and CGP53353 in L6 cells has 
already been described [40].  In addition, LY379196 (at 3 X 10-8 mol/l) was able to 
inhibit ISGT in 6 day-old cultured myotubes [482].  Interestingly, the same inhibitor was 
used to make the case that cPKCs could not regulate L6 ISGT [483].  However, the same 
group also showed that PKCα, PKCβ and PKCζ were activated by insulin in 3T3-L1 cells 
[484].  This would suggest that PKCβ has some role in insulin signaling.  Systemic 
knockout of mouse PKCβ was reported to have no effect on glucose homeostasis in both 
fat and skeletal muscle tissue [485].  This supposedly ruled out PKCβII as a player in fat 
or muscle GLUT4 trafficking.  However, caution must be exercised when drawing 
conclusions from systemic knockouts.  Systemic knockout of GLUT4 has only mild 
perturbations in glucose homeostasis even though it is the bona fide transporter in 
insulin-sensitive tissues.  Tissue selective targeting of GLUT4, however, has dramatic 
effects on ISGT [486].  Adipocyte-specific inducible knockout of PKCβII (future project) 
needs to be performed to definitively determine the role of PKCβII in adipocyte ISGT.  
However, work done here lays a foundation providing preliminary evidence that indeed, 
PKCβII (or at the very least cPKC) is involved in GLUT4 translocation (possibly fusion) 
and adipogenesis.   
 First, specificity of CGP53353 was determined using western blot analysis 
(Figure 65).  Phosphorylation of insulin receptor, PKCδ and PKCζ were not altered.  It 
was important to rule out PKCζ as this PKC isoform is involved in GLUT4 translocation 
[127; 153].  PKCζ activation involves PDK1 mediated Thr410 phosphorylation.  Based 
on the literature we assumed this would be insulin-stimulated [487].  As is obvious, every 
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condition demonstrated pPKCζ Thr410.  Activation of PKCζ has been reported through 
other stimuli including glucose in rat adipocytes [488].  The major activation pathway of 
PKCζ is PI3K-manufactured PIP3.  PDK1 binds with high affinity to PIP3 in order to 
phosphorylate PKCζ.     PKCζ isolated from bovine kidney is phosphorylated via PI3K-
mediated PIP3 in response to growth factors [489].  Interestingly, Alessi et al. have shown 
that PDK1 isolated from unstimulated or insulin-stimulated cells possess the same 
activity towards the Akt target and others.  In 293 cells, insulin stimulation did not 
change the phosphorylation status of PDK1.  It is proposed that PDK1 could be 
constitutively active and that it is the substrate that needs to undergo a conversion in 
order to become phosphorylated [490].  In this same cell line, ceramide was shown to 
activate PKCζ in vitro [491].  3T3-L1 adipocyte ceramide is associated with non-insulin 
dependent glucose uptake.  Ceramide can stimulate PI3K in 3T3-L1 cells [492].  Perhaps 
PKCζ also has a role in basal glucose uptake and this necessitates its constitutive 
phosphorylation.  Phosphorylation of PKCβ S660 (hydrophobic motif) was dramatically 
reduced with drug treatment with total PKCβ protein levels remaining constant.  We also 
attempted to assess the phosphorylation status of PKCα (even though it is almost 
certainly inhibited as well) by using a Cell Signaling pPKCα/βII (T638/641) antibody.  
Only one band materialized and since we did not possess a peptide inhibitor at the time, 
this data could not be interpreted.  Antibodies for pPKCγ were not practical as they cross-
react with pPKCβII.  pPKCβII (T641) (Abcam) was also probed for but there was too 
much background.   
 The dosage used for CGP53353 also needs to be addressed.  Differentiating 3T3-
L1 adipocytes develop impermeable cell membranes.  During differentiation, more than 
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90% of the adipocyte population have reduced junctional permeability [493].  This is 
almost certainly the reason why pharmacologic inhibition can only be achieved by 
spiking the dosage.  Multiple investigators have used high drug concentrations in 3T3L1 
adipocytes to block intracellular signaling.    For example, PD-98059 at 50μM was used 
to inhibit MEK activity and 100 µM naringenin to inhibit PI3K in 3T3-L1 adipocytes 
[494].  LY294002 at 50μM was used to inhibit PI3K activity [495].  SP600125 at 50μM 
was used to inhibition JNK activity and LY294002 at 100μM was used to inhibit PI3K 
activity [496].  These are concentrations at least 10-fold higher than what is required in 
skeletal muscle to block signaling.   
 CGP53353 administration abrogated GLUT4 translocation as evidenced by 
subcellular fractionation and PM sheet assays (Figure 66-67).  This implicates PKCβII as 
a critical regulator of adipocyte ISGT.  In addition, PKCβII may also have a role in 
“priming” GLUT4 for translocation.  Figure 68 (b & d) shows that insulin is able to 
concentrate a pool of GLUT4, near what could possibly be the TGN.  CGP53353 
treatment causes GLUT4 to become more dispersed around the nucleus.  This may 
implicate PKCβII in insulin-stimulated GLUT4 trafficking leading up to translocation.  
This data lends credence to part of Model 2 (Intro) concerning GLUT4 trafficking which 
states that insulin causes more GLUT4 to accumulate at a non-cycling pool near the 
TGN, which will translocate to the PM directly.  Co-immunoprecipitation suggests that 
PKCβII may be able to influence GLUT4 directly or act on the GSVs to direct trafficking 
(Figure 73).   
 There are at least two discrete signaling pathways involved in insulin-regulated 
GLUT4 translocation in muscle and fat cells.  The first involves PI3K and the second 
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involves the proto-oncogene c-Cbl.  The two targets of PI3K that have been identified are 
serine/threonine kinase Akt and PKCζ.  PI3K activates Akt by generating 
phosphoinositides in the inner leaflet of the plasma membrane.  Akt docks to this through 
a pleckstrin homology domain bringing it in close proximity with PDK1 [127].  The 
mechanism of PKCζ activation is not known although it may involve dissociation from 
14-3-3 proteins among other things [19].  Recent reviews describe PI3K signaling 
diverging into two post-PDK pathways [133; 145; 254; 283; 497].  One pathway diverges 
to an atypical PKC pathway shown to be crucial for activation of glucose transport in 
both muscle and fat cells.  The other Akt dependent pathway leads to AS160 
phosphorylation.  Five of six AS160 consensus Akt phosphorylation sites are 
phosphorylated in response to insulin [498].  These phosphorylations render AS160′s 
GAP domain inactive making it unable to negatively regulate Rab proteins.  This allows 
Rab-dependent GLUT4 translocation to occur [497].  Using western blot analysis and 
immunofluorescent staining, CGP53353 selectively inhibited Akt phosphorylation at 
S473 while phosphorylation at T308 remained undisturbed (Figure 69-70).  
Immunofluorescent staining shows strong insulin-dependent recruitment of Akt to the 
PM as well as intracellular deposits that could be part of the GSV trafficking itinerary 
(Figure 70).  This data suggests that PKCβII could be upstream of Akt during insulin 
signaling.  This is not unusual since it has been reported that PKCβII mediates Akt S473 
phosphorylation in a cell type and stimulus-specific event [438].  The importance of Akt 
in ISGT can not be overstated.  James et al. reported that in 3T3-L1 adipocytes, fully 
active Akt is involved in a late stage insulin-induced GLUT4 translocation to the PM.  
This latter process involves docking and fusion of GLUT4 vesicles with the PM [499].  
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Constitutively active Akt stimulated glucose uptake and GLUT4 translocation in 3T3-L1 
adipocytes [180].   A kinase inactive, phosphorylation deficient Akt resulted in almost 
complete loss of L6 cell surface GLUT4 [185].   A similar strategy was used to verify 
Akt′s role in promoting insulin-stimulated cell surface GLUT4 in rat adipocytes [500].  
More direct influence of Akt on GLUT4 has come from studies showing that insulin 
increases association of Akt2 with GSVs and this leads to phosphorylation of GSV 
component proteins [181; 182].  The functional consequence of this interaction, by use of 
fusion constructs with Akt and GLUT4, results in insulin-stimulated GLUT4 
translocation to the PM [501].  PKCβII, through Akt could direct GLUT4 traffic.  If Akt 
were to mimic GLUT4 localization, then PKCβII indirectly causes more GLUT4 to be 
available near the TGN for direct translocation to the PM (Figure 68). 
 The mTORC2 complex is responsible for Akt S473 phosphorylation and thus full 
activation in 3T3-L1 adipocytes.  Phosphorylation of S473 results in the interaction 
between the hydrophobic motif and the N-terminal lobe leading to activation [174; 175; 
229].  mTORC2 can be distinguished from mTORC1 based on residue phosphorylation 
of mTOR serine/threonine kinase.   mTOR phosphorylation at S2481 defines the activate 
mTORC2 complex [61].  To resolve the apparent discrepancy that PKCβII was needed 
for S473 phosphorylation (in our model) and yet mTORC2 was the kinase responsible for 
this (throughout most of the literature), we used CGP53353 inhibition to assess its effect 
on mTORC2 activity.  Figure 71 depicts an insignificant change in mTORC2 S2481 
phosphorylation (and thus activity) when treated with CGP53353.  This suggested few 
possibilities.  One was that PKCβII was downstream of mTORC2 and it was really 
PKCβII that was phosphorylating Akt S473 in this cell line.  Another possibility was that 
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PKCβII associated with the mTORC2 complex and was needed for substrate specificity.  
These assertions are reasonable given that PKCβII is phosphorylated at the turn motif by 
mTORC2 in MEF cells [54].  In addition, the phosphorylation of Akt via mTORC2 has 
not been shown to be direct [502].  Through co-immunoprecipitation, we provide 
evidence that the turn motif phosphorylation of PKCβII is associated with direct binding 
of mTOR (part of mTORC2) (Figure 72).  This association increases with insulin 
treatment compared to control (lane 3 vs. lane 2) and is dramatically reduced with 
CGP53353 drug treatment (lane 3 vs. lane 5).  PKCβII would then go on to 
autophosphorylate itself and subsequently phosphorylate Akt.  Preliminary data is shown 
that suggests that this interaction between PKCβII and Akt is possible (Figure 73). 
 There is ample circumstantial evidence connecting PKCβII to GLUT4 
translocation and ISGT alluded to throughout the introduction.  PKCβII can be localized 
to the pericontron to play a role in hormone responses by controlling the trafficking of 
recycling endosomes containing Rabs.  PKCβII can translocate to the pericentron in a 
biphasic DAG response that depends on PLD-derived DAG  [19].  3T3-L1 adipocytes 
undergo this biphasic DAG reponse [479].    PKCβII (not PKCβI) can activate PLD 
(involved in GLUT4 fusion) [19].  It is important to note that it is the PLD1 isoform 
which is activated by cPKCs in response to insulin.  The PLD2 isoform has high basal 
activity and is not stimulated to the same extent by PKC family members, ARF (ADP-
robosylation factor) and Rho [503].  3T3-L1 adipocytes express both PLD isoforms 
which are confined to LDM as detected by Millar et al.  Within the LDM fraction, PLD2 
is associated with intracellular membranes whereas PLD1 is associated with IRS1 and 
PI3K [504].  Other reports have PLD1 at the perinuclear vesicles and PLD2 at the PM 
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[505].  Subcellular localization of PLD needs further investigation.  In HEK293 cells, 
PKCα and PLCα are both involved in insulin-stimulated PLD1 and PLD2 activation 
[503].  Human pulmonary artery endothelial cells (HPAEC) require PKCε for PLD2 
activation which then goes on to activate PKCζ [506].  In human colon cancer cells, a 
PKC/Ras/ERK/NFκB-pathway is responsible for PLD1 (not PLD2) activation [507].  
Lastly, in the human-airway epithelial cell line (CFNPE9o-), Src and PKCδ are needed 
for PLD1 activation [508].  Clearly, many factors converge on PLD isoforms to regulate 
their activity as well as localization.  Cell-type and agonist-type likely dictate which 
factors are utilized.  Therefore, if PKCβII was needed for PLD1 activation in 3T3-L1 
adipocytes, other factors could compensate by either activating PLD1 or the cell could 
switch to PLD2.   
 PKCβII binds to and is activatd by F-actin where it has been shown to 
phosphorylate many cytoskeletal-associated proteins in vitro including adducin, 
MARCKs, troponin, and vimentin.  PKCβII association with F-actin resulted in a 5-fold 
increase in F-actin phosphorylation, indicating F-actin is a PKCβII substrate [105].  
Disruption of F-actin in 3T3-L1 cells, via cytochalasin D, depolymerizes actin thus 
inhibiting GLUT4 translocation and ISGT.  The dynamic rearrangements of F-actin and 
the actin based cytoskeleton play a critical role in insulin-stimulated GSV translocation to 
the PM [283].   
 As mentioned earlier, PKCβII can phosphorylate Akt S473 in a cell and stimulus 
dependent manner [438].  Data presented leads to a final model whereby the insulin 
signaling cascade in 3T3-L1 adipocytes results in mTORC2 activation.  This leads to 
direct mTORC2-mediated PKCβII phosphorylation and activation.  PKCβII will then 
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phosphorylate and fully activate Akt (S473).  Fully active Akt perpetuates the insulin 
signaling cascade eventually culminating in GLUT4 translocation and ISGT.  Active 
PKCβII may also act on GLUT4 or GSV components to positively regulate ISGT.  Figure 
75 represents a proposed model of 3T3-L1 adipocyte insulin signaling that is dependent 
on PKCβII activity.  Future directions would include studying other potential contributors 
(e.g. AKAP and/or mTORC2 components) in the binding between mTORC2 and 
PKCβII.  Development of an inducible construct that specifically targets the PKCβII exon 
would allow assessment of its role during adipogenesis as well as confirm PKCβII’s role 
in GLUT4 translocation and ISGT.  
Akt
Figure 75.   Hypothetical model for PKCβII-regulated ISGT via Akt activation in 3T3-L1 adipocytes.  Differentiated 3T3-L1 adipocytes
are stimulated by insulin.  Subsequent insulin receptor tyrosine kinase activity recruits IRS leading to PI3K generated PIP3 which sequesters 
both PDK1 and Akt through their PH domains.  Preceding PM localization, Akt is phosphorylated at Threonine 450 by a mechanism that 
depends on mTORC2.  Whether this is a direct phosphorylation by mTORC2 or involves PKCβII is uncertain.  Once PM bound, PDK1 
phosphorylates Akt at Threonine 308 as well as PKCβII at Threonine 500.  Activated mTORC2 (which may require Ras-mediated 
phosphorylation) includes mTOR, Rictor, Protor, Sin1, mLST8, phosphatidic acid (PA) and the TSC1/TSC2 complex.  Since PKCβII can bind 
and activate PLD1 in select cells, the possibility exists that PKCβII is involved in a positive feedback loop for enhanced insulin-stimulated 
mTORC2 activation by indirectly generating PA.  However, in spite of PKCβII inhibition, mTORC2 may still be able to assemble due to other
positive regulators of PLD1.  High basal PLD2 activity could also compensate. Serine 2481 phosphorylation of mTOR during insulin 
stimulation distinguishes mTORC2 activity allowing it to directly phosphorylate PKCβII at Threonine 641 leading to PKCβII 
autophosphorylation at Serine 660.  After PM translocation and pseudosubstrate release,  fully active PKCβII phosphorylates Akt at Serine 473.  
Akt is now fully active and able to elicit GLUT4 translocation to the PM culminating in glucose import.  PKCβII may also be able to act on 
GLUT4, or components of the GLUT4 storage vesicles, directly.  
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